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ABSTRACT
The p53 gene is mutated in more than 50% of human cancers and moreover,
alterations in p53 regulated/regulatory pathways are present in the vast majority of
cancers. Taking into account the numberofcellular processes and pathways that p53
is part of, it is not surprising that loss of p53 function has an influence on many
aspects of carcinogenesis. In addition to p53 inactivation through mutations, a well
documented process leading to abrogation of p53 functions and stability is over-
expression of MDM2 essential negative regulator of p53. A growing body of
evidence indicates that MDM2 can also promote cancer in a p53-independent
manner. The oncogenic potential of MDM2 appears to be mainly the result of
protein-protein interaction. One such MDM2interacting protein that was previously
identified in our laboratory is DNA polymerase ¢. Serendipitously, during the course
of MDM2-DNApolymerase ¢ studies, it was also discovered that MDM2 interacts
with DNA polymerase a (these two protein complexes co-purify in partially
overlapping fractions from mammalian cells). The main aim of the work presented in
this thesis was to further investigate the MDM2interaction with DNA polymerase a
by performing experiments both in vitro andin cells in culture. The results of in vitro
studies indicate that MDM2 can interact directly with the catalytic subunit of DNA
polymerase & (p180) and that first 166 amino acids of MDM2protein seem to be
required for this interaction. Moreover both the carboxy- and amino- termini of p180
contribute to this interaction. In addition, MDM2 appears to be capable of
stimulating the DNA polymerase activity of DNA polymerase « in vitro. We have
also demonstrated that p180 can be modified by ubiquitylation in the cells although
surprisingly, the role Gf any) of MDM2 in this event, may be to suppress this
modification. Finally, and perhaps most revealingly, MDM2preferentially forms a
complex in cells with a non-/hypophosphorylated form of DNA polymerase a which
has been shown to be involved in initiation of DNA replication, thus providing a
possible link between MDM2 oncogenicity and S-phase progression. In conclusion,
the studies presented in this thesis describe direct and indirect interaction of MDM2
with DNA polymerase a, a key enzyme involvedin the initiation of DNA replication
and in so doing may shed light on mechanism/s through which MDM2 might
mediate someofits p53-independent oncogeniceffects.
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 Introduction
CHAPTER I
INTRODUCTION
1.1 Background on cancer
Cancer can be described as a group of diseases characterized by uncontrolled
cell growth and the ability of such cells to invade adjacent tissues and spread
throughout the organism. This type of cell behavior is caused by alterations in the
cell genomeresulting in transformation of normal cells into malignant cancercells.
Alterations in the genomecan occuras an effect of either exogenous factors such as
ionizing radiation, UV radiation or mistakes introduced into the genome during
endogenous cellular processes such as DNAsynthesis. Generally speaking, there are
two categories of genes whosealterations contribute substantially to the development
of cancer. One category comprise genes mainly involved in promoting cell growth
and differentiation whose alteration leads to their activation, whilst the second
category includes genes that are inactivated when mutated, resulting in disruption of
cell cycle control or apoptosis promotion. The latter group of genes are called tumour
suppressors, while the former proto-oncogenes (known as oncogenes whenaltered in
cancer). When oncogenic mutations occur in oncogenes they are dominant, which
means that only one defective copy of the gene is enough to contribute to
carcinogenesis, whereas in general, mutations in tumour suppressors are considered
to be recessive; therefore two copies of a gene need to be mutated in order for altered
function of the gene to be manifested (17).
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A
Component Acquired Capability Example of Mechanism
Self-sufficiency in growth signals Activate H-Ras oncogene
Insensitivity to anti-growth signals Lose retinoblastoma suppressor
EX
ES
E
w
Evading apoptosis Produce IGFsurvival factors
Limitless replicative potential Turn on telomerase
Sustained angiogenesis Produce VEGFinducer
Tissue invasion & metastasis Inactivate E-cadherin
BFao)
Kl fa fi Ge ED hu Siz,co “foXSe
 
Figure 1.1.1 Hallmarks of cancer. Characteristic of cancer cell with (A) examples
of mechanism involved and (B) proposed “order of appearance”in the cell (figure
reproduced from reference 74).
Acquired genomic alterations can have substantial consequences on many
disparate functions of the cell, but only certain combinations can lead to cancer
development. Thesecritical “consequences” have been organised by Hanahan and
Weinberg into six phenotypic traits by which cancerous cells can be characterized
and distinguished from normal ones. These “hallmarks of cancer” include: self
sufficiency in growth signals, insensitivity to growth - inhibitory signals, evasion of
apoptosis, limitless replicative potential, sustained angiogenesis, tissue invasion and
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metastasis. These properties, which can be found inall types of human cancers, are
acquired gradually and the “order of appearance” may vary in different types of
cancer or even within a type of canceras presented in Figure 1.1.1 (74).
Carcinogenesis is typically a long, multistep process and since genome
alterations accumulate with time, cancer is more likely to develop in old age.
However, the occurrence of mutations in germline cells allow for their transfer from
generation to generation. Thereby some people harbourhereditary predispositions to
cancer syndromessuch as: Li Fraumeni (mutations in p53 gene) and Von Hippel —
Lindau (mutations in VHL gene) that increase the probability of affected individuals
developing cancer early in a lifetime (17,191,192). Most cancers are however
sporadic and result from somatic mutations whichare notinherited.
1.2 An introduction to MDM2
Amongall of the genes found in an altered form in cancercells, one deserves
special attention - the p53 gene, which has been observed to be mutated in
approximately 50% of all human cancers (187). p53 is a transcription factor for a
number of genes involved in key processes in cells such as cell cycle control,
apoptosis, DNA repair, angiogenesis and motility. Therefore, it is not surprising that
inhibition of p53 function affects almost every aspect of cancer development (193).
In addition to mutations the activity of p53 can be abrogated as a result of negative
regulation by some oncogenes, with the most notable one being MDM2. MDM2
exerts its inhibitory activity on p53 by inhibiting its role in transactivation, and
furthermore by mediating its ubiquitylation and subsequent degradation by
proteasomes. For this reason, MDM2is therefore an important and widely studied
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protein participating in cancer development. MDM2 can also promote cancer in a
p53-independent manneras will be discussedlater in this chapter (2,18).
The first report on murine double minute 2 (Mdm2) was published more
than twenty years ago, wherein Mdm2 wasidentified as one of three genes amplified
on small chromatin bodies known as double minutes (DMs) in a spontaneously
transformed derivative of the murine 3T3 cell line (3T3DM) (4). Further research
revealed that Mdm2 was the only one of these three genes whose overexpression
enhanced the tumorigenic potential of NIH3T3 and Rat3 cells (3). Since then up-
regulation and overexpression of MDM2 has been reported in many human tumours
(140).
The oncogenic properties of MDM2are displayed when the MDM2 gene,
located on chromosome12 (in humans), is amplified or overexpressedin cell (140,
141). The MDM2geneconsists of 12 exons and its expression is under the control of
two promoters: Pl, located upstream of exon 1, and P2 which lies in intron 1
(142,143,144). Pl is constitutively expressed, whereas P2 has two p53 response
elements and is regulated by p53 (143,144,145). Transcripts from both promoters
encodefull length MDM2protein (p90), with the first start codon of the open reading
frame (ORF) being located in exon 3, however there is a difference in the 5°UTR
which has significant impact ontranslation of themRNAsoriginating from the two
promoters (143). The 5’ untranslated region (5’UTR)is longerin transcripts from the
Pl promoter (long, L-MDM2) compared to the 5’ UTR expressed from the P2
promoter (short, S-MDM2) transcripts (146). Moreover, L-MDM2contains two
upstream open reading frames (uORFs) which affect its translational potential by
reducing ribosomeloadingand as a result L-MDM2is about ten timesless efficiently
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translated than S-MDM2 (147).
In addition to alternative translation the level of MDM2 mRNA varies
amongindividuals asa result of a single nucleotide polymorphism (SNP), either T or
G at position 309 located in the P2 promoter region which can cause increased
MDM2levels, due to greater DNA binding affinity of transcriptional activator Sp]
for the G form of the SNP (148).
Apart from the full length p90 protein, many shorter versions of MDM2
are produced and these products are present in tumours as well as in normaltissues.
Since 1996, when first alternatively spliced MDM2 transcripts were described,
around forty different MDM2 splice variants have been identified (reviewed in 20,
21). The mechanismsresponsible for generation of these variants are usually either
alternative or aberrant splicing resulting in loss of complete exons or fragmented
exons, respectively. Many variants lack either part of, or the entire p53 binding
domain, which has been argued as further evidence for non-p53 regulatory functions
for these proteins. In fact, several MDM2splice variants that are unable to bind to
p53 have been shown to promote tumourigenesis, supporting the notion that MDM2
has p53-independent oncogenic potential (36, 93). Howeverit is hard to determine
whetherproteins are being generated from all the variants and the functions of most
alternatively spliced transcripts remain unclear.
1.2.1 Protein domains of MDM2
The MDM2 full length protein consists of 489 amino acids (aa) in
mice/491 aa in humans. There are several different domains and motifs that have
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been described within MDM2according to their function and/or structure and these
are shown in Figure 1.2.1. The first conserved domain consisting of approximately
100 aa - is located at the very amino terminal end of MDM2andis called the p53
binding domain thusreflecting the role it plays within the protein. MDM2 binds to
the transactivation domain of p53 via a hydrophobic binding pocket formed within
residues 26-108 of MDM2and this results in an inhibition of p53 transcriptional
activity (179).
1 NLS NES NoLS 489
{3 108 v v 237 332 433 V sss!a_i
p93 binding Acidic Zinc finger RINGfinger
domain domain domain domain
Figure 1.2.1 Structure of full length murine MDM2.Theprotein consists of 489
amino acids (based on information provided by reference 2). Location of different
domains and motifs indicated by coloured boxes; NLS — nuclearlocalization signal,
NES — nuclear export signal, NoLS — nucleolarlocalization signal.
The nuclear localization signal (NLS) and nuclear export signal (NES)
motifs are localized between amino acids 170 - 200 and are responsible for MDM2
shuttling between the cytoplasm and the nucleus. It seems that MDM2 shuttling is
related to the function it performsin the cell as a negative regulator of p53, because
interaction between both proteins in the nucleus leads to inhibition of p53
transactivation while export to the cytoplasm allows for ubiquitylation and
degradation of p53 to occur due to MDM2E3ligaseactivity (2,180).
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The central portion of MDM2contains an acidic domain located between
aa 237 — 300 which is involved in binding of a number of MDM?2-interacting
proteins including ARF, MTBP andribosomal protein L5 (151). Several reports
suggest that the acidic domain plays an important role in MDM2 mediated
ubiquitylation and thus influences subsequent degradation of p53. Deletion of the
acidic domain or binding of ARF to this region have been demonstrated to result in
inhibition ofMDM2 — mediated ubiquitylation of p53 (61,181,182).
There is a zinc finger localized next to the acidic domain, whilst a RING
finger domain, approximately 60 aa long, occupies the carboxyl terminal end of the
protein. The RINGfinger domain, whichalso contains a nucleolar localization signal
(NoLS) between aa 464 — 471, has been shownto be responsible for MDM2-MDM2
or MDM2-MDM<Xprotein assembly and also for the E3 ligase ubiquitin activity of
MDM2(19).
1.2.2 E3 ubiquitin ligase activity of MDM2
MDM2is a RING E3 ubiquitin ligase, this means that it can promote the
ubiquitylation process, which entails covalent attachment of one or multiple ubiquitin
moieties to the substrate protein and in so doing may decideits fate (64, 149). This
multi-step process begins with the activation of ubiquitin by an El activation enzyme
in cooperation with ATP, followed by ubiquitin transfer to an E2 ubiquitin
conjugating enzyme. The next step, ubiquitin attachment to the substrate, slightly
differs depending on the type of E3 ligase engaged in this process. RING (really
interesting new gene) type E3 ligases, such as MDM2, promote direct ubiquitin
transfer to a substrate protein, whereas E3 ligases with the HECT (homologous to
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E6-associated protein C terminus) domain first transfer ubiquitin to the HECT
domain and then to the substrate. As a result of ubiquitylation, the carboxy-terminal
end of ubiquitin (actually the absolute carboxy-terminal glycine residue) is
covalently linked to lysine residues of target proteins (149). Monoubiquitylation
usually leads to a change in localization or activity of target proteins, whereas
polyubiquitylation (attachment of at least four ubiquitins moieties) usually results in
proteosome dependent degradation of the substrate protein (149,183). MDM2is
capable of mediating both: mono- and polyubiquitylation via its RING finger domain
and it has been demonstrated that any disruption in the RING finger domain located
on C-terminal end of the protein affects the E3 ligase ubiquitin activity of MDM2
(64,151). A RING domain is generally characterized by the presence of multiple
conserved cysteines (usually with one [C3HC4] or a couple [C3H2C3] ofhistidines)
forming a structure capable of binding two zinc atoms (184). Mutational studies
performed on the RING domain of MDM2 (C2H2C4) have shown that deletion of
the RING domainor substitution of any cysteine residue results in abrogation of zinc
binding, causing loss of E3 ubiquitin ligase activity (64,84,184). Moreover, in order
to perform the function of an E3 ligase, it is necessary for MDM2 to form either a
homodimer or a heterodimer with the homologous protein MDMX and this also
depends on the RING domain(150).
MDM2,as an E3 ligase, has many specific substrates (151) with probably
the most important one being tumor suppressor p53 (81) (this relationship will be
discussed later in more details). In addition to promoting ubiquitylation of other
proteins, MDM2 can also mediate its own ubiquitylation leading to proteosomal
degradation (64). The ability of MDM2to promote ubiquitylation and degradation of
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p53 and itself can be affected by modifications of MDM2andalso by interactions
with different proteins, especially under stress conditions (100). One such exampleis
MDM2modification by the small ubiquitin-like modifier 1 (SUMO-1) mediated by
Ubc9 (E2 SUMO conjugating enzyme) (88). It seems that sumoylation of MDM2
prevents its self-degradation, while p53 ubiquitylation mediated by MDM2 is
enhanced. This process may be regulated partly by SUSP4, a SUMO-specific
protease whose expression is induced upon UV damage, and which has been shown
to reverse the effects of SUMO attachment to MDM2, causing p53 stabilization
(152). In addition to sumoylation, interaction of MDM2 with death-domain-
associated protein (Daxx) and the deubiquitylating enzyme HAUSP canalso alter
MDM2 E3 liagase activity (153). HAUSP has been shownpreviously to stabilize
MDM2by promoting its deubiquitylation (154), whereas Daxx not only enhances
HAUSP and MDM2interaction by binding to both proteins, but also augments p53
ubiquitylation mediated by MDM2. However, under stress condition such as DNA
damage, this complex formation is disrupted leading to Daxx dissociation followed
by increase in MDM2 degradation and this probably contributes to stabilization of
p53 (153). Enhanced degradation of p53 has been also observed upon MDM2
interaction with MTBP, while autoubiquitylation of MDM2 was diminished (57). In
addition, it has been shownthat interaction with MDMxX,a structural homologue to
MDM2,can also have stabilizing effect on MDM2, whilst interaction with ARF
has been shownto abrogate E3 ligase activity ofMDM2 towards p53 (176,177).
MDM2activity is also extensively regulated via phosphorylation, a
posttranslational modification mediated by protein kinases. The “ataxia telangiectasia
mutated” proteine kinase (ATM) has been reported to promote phosphorylation of
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MDM2at residue serine 395 resulting in reduced p53 degradation dueto failure of
nuclear export (89). Apart from phosphorylation by ATM, many different kinases
have been implicated in multisite phosphorylation of MDM2,at least in vitro, such
as: DNA activated protein kinase (DNA-PK), c-Abl protein tyrosine kinase,
phosphatidylinositol 3-kinase (PI3-K/Akt), cyclin A-dependent kinases 1 and 2
(cyclinA-Cdk1/2) (reviewed in 75). Generally speaking, phosphorylation of MDM2
seems to abrogate its interactions with p53. For example reducedability to form a
complex with p53 has been observed upon MDM2phosporylation by A-Cdk2 or
DNA-PK in response to genotoxic stress (90,91). However, PI3-K/Akt pathway
mediated phosphorylation of MDM2 on serine 168 and 186 residues seems to be
essential for MDM2translocation into the nucleus, which is necessary for MDM2’s
ability to interact with p53 andits function as a negative regulator of p53 (92).
Ubiquitylation is the most widely studied, however not the exclusive
modification promoted by MDM2 E3 ligase activity ascribed to the RING finger
domain of the protein. Another modification mediated by MDM2 is NEDDylation,
which is conjugation of a small, ubiqutin-like protein called NEDD8 (135). Similarly
to promoting self-ubiquitylation process, MDM2is capable of promoting its own
NEDDylation, howeverthe precise role of that modification has not been elucidated.
So far, only two other proteins have been reported to be modified by MDM2this
way: p53 and full-length (TA) p73. In both cases, transcriptional activity of targeted
proteins is inhibited by MDM2-mediated NEDDylation (135,136).
10
 Introduction
1.3 MDM2 and humancancer
Mdm2 is an oncogene that is activated by increased expression, and not
surprisingly, high levels of MDM2 have been observed in many different human
tumours. MDM2 overexpression and/or amplification have been reported in, among
others, soft tissue sarcomas (~30%) (32), gliomas (8 — 10%) (37), leukemias (~50%)
(38), breast carcinomas (~70%) (39, 76), and malignant melanomas (~70%) (40,
78). It has also been demonstrated that MDM2status can be a useful prognostic
factor in a wide range of tumours. For example, high levels of MDM2usually confer
worse prognosis in, among others, breast carcinoma (76), leukemia (77) and soft
tissue sarcoma (32) (reviewed in 73). However, in some cases there is a need for
further studies, since observations from the same cancer type may be in contradiction
indicating either worse or better prognosis as observed in case ofsoft tissue sarcoma,
where studies on one cohort of samples revealed worse prognosis for patients
expressing high levels of MDM2, while based on the other studies high levels of
MDM2conferred better prognosis for patients (32, 72).
In addition, it has been observed that high levels of both MDM2and p53
occur in soft tissue sarcomacells (32), bladder cancer (33), clear renal cell carcinoma
(34) and these patients have significantly worse prognosis than patients with only
high levels of either p53 or MDM2.
1.4 p53 —- MDM2interaction
p53 is one of the most important and widely studied tumor suppressor
genes, since p53 mutation is the most frequent genetic alteration in human cancer
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(24). p53 is a potent transcription factor for genes involvedin inhibition ofcell cycle
(i.e. p21 WAFI/CIP1, cyclin G) and blood vessel formation (angiogenesis) (1.e.
TSP1, BAI1), induction of apoptosis (i.e. BAX, GML), DNA replication and repair
(i.e. GADD45), and cellular stress response (i.e. TPS3TGI, CSR) (79). p53 is often
called the “guardian of the genome”, since its proper function seems to be
indispensable for maintaining cellular genetic stability (23). In normal, unstressed
cells p53 protein is maintained at a very low level. When a cell becomesstressed due
to, for example, DNA damageoractivation of oncogenes p53 is stabilized and thusit
can perform its functions (24).
The first report to describe the existence of a p53 - MDM2 complex was
published almost two decades ago where it was shown that MDM2inhibits p53
function as a transcription factor (5). Studies mapping the interacting regions
involved in formation of the MDM2 and p53 complex revealed that amino acids 25 —
109 on human MDM2and19 - 26 on p53 interact to form the complex. In addition,
it has been shownthat not only can MDM2regulate p53 activity, but also p53 can
regulate MDM2 by promoting its transcription via the P2 promoter, as discussed
earlier (26). Thus a negative autoregulatory feedback loop exists between p53 and
MDM2,whereactive p53 stimulates expression of MDM2 whichin turn targets p53
for proteasome — dependent degradation and therefore this results in decreased p53
transcriptional activity, which leads to reduced levels ofMDM2.
MDM2regulation of p53 is crucial during development. It has been
demonstrated that MDM2-null animals could not undergo normal embryogenesis
and died during the first week of gestation; however the absence of both p53 and
MDM2allows normal development, suggesting that MDM2is an essential negative
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regulator of p53 during embryo developmentin mice (27, 80).
MDM2 is a key negative regulator of p53 that acts by inhibiting
transcriptionalactivity of p53, but also by mediating ubiquitylation and proteasome-
dependent degradation of p53 (81, 137). As described earlier in this chapter, MDM2
has an E3 ligase activity located on its RING finger domain at the C — terminal end
and is capable of mediating both mono- and polyubiquitylation of p53. It has been
shown that the presence of p300 might be necessary for MDM2-mediated
polyubiquitylation of p53 leading to proteasome degradation (64,83,137). According
to early studies, proteasome degradation of p53 was exclusively ascribed to
cytoplasm, therefore MDM2-p53 nuclear export was considered to be indispensable
for efficient p53 degradation (82, 85). However, there is a growing body of evidence
suggesting that MDM2-mediated degradation of p53 can occurin the nucleusas well
as in the cytoplasm, thus the nuclear export is not an absolutely required step in this
process (86, 87).
Via its E3 ligase activity MDM2 also promotes NEDDylation of p53,
resulting in inhibition of its transcriptional activity (135). Recent findings have
revealed that ubiquitylation and NEDDylation mediated by MDM2, due to its E3
ligase activity, can be regulated independently of each other. One example comes
from the studies on Tip60, transcription cofactor and MDM2binding protein, which
is able to inhibit MDM2 mediated NEDDylation of p53, while MDM2ability to
promote p53 ubiquitylation seemsto be intact (138).
p53/MDM2 complex formation and function are regulated by several
mechanisms such as phosphorylation of either p53, MDM2orboth; acetylation of
p53; oligomerization of p53; and interactions with other proteins (75). In some cases
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p53 and MDM2are phosphorylated simultaneously by the same kinase (e.g. ATM)
resulting in stabilization and restoration of p53 function due to release from
inhibitory effect of MDM2-p53 complex (101). In addition, acetylation of p53 was
shownto affect the interaction of MDM2 with p53-responsive promoters, allowing
p53 to perform its transactivation function independently of its phospohorylation
status (176). It has also been shownthat oligomerization deficient p53 mutants have
reduced affinity for binding to MDM2, therefore p53 oligomerization seems to be
required for efficient binding to MDM2 and MDM2 mediated degradation (107).
1.5 p53 - independent function of MDM2
Oncogenic properties have been ascribed to MDM2 mainly onthe basis
ofits interaction with p53, wherein MDM2blocks p53 tumoursuppression functions.
However, a growing body of evidence supports the idea that MDM2 maycontribute
to cancer development through involvement in several cellular pathways in a p53-
independent manner (18). Most of the well defined examples of p53-independent
involvement ofMDM2in tumourigenesis are presented below:
- presence of high levels of both MDM2 (due to amplification/overexpression)
and p53 (due to mutation) in several types of cancer including: soft tissue
sarcomas and bladder cancers and confers worse prognosis (32,33); this
shows that overexpressed and/or amplified MDM2 and mutated p53 may
affect different pathways during carcinogenesis.
- overexpression of an MDM2transgene in p53 null mice resulted in a higher
rate of sarcomas in comparison to the incidence in p53 null mice (without
14
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MDM2transgene) (35); this study has provided in vivo evidence of MDM2-
p53 — independent oncogenic mechanism/s.
identification of around 40 different splice variants of MDM2 in tumours,
that in most cases lack the p53 binding domain (20, 21); since they are unable
to interact with p53, it is possible that they play p53-independentrole/s in the
cell. The example of the MDM2 — B variant, that has been shownto promote
cell growth and inhibit apoptosis in a p53 independent manner, andalso to
induce tumour formation in transgenic mice supports this suggestion (36).
overexpression of MDM2in epithelial cells of murine mammary gland led to
polyploidy in 30-45% of the cells and this was observed in both wild-type
and p53 null mice. This observation suggests that overexpressed MDM2
might be involvedin the initiation of DNA replication process (97).
interaction between MDM2 and Nbs! (Nijmegen breakage syndrome 1), a
component of a DNA double strand break repair complex (Mrel1-Rad50-
Nbs1), suggests MDM2 p53-independent involvement in regulation of
genomestability (175).
interaction of MDM2 with a numberof proteins involved in various cellular
processes such as: cell cycle, differentiation, DNA synthesis, ribosome
synthesis or transcription as shownin Figure 1.5.1 (18).
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Figure 1.5.1 Diagram of MDM2 interacting proteins (figure reproduced from
reference 2).
1.6 MDM2interactions with other proteins
Apart from interaction with p53, MDMz2has been shownto interact with
many others proteins involved in different pathways in a cell (Figure 1.5.1). These
proteins usually either regulate (e.g. plL9YARF, TSG101) or are regulated by MDM2
(e.g. E2F/DP1) or sometimesplay both functions(e.g. p53).
In addition to the MDM2interaction with p53 which has already been
described, for the purpose of this thesis I will describe, in more detail, MDM2
interactions with key cell cycle regulators such as: E2F/DP1 and retinoblastoma
protein (Rb), MDMX and interacting proteins discovered in our laboratory, such as:
MDM2 binding protein (MTBP), dihydrofolate reductase (DHFR) and DNA
polymerase€.
- E2F1/DP1, which exists as a heterodimer, is a transcription factor for genes
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involved in S-phase progression, whereas retinoblastoma protein (pRb), is a tumour
suppressor that negatively regulates cell cycle by binding to E2F transcription
factors. Upon phosphorylation of pRb, E2F1/DP1 is released and thus capable of
performing its function as a transcription factor, leading to cell cycle progression.
Interaction of MDM2 with pRb has been shown to inhibit its function as tumour
suppressor, resulting in cell cycle promotion (53). Direct binding of MDM2 to
E2F1/DP1 results in enhanced transcriptional activity and this effect is mediated
independently of pRb (and p53) (98,99). Moreover, MDM2 was shownto prevent
E2F1/DP1 degradation by binding to a domain engaged in E2F1/DP1 ubiquitylation,
thus stabilizing this protein (155). Therefore, interaction of MDM2 with both
E2F1/DP1 and/or pRB canlead to enhancedcell cycle progression (51,52,98,99).
- MDMX (aka MDM4)is structurally very similar to MDM2 based on observations
that MDMX contains a RING finger-like domain (but unlike MDM2 does not
possess E3 ligase activity), nucleolar localization signal (NoLS) within RING
domain and p53-binding domain at the amino-terminal end. Similarly to MDM2,
MDMxXhasbeen shownto interact with p53 and inhibit its transcriptional activity
(54), mostly by direct interaction. Studies performed using yeast two — hybrid system
and in vitro/in vivo binding assays have demonstrated that MDM2 and MDMX
interact with each other via their RING finger domains located at C — terminal end of
each protein. Co-expression of MDMX and MDM2in 293 cells resulted in
suppression of proteasome dependent degradation of MDM2, suggesting that
MDM<xXhasa stabilizing effect on MDM2(55).
Research performedin our laboratory using yeast — two hybrid screen has
revealed novel MDM2interacting proteins: MTBP and DNApolymerase € (56 — 59),
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whilst a proteomics-based approach led to the discovery of DHFR as a MDM2
binding protein (134).
DHERis a vital componentof the cell machinery involved in a numberof
important processes, including DNA synthesis. MDM2seemsto interact with DHFR
and this interaction results in monoubiquitylation of DHFR, which requires an intact
RING finger domain of MDM2. As a result of monoubiquitylation, the activity of
DHFRis inhibited by MDM2 in a dose dependent manner, while DHFRstability
remains undiminished. It should be noted that most of the experiments in these
studies were performed in a p53 null background and therefore this interaction may
be addedto the list of p53-independent functions of MDM2(134).
MTBPhas been shownto bind to MDM2region between 167 and 304 aa
by its carboxy-terminal 380 amino acids domain. It has been demonstrated that
MTBPhasthe ability to induce a p53 — independent G1 arrest and that, this effect
can be overcome by MDM2(56). Further studies on MTBPfunction have suggested
that it regulates the ubiquitin ligase activity of MDM2.It seems to enhance MDM2 —
mediated ubiquitylation and degradation of p53, but inhibits autoubiquitylation of
MDM2leading to MDM2stabilization (57).
DNApolymerase € is a DNA polymerase implicated in several essential
processesin the cell specifically replication, DNA repair and checkpointcontrol(29).
It has been shownthat the carboxyl — terminal region of DNA polymerase € catalytic
subunit is required for the interaction with the amino — terminal region of MDM2
(between aa 50 — 166) (58). Moreover, human MDM2expressed in insect cells as
well as in Escherichia coli has the ability to stimulate DNA polymerase € activity
and regions involved in protein interaction are indispensable for this stimulation (59).
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1.7 Eukaryotic DNA polymerases— general information
DNA polymerases are enzymesthat play a key role in processes that are
vital for cell survival and proliferation, such as DNA replication and repair.
Polymerases catalyse phosphoryl transfer reactions, and in order for the
polymerization reaction to occur cooperation with two metal ions (usually
magnesium-Mg”"), that stabilize the formation of phosphodiester bond between
3’hydroxyl (3’OH) group of the primer and incoming nucleotide as well as
conformational change of the enzymeitself are all necessary (29,164). Most DNA
polymerases have a specific conserved structure, which resembles a right hand with
palm, fingers and thumb, as presented in Figure 1.7.1. The catalytic site of the
enzymeis located on the “palm” and by movingthe “fingers” subdomainsform fist
shape whichcreates a binding space for a new nucleotide (29,165).
DNA polymerases can be distinguished partly by features such as
processivity and fidelity which vary significantly among different polymerases
(28,173). The latter defines the accuracy with which a polymerase adds nucleotides
based on template sequence, whilst processivity can be defined by the number of
nucleotides added by a DNA polymerase per interaction with the 3’OH-endofthe
primer (28). It seems that processivity might be correlated with the function that a
particular polymerase performsin the cell. For example, DNA repair polymerasesare
in general characterized by lower processivity than polymerases involved in
replication (28,174). In terms of fidelity, some polymerases possess intrinsic
exonuclease activity (3’— 5”), which allow them to correct their own mistakes by
excision ofan incorrect nuclotide and replacing it with a correct one (28).
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Figure 1.7.1 Structure of DNA polymerase. “Right hand”structure of bacteriofage
T7 DNApolymerase representing polymerases class A (A) and bacteriofage RB69
DNA polymerase representing class B DNA polymerases (B) with a dideoxy-
terminated primer-template DNA and an incoming base-paired dNTP (figure
reproduced from reference 42).
There are around 20 polymerases that have been described in eukaryotic
cells (including terminal transferase and telomerase) (reviewed in 29). Based on the
presence of conserved regions eukaryotic DNA polymerases can be divided into four
classes/families (6), Table 1.7.1 shows the organization of polymerasesinto classes
and their respective functions.
The general function of each class of polymerases can be described as
follows: class B consists of polymerases responsible mainly for replication, class X
consists of polymerases required for DNArepair, class Y gathers together translesion
synthesis polymerases (TLS) and class A includesreplicative (pol y mitochondrial
replication) and repair polymerases (8) (Table 1.7.1) (29). However, in most cases
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one polymerase maybe involved in more than one functional assignment within a
cell. One such example are B class polymerases, which are primarily involved in
DNAreplication, wherein DNA polymerase © initiates this process by synthesizing
primers on the leading as well as lagging strand and further DNA elongation as a
process that is taken over by DNA polymerases e€ and 4, respectively (42). Apart
from involvement in DNA synthesis, eukaryotic polymerases belonging to class B
can also take part in DNArepair, checkpoint control and telomere maintenance(29).
 
 
 
 
 
CLASS POLYMERASE FUNCTION
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B - DNAreplication
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Table 1.7.1 Classes of eukaryotic DNA polymerases.
1.8 Structure and biological function of DNA polymerse o
DNA polymerase belongs to class B of the DNA polymerase family
(6). It consists of a heterotetrameric complex that exhibits DNA polymerase activity
as well as RNA polymerase activity and has a unique ability to initiate DNA
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synthesis de novo. Compared to other polymerases involved in the replication
process, such as polymerase 6 and e, DNA polymerase « processivity is lower. In
addition, DNA polymerase & does not possess intrinsic 3’-5’ exonucleaseactivity,
thus the enzyme is not capable of correcting its own mistakes introduced during
DNA synthesis (28). The error rate of DNA polymerase a, however, can be
diminished via the extrinsic exonuclease activity of DNA polymerase 6 (166), and
the fidelity of DNA polymerase « also seems to be enhanced via interaction with
replication protein A (RPA) which seems to function partly to prevent DNA
polymerase from introducing incorrect nucleotide (69).
 
 
Organism
Sacharomyces Drosophila Mus Homo
Subunit cerevisiae melanogaster musculus sapiens
(102) (104) (9) (103)
Catalytic 167 182 180 180subunit
B subunit 79 73 68 68
» large 62 61 54 58
Ss&<= small 48 50 46 48        
Table 1.8.1 Molecular weights (kDa) of DNA polymerase @ in different
eukaryotic organisms.
DNA polymerase a is composed of four subunits and the molecular
weights of all four subunits vary slightly between different eukaryotic organisms
(examples are presented in Table 1.8.1) (29). Despite the small differences in
molecular weights, the functions ascribed to each particular subunit of DNA
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polymerase © seem to be the same in all eukaryotic organisms (29). Polymerase
enzymatic activity is localized within the largest subunit called the catalytic subunit
whilst the primase consists of the two smallest subunits of the complex. The fourth
subunit, called the B subunit, does not seem to have any enzymatic activity and most
likely has a regulatory andstructural role (7, 8, 71).
Catalytic
subunitwr
  
 
Primase
B subunits
subunita
Figure 1.8.1 Diagram of murine DNA polymerase & complex (based on
information provided by reference 9).
Asstated already DNA polymerase © is a multisubunit enzyme, therefore
in order to better understand its functioning and potential interactions with other
proteins and factors within cell, it is important to establish the order of assembly
and structure of the complex. Studies on interactions between subunits during their
assembly have been performed by co-expressing all components of the murine DNA
polymerase & complex in COS — 1 cells (9). All reported components of DNA
polymerase & complexes comprising either all four subunits, three subunits:
p180/p68/p54, or heterodimers of p180/p68 and p54/p46can betranslocated into the
nucleus. It should be noted however that for complexes consisting of three subunits:
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p68/p54/p46 or p180/p68/p46, specifically p68 and p46, respectively, remained in
the cytoplasm, whilst dimers p54/p46 and p180/p68 weretranslocated to the nucleus.
It has also been reported that nuclear localization sequences (NLS) are present on
both p180 and p54 subunit. According to these findings, it has been suggested that
p68 and p54 bind directly to the p180 subunit and that p46 binds to the complex via
p54 (Figure 1.8.1). Several regions present in the p54 (p58 in human, see Table
1.8.1) sequence have been shownto be involved in interactions with the smaller
primase subunit (30). Similar results were obtained for the B subunit, whichinteracts
with p180, but interacting regions are distributed throughout the protein (41).
p180, the catalytic subunit of DNA polymerase @ has been analysed in
more detail. Studies carried out on murine DNA polymerase o have revealed that the
catalytic subunit contains three domains as shown in Figure 1.8.2. The minimal
region required for DNA polymeraseactivity lies between aa 330 and 1279 and is
called the core domain, whilst both amino (1-329 aa) and carboxy-terminal (1280-
1465 aa) domains are dispensable for polymeraseactivity (9). With regard to subunit
assembly, only the carboxy-terminal domain of the catalytic subunit has been
described to be involved in interaction with p68 and p54 subunits. There are several
conserved regions within the catalytic subunit: six regions (from I to VI) seem to be
highly conserved among class B polymerases (prokaryotic and eukaryotic), and
another five regions (A-E) are conserved in eukaryotic DNA polymerases ©
(167,168). Highly conserved regions are located in different parts of a hand shape
structure (Figure1.7.1) and are involved in performing crucialactivities/functions of
the enzyme. For example,regionsI and II located on the palm subdomain, along with
region III on the fingers subdomain seem to be involved in deoxynucleotide
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triphosphate (dNTP) binding, whereas region V, located on the thumb,seemsto play
a role in DNAbinding and enzymeprocessivity (29, 164, 169).
1
329+ r
Amino terminal Core domain Carboxy] terminal
domain domain
 
 
Figure 1.8.2 Structure of murine DNA polymerase « catalytic subunit (p180).
Core domain harbours polymerase activity, while carboxyl terminal domain is
engaged in subunits assembly; Zn — zinc finger region, NLS — nuclear localization
signal (based on information provided by reference 9).
The main function of DNA polymerase a is DNA polymerization during
DNAreplication. The enzymatic activity of DNA polymerase @ is carried by the
largest, catalytic subunit, whereas the heterodimeric complex of the smallest subunits
of DNA polymerase & possesses primase activity and has a uniqueability to initiate
DNAsynthesis de novo (8). DNA polymerase a, due to its primase activity (DNA
directed RNA polymerase) is capable of synthesizing short (7 — 10 ribonucleotides)
RNAprimers on both leading and lagging strands (Okazaki fragments) during DNA
replication (10). Primase catalytic activity is localized entirely within the smallest
subunit, however the presence of the second subunit of the primase complex is
indispensable for its proper function and required for both primer initiation and
elongation (11).
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Figure 1.8.3 Assembly of the pre-replicative and pre-initiation complexes(figure
reproduced from reference 196).
In order to perform its catalytic functions during DNA synthesis DNA
polymerase « needs to be recruited to an origin of replication. However, several
events need to take place prior to enzyme loading (as shownin Figure 1.8.3), starting
with recognition of replication origin by origin recognition complex (ORC). ORC
serves as a binding platform for cell division cycle 6 (Cdc6) and chromatin
licensing/DNAreplication factor 1 (Cdt1) that are required for subsequent loading of
a minichromosome maintenance 2-7 proteins (MCM2-7), which completes the
formation of the pre-replicative complex (pre-RC) during the G1 phase ofthe cell
cycle (42). During the next step, S phase-promoting cyclin-dependent kinases
(CDKs) and Dbf4-dependent kinase (DDK) mediate recruitment of minichromosome
maintenance protein 10 (Mcm10), cell division cycle protein 45 (Cdce45), GINS,
Dpb11, Sld 2 and 3 proteins, forming the pre-initiation complex (pre-IC) (1 14). Upon
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transition to pre-IC the helicase activity of the CMG complex, consisting of Cdc45,
GINS and Mcm2-7, is triggered leading to origin DNA unwinding (125,126).
Replication protein A (RPA) is loaded onto single stranded DNA and along with
Cdc45 and Mcm10 recruits DNA polymerase ©, and this initiates DNA replication
by synthesizing oligomeric-ribonucleotide primers (119, 120). RNA primer synthesis
involves five major steps: initially DNA polymerase a binds to a template (single
stranded DNA) followed by binding of two nucleotide triphosphates (NTPs), first of
which is usually purine (12). During the next step NTPs are polymerized to create a
RNA primer of 7- 10 oligoribonucleotides in length. The mechanism involved in
primer nucleotide “counting” is still unclear, however it has been shownthat the
larger subunit of the primase complex mayplay role in this process (11). After a
RNAprimer of defined length is synthesized (typically c. 10 nuclotides), it is
transferred to the DNA polymerase active site where approximately 20 DNA
nucleotides are added (12). When the RNA/DNAprimer of approximately 30
nucleotides is synthesized on the leading strand, as well as on the lagging strand
(Okazaki fragments), DNA polymerase & seemsto be replaced by polymerases € and
6 respectively, in order to continue the process ofDNA synthesis (42).
Even though the main function of the DNA polymerase o complex is the
initiation of DNA synthesis during DNAreplication, it also seems to be involved in
cell cycle regulation (66,67), telomere maintenance (68) and epigenetic control
(156,160).
A few early reports suggested that primase subunits of DNA polymerase
a, in addition to being capable of RNA primersynthesis, may also be indispensable
for activation of the S/M checkpointof the cell cycle (66). It has been demonstrated
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that abrogation of primase activity, either due to inhibition or mutation results in
failure to induce Chk1 phosphorylation (66,163). This is important because Chk1, a
checkpoint kinase, becomes phoshorylated by ATR (ataxia telangiectasia mutated
and Rad3-related protein kinase) upon DNA damage (162).
There is a growing body of evidence suggesting that DNA polymerase a
is also involved in telomere maintenance. Telomerase is the main enzyme
responsible for synthesis of the leading strand (G-rich) at the end of chromosomes,
however complementary strand synthesis requires a different mechanism to be
engaged (159). DNA polymerase & seemsto contribute to this process by interacting
with proteins involved in telomere maintenance and also by synthesizing the C-rich
strand (lagging strand) of telomeric DNA (68, 156-8).
Results obtained from experiments performed with Sacharomyces
cerevisiae arrested in M phase, have suggested that CDC17 and Pri2 (yeast DNA
polymerase « and primase, respectively) are required not only for telomere lagging
strand synthesis, but also to coordinate telomerase mediated leading strand
duplication (68). These findings have been further supported by experiments with
CDC17 temperature-sensitive mutants showing that proper regulation of telomere
lengthening was disrupted upon CDC17 mutation (156). Moreover, an interaction
between the catalytic subunit of DNA polymerase a and telomere binding protein
Cdcl3p has been observed in yeast, which could explain how the DNA polymerase
might be recruited to telomeres (157). Apart from the catalytic subunit, the B subunit
(Poll2 in yeast) of DNA polymerase o has been described to interact with a protein
involved in telomere protection and length regulation known as Stnl (158).
Mutationsin either catalytic or B subunit of DNA polymerase & can cause abnormal
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telomere elongation, suggesting that this subunit of the enzyme also hasa role in
telomere maintenance (157,158).
Along with the role in telomere maintenance in yeast, a potential role for
DNA polymerase & in epigenetic control has been discovered (156). It has been
shownthat transcriptional silencing in telomeres as well as in centrosomes and the
mating-type region of fission and budding yeast was lost in CDC17 (yeastcatalytic
subunit of DNA polymerase 0) yeast mutants (156,160). Epigenetic control of gene
regulation by DNA polymerase & might be mediated by the enzymeinteraction with
Swi-6 chromodomainprotein, since localization of Swi-6 protein at silenced loci was
abrogated in DNA polymerase © mutants displaying silencing defects (160,161).
DNA polymerases play central roles in processes that control genome
integrity (DNA replication and repair and cell cycle checkpoint control) andit is
therefore not surprising that they are also implicated in cancer (170). In particular,
overexpression of specialized polymerases such as B, A and t has been found in
numberof cancer samples (105, 170). In addition, a greater than two — fold increase
in DNA polymerase a expression levels has been observed in tumourcells compared
to normaltissue (105). Since DNA polymerase o is an indicatorofcell proliferation,
it is unclear whether its overexpression is just a consequence or rather an
independentcause of carcinogenesis.
Additional studies, supporting a role for DNA polymerase a in cancer
development, have demonstrated that dehydroaltenusin, a specific inhibitor of DNA
polymerase © activity (originally obtained from fungus (A/ternaria tennuis)) seems
to have anti-tumourproperties. Growth of human cancercells in culture, as well as
proliferation of tumourcells in vivo have been shownto be inhibited upon addition
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of dehydroaltenusin, which appeared to interact with the catalytic subunit of DNA
polymerase a (106,172). Based on these studies, it is conceivable that
dehydroaltenusin maybethefirst of a new family of potential anti-cancer agents that
target DNA polymerases.
1.9 Regulation of DNA polymerase & activity
DNAreplication is one of the most important processes in a cell and
therefore needs tobetightly regulated at each step. The activity of DNA polymerase
a, the only enzyme capable of initiating DNA synthesis de novo, is controlled by
interactions with a numberofcellular proteins and factors. Some ofthe interactions
between DNA polymerase and proteins taking part in formation of pre-
replication/initiation complex and progression of the replication fork have already
been briefly described above and someofthese are described in more detail below
(42).
Minichromosome maintenance protein 10 (Mcm10)
After formation of the pre-replicative complex consisting of ORC, Cdc6,
Cdtl and Mcm2-7, Mcm10is recruited to the origin of replication (42). Mcm10 is
involved in loading of DNA polymerase « onto DNA along with cell division cycle
protein 45 (Cdc45) and replication protein A (RPA) (119, 120). Apart from the
physical interaction with DNA polymerase ot (43, 120), it has been demonstrated that
Mem10 canalso stimulate DNA polymerase © activity in vitro (43). Moreover,it has
been shownthat in the absence of Mcm10,the catalytic subunit of DNA polymerase
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a is destabilized and DNA synthesis is inhibited, whereas the absence of DNA
polymerase a only delays the replication (121,122). It seems that Mcm10 somehow
“recycles” DNA polymerase a activity and in addition it also contains primase
activity on its own (123).
leading
    CMG
lagging
Figure 1.9.1 Schematic representation of the replication fork
(figure reproduced from reference 125).
GINS(Go,Ichi, Nii, San-Japanese; five, one, two, three-English)
Even though it has been discovered only recently, the GINS protein complex
appears to be a vital factor in the DNA synthesis process. This protein complex is
highly conserved in eukaryotes, andis also present in archaea (118,124). The main
roles ascribed to GINSareinitiation and progression of DNAreplication (124,125).
It has been shown that in the presence of GINS, minichromosome maintenance
proteins (MCMs) can interact with cell-division cycle protein 45 (Cdc45) and
perform helicase function (125, 126). These proteins actually form a CMG (Cdc45-
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Mcm2-7-GINS) complex, that seems to be indispensable for progression of the
replication fork (125, 127, 128) (Figure 1.9.1).
The role of GINS in regulation of DNA polymerase « activity has been
studied in vitro, where it has been demonstrated that recombinant human GINS
(hGINS) complex can interact with primase subunits and stimulate polymerase
activity of DNA polymerase & (129). Despite physical interaction between GINS and
DNA polymerase a, GINS complex does not seem to be involved in loading of the
enzyme onto the chromatin. Curiously, inactivation of one of the four components of
the GINS complex has been shownto abolish DNA polymerase € loading, whereasit
does not affect the loading of DNA polymerase a (130), which is in accordance with
previous findings (119, 120).
Cell division cycle protein 45 (Cdc 45)
Studies carried out on budding yeast have demonstrated that Cdc45, by
interacting with minichromosome maintenance proteins (MCMs), takes part in
initiation of DNA replication (131). In addition, it has been shown that Cdc45
isolated from Xenopus egg extracts is responsible for loading the DNA polymerase &
complex onto chromatin, but this action also required the activity of cyclin-
dependent kinases (CDKs) engaged in S - phase (50). Furthermore, results from
experiments using human proteins have demonstarted that Cde45 can interact with
the p68 subunit of DNA polymerase « and Mcm7 protein, supporting above
mentionedfindings (49).
In the light of more recent results, loading of DNA polymerase © onto
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chromatin is not only dependent on Cdc45, protein but also on the action of Mcm10
and RPA (119, 120).
Replication protein A
Replication protein A (RPA)is a heterotrimeric protein, consisting of
subunits of approximately 70kDa, 30kDa and 14kDa (44). RPA bindsto single —
stranded DNA via its largest subunit. Using the simian virus 40 (SV40) model of
replication it has been demonstrated that RPA is required for the formation of the
primosomein which a complex containing T antigen and RPAis recognized by DNA
polymerase a. Binding occurs between primase subunits of DNA polymerase and
the 70kDa subunit of RPA andthis interaction seemsto be essential for initiation of
the replication process of SV40 (45).
In addition, the 70kDa subunit of RPA seems to stimulate DNA
polymerase © activity in vitro (46,132). This effect is mediated by a region of 327 aa
located at the amino-terminal end of the 70kDa subunit whilst a region between aa
169 and 327 has been shownto increase the processivity of DNA polymerase
(132). Moreover, RPA seemsto function as a “fidelity clamp” stabilizing the DNA
polymerase & complex, and since this enzyme does not have 3’-5’ exonuclease
activity this reduces the numberofmistakes introduced by DNA polymerase © (69).
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T antigen
T antigen is a helicase involved in DNA unwinding and together with
host proteins plays an important part in SV40 replication. Interaction between DNA
polymerase a and T antigen has been identified during studies on proteins
participating in a replication process with T antigen (47). It has been shownthat the
p180 subunit of DNA polymerase « is sufficient for complex formation with T
antigen (45) and that T antigen enhances enzymatic activity of DNA polymerase a
(48).
p53
Using Biomolecular Interaction Analysis (BIA) based on surface plasmon
resonance, it has been shown that p53 can form a complex with heterotetrameric
DNA polymerase @, as well as with a heterodimer composed of the two largest
subunits of DNA polymerase a. In order to determine the region of p53 that is
responsible for binding to DNA polymerase a, a series of p53 deletion mutants was
examined and this showed that the carboxy-terminal domain of p53 plays a role in
formingstable interactions with the enzyme. In addition, it has also been shownthat
p53 and T antigen compete for binding to DNA polymerase o (13).
Further studies performed on CEM cells confirmed the presence of p53 —
DNA polymerase & complex in human cells (14). Moreover, since p53 has been
described to have a 3’->5’ exonuclease activity, question arose whether this function
has an application with regards to the DNA polymerase a complex function. It has
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been shown that a p53-DNA polymerase « complex was able to cut unpaired 3’
nucleotides and elongate the strand. However, due to the low velocity of this
reaction, p53 activity has not been considered as an external proofreading
exonuclease for DNA polymerase (14).
Retinoblastoma protein (Rb)
Retinoblastoma protein (Rb) is a well known tumoursuppressorthat inhibits
cell cycle progression mainly via interactions with members of the E2F family of
transcription factors. The hypophosphorylated form of Rb is an active form of the
protein capable of performing its inhibitory functions, whereas the phosphorylated
form can no longer bind to E2F,thus allowing the cell cycle progression.It has been
described, based on immunoprecipitation experiments, that DNA polymerase @ can
form a complex with Rb in Raji cells (15). Rb interacts with the catalytic subunit of
heterotetrameric DNA polymerase a complex. Furthermore, phosphorylated form of
Rb has been shownto increase the rate of switching from RNA to DNA,stimulate
DNApolymerase © activity and enhanceits processivity (16).
In addition to protein-protein interactions, DNA polymerase @ activity can
also be regulated by phosphorylation as described below.
Phosphorylation of DNA polymerase & - primase
The activity of a number of components of replication machinery, including
DNA polymerase © are regulated by phosphorylation (109,110,111,112,114). The
DNA polymerase a heterotetrameric enzyme is phosphorylated only on its two
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biggest subunits — the catalytic subunit (p180 in mammals) (Thr174, Ser209, Thr219)
and structural B subunit (Serl41, Serl47, Ser152, Thr156) (109,116). Cyclins A and
E seem to play a key role in the phosphorylation of DNA polymerase a, and as
presented in Figure 1.9.2 their activity peaks reflect their involvement in progression
to particular phase during cell cycle (110,111,112,133).
Phosphorylation of DNA polymerase & has been described to occurin a cell
cycle-dependent manner (70, 71, 113). When the enzymeis actively engaged in the
DNA replication process it seems to be less phosphorylated i.e. during Gj/S
transition, whereas it is more phosphorylated in late S phase and also G2/M
transition (71, 116). It is noteworthy that the DNA polymerase o form active during
GI/S phase also seems to have higher affinity for single stranded DNA than the
“more” phosphorylated mitotic enzyme(71).
 
Cyclin E- Cyclin A- Cyclin B-
Cdk2 Cdk1/Cdk2 Cdk1
G1 phase S phase G2 phase M phase
Figure 1.9.2 Schematic representation of activity of selected cyclins during cell
cycle. Cyclin E-Cdk2 is involved in a progression from G1 to S phase, cyclin A-
Cdk1/2 is active mainly in S — phaseto ensure its completion and cyclin B — Cdk]
triggers M phase(figure reproduced from reference 133).
Moreover, DNA polymerase © activity seems to depend on whichparticular
cyclin has been involved in the modification (70, 116). As an illustration, initiation
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of SV40 replication seemsto be inhibited upon phosphorylation of DNA polymerase
o with cyclin A-Cdk2, but not with cyclin E-Cdk2 kinase (70, 115, 116, 117). More
importantly, it appeared that depending on the cyclin involved in phosphorylation
(either E or A), DNA polymerase o-primase can form two distinct subpopulations
which can be distinguished using two different antibodies (116). The
hypophosphorylated subpopulation associated with cyclin E-Cdk2 (and protein
phosphatase 2A-PP2A) appears in G;, whilst more phosphorylated subpopulation
associated with cyclin A—Cdk2 is present during S and G2 phase ofthe cell cycle
(116). Based on the visualization of the active DNA synthesis sites by BrdU staining,
colocalization and immunoprecipitation studies with MCM2 protein the
hypophosphorylated form of DNA polymerase o-primase is thought to be involved
in initiation of DNA replication on the leading strand, whereas phosphorylated
enzymeis engaged in primer synthesis on the lagging strand (116). It appeared that
different phospohorylation status of DNA polymerase has an effect on the activity
and function of the enzymeinthecell.
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AIMS OF THIS STUDY
After many years of research on MDM2,itis clear that the primary oncogenic
potential of this protein is mainly displayed via its ability to negatively regulate p53.
MDM2 binds to p53 and in doing so inhibits its transactivation function, and in
addition down-regulates p53 by promoting ubiquitylation and subsequent proteasome
dependent degradation. However, a growing body of evidence indicates that MDM2
in addition to functions related to p53 manifests p53-independet activities. Since
MDM2protein — protein interactions seem to play the most important role in
determining its activities, our research group has focused on identifying MDM2
binding partners and then studying the significance of such interactions for cell
function. During the course of studies on the relationship between MDM2 and DNA
polymerase € performed by membersof our research group, it was discovered that
MDM2co-purifies with DNA polymerase a, and this served as the basis for the
studies performed in this thesis. In order to further investigate the interaction
between MDM2 and DNApolymerase o, a key enzyme engaged in DNA synthesis,
wehave performed experiments to:
e determine whether MDM2 interacts directly with DNA polymerase
catalytic subunit (p180),
e map regions involvedin the interaction between MDM2andcatalytic subunit
of DNA polymerase o (p180) by performing in vitro binding assay and co -
immunoprecipitation experiments with MDM2deletion mutants,
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e study the effect of MDM2 on DNA polymerase & enzymatic activity in vitro
utilizing DNA polymerase assay (MDM2stimulates the enzymaticactivity of
DNA polymerase € and both polymerases are members of the B family of
polymerases),
e examine the ability of MDM2 E3 ligase activity to promote p180
modifications,
e examine MDM2 and DNA polymerase interactions in vivo taking into
account existence of two different subpopulations of DNA polymerase a
depending onits phosphorylationstatus.
Performing these experiments should allow us to gain insight into the
significance of the MDM2-—DNA polymerase a catalytic subunit (p180) interaction
in cells and begin to ask key questions regarding the potential contribution ofthis to
S-phase promotion, a candidate mechanism through which MDM2 might mediate
someofits p53—independent oncogeniceffects.
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CHAPTERI
MATERIALS AND METHODS
2.1 Plasmids and constructs
pQE32 Mdm2 encodes full length murine 6xHis-tagged MDM2; used for
expression and purification of protein from bacterial cells, pQE32 vector is
commercially available from Qiagen.
pQE30 amino (N-) terminal half of Mdm2 encodes approximately 246 amino
terminal amino acids of human 6xHis—tagged MDM2; used for expression and
purification of protein from bacterial cells, pQE30 vector is commercially available
from Qiagen.
pQE32 carboxy- (C-) terminal half of Mdm2 encodes approximately 252 carboxy-
terminal amino acids of human 6xHis—tagged MDM2; used for expression and
purification of protein from bacterial cells, pQE32 vector is commercially available
from Qiagen.
pQE31 A166Mdm2 encodes murine 6xHis-tagged MDM2 lacking 166 amino
terminal amino acids; used for expression and purification of protein from bacterial
cells, pQE31 vector is commercially available from Qiagen.
pQE31 p53 encodes full length human p53; used for expression and purification of
protein from bacterial cells, pQE31 vector is commercially available from Qiagen.
pBTBc601c encodes a 6xHis—tagged C-terminal variant of the apical domain of the
mycobacterial heat shock protein CPN60.1; used for expression and purification of
protein from bacterial cells, construct was kindly provided by Dr. Peter Tormay.
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pBlueBacHis2p180 encodes catalytic subunit of 6xHis—tagged human DNA
polymerase a; used for expression and purification of protein from insect cells,
pBlueBacHis?2baculovirus transfer vector is commercially available from Invitrogen.
pSK-BBV FL p180 encodesfull length of human p180 - catalytic subunit of DNA
polymerase a; used for in vitro transcription/translation under control of T7
promoter, derivative of pBluescript SKI+ (commercially available from Stratagene)
modified by Dr. Mark Boyd and Dr. Nikolina Vlatkovi¢.
pSK-BBV N-terminal half of p180 encodes approximately 800 amino terminal
amino acids of human p180- catalytic subunit of DNA polymerase a; used for in
vitro transcription/translation under control of T7 promoter, derivative of pBluescript
SKII+ (commercially available from Stratagene) modified by Dr. Mark Boyd and Dr.
Nikolina Vlatkovic.
pSK-BBV C-terminal half of p180 encodes approximately 700 carboxy-terminal
amino acids of human p180- catalytic subunit of DNA polymerase a; used for in
vitro transcription/translation under control of T7 promoter, derivative of pBluescript
SKII+ (commercially available from Stratagene) modified by Dr. Mark Boyd andDr.
Nikolina Vlatkovi¢.
pSK-BBV 65 encodes carboxy-terminal half of DNA polymerase € catalytic subunit;
used for in vitro transcription/translation under control of T7 promoter, derivative of
pBluescript SKII+ (commercially available from Stratagene) modified by Dr. Mark
Boyd and Dr. Nikolina Vlatkovic¢.
pBBV MDM2 encodes full length human MDM2; used for in vitro
transcription/translation undercontrol of T7 promoter; construct was kindly provided
by Dr. Dale Haines.
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pGEX2TK-GSTMdm2encodesfull length human Glutathione S-transferase (GST)
tagged MDM2; used for expression and purification of protein from bacterial cells,
pGEX2TK vector is commercially available from GE Healthcare.
pGEX-6P-1 GST encodes Glutathione S-transferase; used for expression and
purification of protein from bacterial cells, pGEX-6P-1 vector is commercially
available from GE Healthcare.
pCMVNeoBam Mdm?encodes full length human MDM2; used for expression in
mammalian cells, construct was kindly provided by Dr. Bert Vogelstein.
pCMVNeoBam A49 Mdm2 encodes human MDM2lacking of 49 amino terminal
amino acids; used for expression in mammaliancells.
pCMVNeoBam3 Cys464Ala Mdm2 encodes RING finger mutant of human
MDM2;used for expression in mammaliancells.
pCMVHA166, 205, 230, 280, 335 Mdm2 encode respectively, amino terminal 166,
205, 230, 280, 335 amino acids of human hemagglutinin (HA) tagged MDM2; used
for expression in mammalian cells, pCMVHA vector is commercially available from
Clontech.
pcDNA3 NEDD8 encodes full length human NEDD8; used for expression in
mammalian cells, construct was kindly provided by Dr. Dimitris Xirodimas.
pBluescript SK ~ His Ubiquitin encodes six human ubiquitins; used for expression
in mammaliancells.
His Ubiquitn mutant Lys29,48,63Arg construct was kindly provided by Dr. Sylvie
Urbe.
pBluescript SK ~ HA Ubiquitin encodes eight human ubiquitins; used for
expression in mammaliancells.
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pET32ap180 encodes full length human p180 — catalytic subunit; pET32a vectoris
commercially available from Novagen.
Cloning of pCMVHA A166 Mdm? which encodes human MDM2 lacking amino
terminal 166 aminoacids. Following primers were used to amplify the fragment from
pCMVNeoBam Mdm?template and introduce KpnIrestriction endonuclease site:
5’ Mdm2 KpnIprimer (MWG)— 5’gagaggtaccgagacagaagaaaattcagatgaa3’;
3’ Mdm2 KpnI primer (MWG) — 5’gagaggtaccctaggggaaataagttagcacaatc3’.
The amplified fragment wasligated into a pCR2.1-TOPOcloning vector (Invitrogen)
and sequenced (MWG)to check for mutations that may have been introduced by the
PCR. The correct Al66 Mdm2 fragment was then subcloned into pCMVHAvector
(Clontech) using KpnI restriction endonuclease (New England Biolabs Inc.),
construct has been used for expression in mammaliancells.
Subcloning of p180 — catalytic subunit of DNA polymerase @ into pCEP4 vector
(Invitrogen). The p180 fragment (without TAGs) was excised from pET32a p180
construct with KpnI and subcloned into KpnI site of pCEP4 vector, construct has
been used for expression in mammaliancells.
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2.2 Antibodies
Primary antibodies
- N-19 (Santa Cruz Biotechnology Inc.) is a goat polyclonal antibody against
DNApolymerase o that has been raised using a fragment of human DNA
polymerase © localized close to N — terminus of the enzyme. This antibody
wasused both: in western blotting and immunoprecipitation experiments.
- HP180-12 and SJK 132-20 (a kind gift from Professor Irene Dornreiter) are
mouse monoclonal antibodies against p180 (catalytic subunit of DNA
polymerase a). SJK 132-20 preferentially detects the phosphorylated form of
DNA polymerase a, whilst HP 180-12 exclusively binds to either non- or
hypophosphorylated form of DNA polymerase a.
- PRIM1 (Aviva Systems Biology) is rabbit polyclonal antibody against
primase 49kDa subunit that recognizes region of human PRIMI with an
internal ID of P26856.
- PRIM2 (Aviva Systems Biology) is rabbit polyclonal antibody against
primase 58kDa subunit that recognizes region of human PRIM2 with an
internal ID of $24607.
- Ab-1 (clone IF2, Oncogene) is a mouse monoclonal antibody against MDM2
that recognizes an epitope between aminoacids 26 and 169 of human MDM2
protein.
- Ab-6 (clone 5B10C, Oncogene) is a mouse monoclonal antibody against
MDM2that recognizes an epitope between amino acids 383 and 491 of
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human MDM?protein.
Ab-2 (clone 2A10, Oncogene) is a mouse monoclonal antibody against
MDM2that recognizes an epitope between amino acids 294 and 339 of
human MDM2?protein.
N-20 (Santa Cruz Biotechnology, Inc.) is a rabbit polyclonal antibody against
MDM2raised against a peptide mapping at the N-terminal of human MDM2.
C-18 (Santa Cruz Biotechnology,Inc.) is a rabbit polyclonal antibody against
MDM2raised against a peptide mapping at the C-terminal of human MDM2.
SMP14 (Santa Cruz Biotechnology, Inc.) is a mouse monoclonal antibody
against MDM122raised against amino acids 154 - 167 of human MDM2.
2433 (Abcam) is a rabbit polyclonal antibody against p53, raised against a
peptide corresponding to internal sequence amino acids 277-296 of human
p53.
16B12 (Clone HA.11, Covance Research Products) is a mouse monoclonal
antibody against hemagglutinin (HA) tag that was raised against the twelve
amino acid peptide CYPYDVPDYASL.
12CA5 (Roche) is a mouse monoclonal antibody against hemagglutinin
(HA) tag that recognizes the HA peptide sequence YPYDVPDYAderived
from the human influenza hemagglutinin protein.
E-18 (Santa Cruz Biotechnology, Inc.) is a goat polyclonal antibody against
dihydrofolate reductase (DHFR)raised against a peptide mapping within an
internal region of human DHFRprotein.
C-2 (Santa Cruz Biotechnology, Inc.) is a mouse monoclonal antibody
against actin that recognizes an epitope within the C-terminus of human
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actin. This antibody was primarily used to assess the total amountof protein
loaded onto SDS-PAGEgelin western blotting.
- Ab-1 (clone 200-193, Oncogene) is a mouse monoclonalantibody against B-
galactosidase that recognises bacterial B-galactosidase and fusion proteins
that contain the amino terminal 1020 aminoacids of fB-galactosidase. This
antibody was usedto assessthe efficiency of transfection of mammalian cells
by western blotting.
- Leu-16 (clone L27, Becton Dickinson) is a mouse monoclonal antibody
against CD20 used as an immunoglobulin isotype control in
immunoprecipitation experiments.
Unless stated otherwise, primary antibodies were used at the concentration of
3 pg /ml for detection of proteins by western blotting.
Secondary antibodies
- Anti-mouse IgG (Amersham/GE Healthcare Life Sciences) is a Horseradish
Peroxidase (HRP) Linked Species-Specific Whole Antibody (from sheep)
used at a dilution of 1:2500.
- Anti-goat IgG (Jackson Immunoresearch Laboratories Inc.) is a HRP-
conjugated AffiniPure Mouse Anti-Goat IgG (H+L), used at a dilution of
1:20000.
- Anti-rabbit IgG (Amersham/GE Healthcare Life Sciences) is a Horseradish
Peroxidase (HRP) Linked Species-Specific Whole Antibody (from donkey)
used at a dilution of 1:5000.
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2.3 Cell lines
H1299 (human non — small lung carcinomacell line, p53 — null) and Clone 9
of H1299 cells (H1299-9) which overexpresses MDM2 are grownroutinely in our
laboratory. Cells were maintained in RPMI 1640 (Sigma) medium supplemented
with 10% fetal bovine serum (FBS) (Sigma) at 37°C in a 95% air, 5% COn,
humidified cell incubator.
HEK (human embryonic kidney) 293 cells and HEK 293 T cells (express the
simian virus 40 (SV-40) Large T antigen) were maintained in DMEM HEPES
modification medium supplemented with 10% FBS and 2 mmol/L t-glutamine
(Sigma-Aldrich) at 37°C in a 95% air, 5% COz, humidified cell incubator.
The High Five™cell line (BTI — TN — 5B1 — 4) is derived from the
Trichoplusia ni (cabbage looper) ovarian cells. Cells were grown at 27°C in the
incubator, CO, exchangeis not required for insectcell culture. Cells were maintained
in EX — Cell 405 insect serum free medium (Sigma).
All cells were cultured as a monolayer using standard tissue culture
techniques.Insect cells were also grownin suspensionculture, prior and during virus
infection.
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2.3.1 Cell cultures techniques
All the work related to maintaining eukaryotic cells was performed in the
laminar flow cabinet understerile condition.
Mammalian cells were maintained in the media described in Cell line section
and passaged upon reaching 90 — 100% confluence.In the first step, after discarding
the growing medium, Dulbecco’s phosphate buffered salin (PBS-Dulbeccos) (Sigma)
was addedto cells to wash them and remove any traces of serum, whichis present in
the growing media and capable of inhibiting Trypsin-EDTAactivity. Following the
washing step, PBS was discarded and Trypsin-EDTA (Sigma) solution was added
and incubated for few minutes at 37°C to allow cell detachment from the flask
surface. After short incubation, equal volume of growing media was added to
neutralize trypsin and then according to future application, the required volume of
cells mixture was added to a new flask containing fresh growing media.
Insect cells were maintained in the medium described in Cell line section and
passaged upon reaching 80 - 90% confluence. Growing medium wasdiscarded and 8
ml of fresh media addedto the flask. In order to detach cells from flask surface, flask
was harshly tapped few times. Upon cells detachment, Iml of cell suspension was
transferred to new flask filled with 19 mlof fresh growing medium.
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2.3.2 Preparation of cryostocks
Buffers and reagents used
- Dimethyl] sulfoxide (DMSO)(Sigma)
- Fetal bovine serum (FBS) (Sigma)
- EX — Cell 405 insect serum free medium (Sigma)
Mammalian cells were harvested by trypsinization and centrifuged for 5
minutes at 1000g. Supernatant was discarded and pellet resuspendedin a solution of
10% DMSO in FBSto obtain cell concentration of 2x10°. Afterwards, 1ml ofthat
mixture was transferred into cryotubes (Fisher) and stored overnight at —80°C,
followed bytransferinto liquid nitrogen tank.
In order to start growing frozen mammaliancells, they need to be thawed at 37°C
followed by resuspention in 24 ml of appropriate growing medium andtransfer into
appropriate flask.
Insect cells (High five™) were harvested at ~80% confluence by tapping the
flask containing cells growing in a monolayer and centrifuged for 5 minutes at
1000g. Supernatant was discarded and pellet resuspended in a solution of 10%
DMSOin EX — Cell 405 medium. Afterwards, Iml of that mixture was transferred
into cryotubes (Fisher) and stored overnight at —80°C, followed by transfer into
liquid nitrogen tank.
In order to start growing frozen insect cells (High five™), they need to be rapidly
thawed at 37°C, followed by resuspension in 30 ml of EX — Cell 405 medium and
centrifugation for 5 minutes at 1000g. After discarding the supernatant, cell pellet
was resuspended in 20 ml of EX — Cell 405 mediumandtransferred intoflask.
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2.4 Transfection of mammaliancells
Transfection refers to delivery of exogenous DNA into mammaliancells.
Buffers and reagents used
- GeneJuice ® Transfection Reagent (Novagen)
- RPMI 1640 medium (Sigma)
H1299 cells were transfected using GeneJuice with a ratio of GeneJuice to
DNA at 3 pl to 1 pg respectively, according to the manufacturer’s protocol. Cells
were at about 50% confluence at the time of transfection. GeneJuice was added to
serum free RPMI 1640 medium, vortexed and left for 5 minutes at room temperature.
DNA was added to GeneJuice — serum free medium, mixed by tapping the tube and
incubated for 15 minutes at room temperature. After incubation, GeneJuice - DNA
mixture was added drop-wise tothe cells.
2.5 siRNAtransfection of mammaliancells
Buffers and reagents used:
- Lipofectamine ™ 2000(Invitrogen)
- Opti - MEM@®I reduced - serum medium(Invitrogen)
- siRNAs (Dharmacon) for MDM2:
- MDM2#1 (5'GCCACAAAUCUGAUAGUA)
- scrambled siRNA (5'GGACGCAUCCUUCUUAAU)
siRNA transfection was performed on H1299 and H1299-9 cells using
Lipofectamine '™ 2000 according to the manufacturer's instructions.
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For a typical transfection of cells in 10 cm dishes, cells were plated one day before
transfection to reach confluency of 30 — 50% at the time of tranfection. For each
sample oligomer — Lipofectamine’ 2000 complexes were prepared as follows: 250
pmol of siRNA was diluted in 800 pl Opti-MEM® I reduced - serum medium,
mixed by vortexing and incubated for 5 min at room temperature. The
Lipofectamine’™ 2000, 16 pl per 10 cm dish, wasalso diluted in 800 pl Opti-MEM®
I reduced - serum medium, mixed by vortexing and incubated for 5 min at room
temperature. After that incubation time, diluted siRNA and Lipofectamine™ 2000
were combined, mixed gently and incubated for another 20 min at room temperature.
siRNA- Lipofectamine’™ 2000 complexes were then added drop-wise to each 10 cm
dish containing cells and 6.4 ml of growth medium. Content of each dish was mixed
by rocking the plate back and forth. The final concentration of siRNA was 40nM.
Medium in plates was changed after 6 hours. Twenty four hours after transfection
cells from each 10 cm dish were split into two dishes, and harvested by
trypsynization after another 24 h.
2.6 Bradford assay
Estimation of protein concentration in cell lysates was performed using
Bradford assay based on an absorbance shift in the dye - Coomasie Brilliant Blue G—
250 upon bindingto proteins.
51
 Buffers and reagents used
Stuart Linn Immunoprecipitation Buffer (SLIP buffer)
50mM HEPES(pH7.5) (Calbiochem)
150mM Sodium chloride (NaCl) (VWR)
10% Glycerol (Sigma)
0.1% Triton X-100 (Sigma)
Protein sample buffer
0.25M Tris (pH 6.8) (Calbiochem)
8% Sodium dodecyl sulphate (SDS) (VWR)
40% Glycerol (Sigma)
4mg/ml BromophenolBlue (Sigma)
1% B-Mercaptoethanol (Sigma)
- Aprotinin (A) (2 pg/ml) (Roche)
- Leupeptin (L) (0.5 pg/ml) (Roche)
- Pepstatin (P) (1 pg/ml) (Roche)
- Soybean Trypsin Inhibitor (STI) (100 pg/ml) (Roche)
- Phenylmethylsulphony] fluoride (PMSF) (1mM)(Fluka)
- Protein assay dye reagent concentrate (Biorad)
- Bovine serum albumin (BSA) (Fluka)
Materials and methods
In orderto estimate protein concentration in samplescell pellets were lysed onice in
SLIP buffer supplemented with protease inhibitors: aprotinin, leupeptin, pepstatin,
soybean trypsin inhibitor and phenylmethylsulphonyl fluoride at the concentrations
stated above. After 10 minutes incubation lysates were centrifuged at 16000xg at 4°C
for 10 minutes and then supernatants transferred to clean tubes kept on ice. From
each tube 2 pl of supernatant was taken and added to 1 ml of protein assay dye
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reagent (diluted 1:5 with water), followed by measurement of absorbance at 595nm
in spectrophotometer. The spectrophotometer waspreviously calibrated using 2 pl of
protein standards in | ml of protein assay dye reagent (diluted 1:5 with water).
Protein standards were prepared by mixing BSA with | ml of SLIP buffer to obtain
protein concentration of 20, 10, 5, 2.5, 1.25, 0.6, 0.3 mg/ml. Protein concentration in
samples was estimated based on comparison with standard curve of BSA with known
concentrations ranging from 0.3 to 20 mg/ml. Based on protein concentration
estimated for samples, usually 50 pg of total protein in 20 pl volume of sample
buffer was prepared for further analysis by SDS-PAGEfollowed by western blotting.
2.7 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE is a commonly used technique, which enables separation of
proteins on the gel accordingto their molecularsize.
Buffers and reagents used
 
     
SDS-PAGE SDS-PAGEComponent resolving gel staddue eel10% B65
H20 4.8 ml 7.225 ml
40% acrylamide mix(VWR) 2.5 ml 1.275 ml
1.5M Tris (pH 8.8) _(Calbiochem) Zone
1 M Tris (pH 6.8) - 1.25 ml
10% SDS (VWR) 0.1 ml 0.1 ml
10% Ammonium
peroxosulfate (BDH) ok tal oc. mm
10% N,N,N',N'-
tetramethylethylenediamine 0.008 ml 0.010 ml(TEMED)
Table 2.7.1 Components of SDS-PAGEgels.
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Tris-Glycine electrophoresis buffer (running buffer)
- 25mM Tris (Calbiochem)
- 250mM Glycine (Fisher)
- 0.1% SDS (VWR)
- Prestained protein marker, broad range (7-175 kDa) (NEB)
SDS-PAGE was performed using Mini-PROTEAN®-3 system supplied by
Bio-Rad. Amount of acrylamide, thus the percentage of resolving gel may vary
depending on thesize of proteins to be analyzed (list of components for 10% gel is
presented in Table 2.7.1), while stacking gel is always prepared with the same
amount of acrylamide mix. Resolving gel was poured into glass cassette sandwich
and allowed to polymerize, followed by pouring of stacking gel on the top and
placing comb to create wells. After polymerization of stacking gel comb was
removed and glass cassette placed in the tank filled with running buffer. Protein
samples were boiled for a few minutes to allow protein denaturation and loaded on
the gel, alongside with pre-stained protein markeras a size standard. Typically, a gel
wasrun in a tankfilled with running buffer for approximately 1 hourat 200 V.
2.7.1 Brilliant Blue G staining of polyacrylamidegel
After performing SDS-PAGEit is possible to visualize protein bands being
present on the gel by staining with Coomasie Brilliant Blue G dye. Moreover, the
staining enables to estimate the amount of analyzed protein when compared to the
knownprotein amount on the samegel.
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Buffers and reagent used
- Fixing solution (Sigma)
- Brilliant Blue G Colloidal Concentrate (Sigma)
After running, the gel was taken out from the glass cassette and placed for 30
minutes in a fixing solution to fix proteins on the gel prior staining with Brilliant
Blue G dye. Followingthis, gel was placed in the dye and incubated for few hours in
order to visualize protein bands on the gel, then to minimize the background gel was
washed few times with water.
2.7.2 Western blotting
Western blotting is a immuno-technique which allows to identify specific
proteins resolved by SDS-PAGEandtransferred onto membrane.
Buffers and reagents used
Transfer buffer
- 25mMTris (Calbiochem)
- 192mM Glycine (Fisher)
- 20% Methanol (BDH)
PBS/Tween
- 0.065M Na2HPO, (Sigma)
- 0.015M NaH2PO,4xH20 (Sigma)
- 0.075 NaCl (VWR)
- 0.1% Tween 20 (Sigma)
- Ponceau S (Sigma)
- Non-fat dry milk (Bio-Rad)
- Western lightning chemiluminescencereagent plus (Perkin Elmer)
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The Mini trans-blot® electrophoretic transfer system (Bio-Rad) was used to
transfer proteins from gel onto membrane. After resolving the samples, gel was
placed on the Hybond ECLnitrocellulose membrane (GE Healthcare) in the cassette
between sponges and Whatmanpaper. Followingthis, the cassette along with an ice
pack (used to provide cooling during the transfer) was put in the tank filled with
transfer buffer and transfer run for | hour at 100V. Afterwards, to check whether
protein transfer was equal, membrane was stained with Ponceau S for 1 minute
followed by several washes in water. Stained membrane was cut according to the
size of proteins of interest with reference to the protein size marker. Followingthis,
the membrane was completely destained with PBS/Tweenand put in a 5% solution
of non-fat dry milk in PBS/Tweenfor at least one hourin order to block nonspecific
antibody binding to the membrane. After blocking, specific primary antibody was
applied on the membrane, usually at the concentration of 3 pg/ml in 5% non-fat dry
milk/PBS/Tween, and incubated for 1 hour with agitation. Afterwards, membrane
was washed 3 times for 10 minutes in PBS/Tween and secondary antibody
conjugated to horseradish peroxidase (HRP) applied on the membrane(e.g. at the
dilution of 1:2500 for anti-mouse antibody in 5% non-fat dry milk in PBS/Tween)
for 1 hour incubation with agitation. The membrane was washed 3 times for 10
minutes in PBS/Tween after incubation with secondary antibody. To visualize
presence of specific proteins on the membrane after probing with primary and
secondary HRP-conjugated antibody chemiluminescence reagent was used (ECL
reagent). Following 1 min incubation with Western Lightning Chemiluminescence
Plus ECL reagent, the membrane was either put in a cassette with the film or a
Kodak IM4000 imagestation was used to detect luminescencesignal.
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2.8 In vitro binding assay
In vitro binding assay is a method which allows identification of direct
interaction between twoproteins (one of whichis usually radiolabeled).
In vitro binding assay was performed using 6xHis-tagged MDM2boundto Ni-
NTA (nickel- nitrilotriacetic acid) agarose beads and in vitro translated (IVT),
radiolabeled DNA polymerase o (catalytic subunit), as shown in Table 2.8.1. As a
negative control 6xHis-tagged 23kDa fragment of the mycobacterial heat shock
protein CPN60.1 (kindly provided by Dr. Peter Tormay) was used.
 
6xHlis— tagged proteins In vitro translated pol a
 
 
 
(p180)
pola full length
Mouse MDM2 pol a N-terminal halffull length
pol a C-terminal half
pol o full length
Human MDM2 pol a N-terminalhalf
N-terminal half pol a C-terminal half
pol a full length
 Human MDM2 pol a N-terminalhalfC-terminal half
pol a C-terminalhalf
 
 
 
pol a full length
Mouse MDM2 pol a N-terminalhalfA166
pol a C-terminal half
pol a full length
CPN60.1 pol a N-terminal half
pol a C-terminal half   
Table 2.8.1 Jn vitro binding assay pairingstested.
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2.8.1.1 Purification of 6xHis—tagged MDM2
Buffers and reagents used:
Buffer B, pH 8.0
- 8M Urea (BDH)
- 100mM NaHPO, (Sigma)
- 10mM Tris (Calbiochem)
Buffer C, pH 6.3 and 6.8
- 8M Urea (BDH)
- 100mM NaHPO, (Sigma)
- 10mM Tris (Calbiochem)
Buffer D, pH 5.9 and 6.4
- 8M Urea (BDH)
- 100mM NaH,PO, (Sigma)
- 10mM Tris (Calbiochem)
Buffer E, pH 4.5 and 5.0
- 8M Urea (BDH)
- 100mM NaH>PO,(Sigma)
- 10mM Tris (Calbiochem)
Protein sample buffer
- 0.25M Tris (pH 6.8) (Calbiochem)
- 8% Sodium dodecyl sulphate (SDS) (VWR)
- 40% Glycerol (Sigma)
- 4mg/ml Bromophenol Blue (Sigma)
- 1% B-Mercaptoethanol (Sigma)
Materials and methods
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- Luria Bertani (LB) (Sigma)
- Ampicillin sodium salt (Sigma)
- Isopropyl — B — D -thiogalactopyranoside (IPTG) (VWR)
- L- Arabinose (VWR)
- Nickel-nitrilotriacetic acid (Ni — NTA) agarose beads (Qiagen)
Preparation of 6xHis—tagged proteins was performed according to QIAGEN
manufacturer’s The QIAexpressionist/™ handbook.
Optimization of purification conditions
Prior to large scale purification, described below, small scale purification was
performedin order to establish optimal conditions in terms of expression time course
and also the pH value of buffers used.
1) Determination of optimal induction time for 6xHis-tagged MDM2
3 ml of Luria Bertani (LB) medium (containing appropriate antibiotic) was
inoculated with 3 pl of glycerol stocks of bacterial cells harbouring expression
construct (with gene ofinterest) introduced by transformation. Cultures were grown
overnight at 37°C, with shaking at 225 rpm in bacteria incubator. Next day, 1 ml
from the night culture was inoculated into 9 ml of LB and grownin the incubator
until the culture has reached an OD600 (optical density at 600 nm) of 0.7 — 0.9. At
this point, 1 ml of that bacterial culture was taken to serve as a non-induced control,
followed by centrifugation at 15000g for 5 minutes, resuspension in 200 pl of buffer
B and finally addition of 66 pl of 4x sample buffer. In order to induce protein
expression, IPTG was added to the remaining bacterial culture to a final
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concentration of 2mM. Sample volume of Iml was collected 1, 2, 4, 6 and 8 hours
after the addition of IPTG and processed as described for non-induced control. All
samples were analyzed by SDS — PAGEfollowed by western blotting.
2) Optimization of wash buffer pH value for purification of 6xHis-tagged
MDM2
Cultures were grown and protein expression induced as described above. Post
induction cultures were incubated for 4 hours at 37°C, with shaking at 225 rpm in a
bacteria incubator. Afterwards, cells were harvested by centrifugation at 4°C for 4
minutes at 3800g, pellets were resuspended in 2 ml of buffer B and lysates were then
boiled for around 7 minutes to ensure propercell lysis. In order to removecellular
debris lysates were centrifuged for 6 minutes at 3800 g. Afterwards, supernatants
were transferred into fresh tubes and - 500 pl of a 50% Ni — NTAagarose beads
slurry was added to each tube and incubated for 2 hours on a nutator at 4°C. After
incubation the whole content of the tube was applied to Poly — Prep Chromatography
Columns (Bio — Rad) and flow through wascollected. In addition, to make sure that
all of the beads were collected, walls of the tubes were washed with 2ml of buffer B
and applied to the Bio - Rad columns. Columns were then washed with 5 x 500 pl of
each of the buffers with two different values of pH as follows: buffer C pH 6.3 and
6.8, buffer D pH 5.9 and 6.4, buffer E 4.5 and 5.0 and each fraction (~500 pl) was
collected. In order to test the amount ofprotein left on the beads after wash/elution
with buffer E - 30 ul of beads was taken from each column and resuspendedin 60 pl
of 1x sample buffer. Each fraction was subject to SDS-PAGE and western blot
analysis.
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Large scale 6xHis-tagged protein purification
100 wl of the glycerol stocks of bacterial cells harbouring expression
construct (with gene of interest) introduced by transformation was inoculated into
100 ml of autoclaved LB media containing appropriate antibiotic and this culture was
grown overnight at 37°C shaking in the incubator. The next day 100ml of the
overnight culture was inoculated into 900 ml of autoclaved LB media containing
antibiotic, grown at 37°C in the incubator with shaking until OD600 was between 0.7
— 0.9 and to induce protein expression, IPTG was addedto a final concentration of
2mM to MDM?cultures. CPN60.1 expression was induced by adding L - arabinose
to a final concentration of 0.04%. After 4 hours incubation cells from each culture
were harvested by centrifugation for 5 minutes, at 3000 rpm at 4° C. After
centrifugation supernatant was discarded andpellets stored at — 80° C overnight. The
next day pellets were resuspended in 80 ml of buffer B (80 ml of buffer B per one
day culture), lysates were transferred into 50 ml Corning tubes and boiled for 5 — 10
min. After cooling down for a few minutes, lysates were transferred into tubes
suitable for centrifugation in Sorvall SS — 34 rotor and centrifuged for 30 minutes at
15000 rpm at 15° C. Supernatants were transferred into fresh 50 ml Corning tubes
and Ni — NTA agarose beads were added (1 ml of 50% slurry per day culture) and
incubated for 1 hour at 4° C on the nutator. After incubation tubes were placed at
room temperature to allow settling down of the beads (for approximately | hour).
Supernatants were removed (without disturbing beads pellets) and beads were
resuspended in 10 ml of buffer B andagainleft for 1 hour to allow for settling down
of the beads. After this supernatants were removed, beads resuspended in 10 ml of
buffer B and applied to the Poly — Prep Chromatography Columnsthat were pre —
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washed with H,O. To make sure that all of the beads were collected, walls of the
tubes were washed with 10 ml of buffer B and this was also applied to the column.
Columns were then washed with 10 ml of buffer B, 15 ml of buffer C (pH 6.8) and
15 ml of buffer D (pH 6.4). Based on results from the small scale test purifications
we determined that majority of the protein come off in washes with buffer E.
Therefore, in order to have protein bound to the beads, washes were stoppedafter
buffer D, columns were blocked, beads resuspended in buffer B (~0.5 ml per column,
to obtain 50% slurry) andstored at 4° C for futureuse.
2.8.1.2 In vitro transcription/translation of proteins
Buffers and reagents used:
- TNTT7 Coupled Reticulocyte Lysate System (Promega)(see Table 4)
- [°°S] methionine (TRAN35S-Label™ ; MP Biomedicals,Inc.)
- RNasin® Ribonuclease Inhibitor (Promega)
In vitro protein synthesis was performed using TNT® T7 Coupled
Reticulocyte Lysate System (Promega), which is a cell free system allowing for
coupled transcripition/translation using phage T7 RNA polymerase and DNA
template with the gene of interest cloned downstream from T7 RNA polymerase
promoter e.g. in pSK-BBV vector (described in Plasmids and constructs section).
Example of a typical TNT® T7 Coupled Reticulocyte Lysate System reaction using
[°°S] methionine, according to Promega Technical Bulletin Part# TB126, has been
presented below (Table 2.8.2).
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: Component Volume
TNT Rabe Reticulocyte 25 ul
ysate
TNT. Reaction Buffer 2 pl
TNT. T7 RNA Polymerase 1 ul
Amino Acid Mixture, Minus Lu
Methionine (1mM) B
[°°S] Methionine (10mCi/ml) 4ul
RNasin® Ribonuclease ulInhibitor (40 U/l) B
DNAtemplate (1 pg)
(gene ofinterest cloned into
pSK-BBVvector)
Nuclease-free H2O
Final volume 50 pl  
Table 2.8.2 Componentsof in vitro transcription/translation reaction TNT® T7
Coupled Reticulocyte Lysate System (Promega). RNasin® Ribonuclease Inhibitor
was supplied separately in order to create a ribonuclease — free environment; [Ss]
methionine was addedto the reaction to allow subsequent radioactive detection of in
vitro synthesized protein.
The reaction mixture of the final volume of 50 ul was incubated at 30°C for 90
minutes, after incubation when neededstored in - 80°C forthe future use.
2.8.2 In vitro binding assay
Buffers and reagents used:
Buffer B, pH 8.0
- 8M Urea (BDH)
- 100mM NaHPO,(Sigma)
- 10mM Tris (Calbiochem)
Dignam buffer
- 20mM HEPES(Calbiochem)
- 20% Glycerol (Sigma)
- 0.1M Potassium chloride (KCl) (VWR)
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0.25M Tris (pH 6.8) (Calbiochem)
8% SDS (VWR)
40% Glycerol (Sigma)
4mg/m1 BromophenolBlue (Sigma)
1% B-Mercaptoethanol (Sigma)
Fixing solution
HO:isopropanol: glacial acetic acid (65:25:10) (VWR)
- Aprotinin (A) (2 pg/ml) (Roche)
- Leupeptin (L) (0.5 ug/ml) (Roche)
- Pepstatin (P) (1 pg/ml) (Roche)
- Soybean Trypsin Inhibitor (STD) (100 pg/ml) (Roche)
- Phenylmethylsulphonyl!fluoride (PMSF) (0.5mM)(Fluka)
- DL dithiothreitol (DTT) (0.5mM)( Sigma)
- Imidazole (VWR)
- Amplify™ Fluorographic Reagent (Amersham)
- Kodak GBX Developer and Fixer (Sigma)
Materials and methods
In order to perform in vitro binding assay purified 6xHis—tagged proteins
bound to Ni-NTA agarose beads and in vitro synthesized radiolabeled proteins were
mixed as shownin Table 2.8.1.
Priorto starting the in vitro binding assay incubation, 6xHis-tagged proteins boundto
the Ni-NTA beads which were kept in denaturated form in 8M urea buffer B, were
renatured using serial dilution of 8M buffer B in Dignam buffer (starting with 4M
and finishing with 0.06M)in the presenceofprotease inhibitors aprotonin, pepstatin,
leupeptin, soybean trypsin inhibitor, phenylmethylsulphonyl fluoride and DL
dithiothreitol. After washes with buffer B in Dignam buffer, 6xHis-tagged proteins
bound to Ni-NTA beads were resuspended in Dignam buffer with protease inhibitors
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to obtain 50% beadsslurry - ready to usein the assay.
Afterwards, 100 pl of 50% slurry of 6xHis — tagged proteins bound to Ni-NTA beads
was mixed with 10 ul of in vitro translated, radiolabeled proteins in 5 ml propylene
tubes and incubated at 30° C for three hours, with shaking at 220 rpm. After
incubation, contents of the tubes were transferred to 1.5 ml Eppendorf tubes and
washed 4 times with 0.5 ml Dignam buffer (containing PMSF and DTT)
supplemented with 75 mM imidazole. Beads were then resuspended in 30 pl of 1x
sample buffer and run on the polyacrylamide gel, followed by gel fixing in H2O:
isopropanol: glacial acetic acid (65:25:10) solution for 30 minutes on shaking
platform. Afterwards, gel was incubated with Amplify™ Fluorographic Reagentfor
another 30 minutes on a shaking platform followed by drying for 1 hour at 60° (flat
cycle; Gel dryer model 543, BIORAD). The dried gel was exposed to X — ray film
(FujiFilm RX NIF sheets 180mm x 240mm (Fisher)) in a cassette at —80°C and
developed using Kodak GBX Developer and Fixerin the darkroom.
2.9 p180 production and purification from the insectcells
Buffers and reagents used:
SLIP Buffer
- 50mM HEPES(pH 7.5) (Calbiochem)
- 150mM Sodium chloride (NaCl) (VWR)
- 10% Glycerol (Sigma)
- 0.1% Triton X-100 (Sigma)
- EX — cell 405 Insect Serum Free Medium (Sigma)
- Aprotinin (A) (2 pg/ml) (Roche)
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- Leupeptin (L) (0.5 ug/ml) (Roche)
- Pepstatin (P) (1 ug/ml) (Roche)
- Soybean Trypsin Inhibitor (STI) (100 pg/ml) (Roche)
- B — mercaptoethanol (Sigma)
- Ni— NTAagarose beads (Qiagen)
- Imidazole (VWR)
- Brilliant Blue G-colloidal concentrate (Sigma)
Three 60 ml High Five cells suspension cultures (in 250ml flasks) were
infected with pBlueBacHis2p180 (multiplicity of infection (MOJ) 1 or conferring 1)
at 1x10° cells per milliliter cell density and incubated with a spin rate of 180 rpm for
96 hours at 27°C. Following this, cells were harvested by centrifugation andpellets
resuspended in 30 ml of SLIP buffer, containing protease inhibitors (A, L, P, STT)
and 20 mM of $B — mercaptoethanol. After 30 minutes lysis on ice, lystes were
clarified by centrifugation at 4° C for 15 minutes at 10500 rpm in Sorvall SS — 34
rotor. Supernatants were transferred into fresh tubes and 2 ml of 50% Ni —- NTA
slurry was added (prior use beads were washed 3 times with SLIP buffer).
Supernatant with Ni-NTA beads wasincubated for 90 minutes at 4°C on thenutator.
Afterwards, mixture was passed through the Poly — Prep Chromatography Column
(Bio-Rad) and washed with SLIP buffer supplemented with protease inhibitors and
20mM imidazole in order to remove unspecifically bound proteins. The column
washes fractions were collected and protein presence monitored by reading optical
density values at 280 nm in ultraviolet spectrophotometer; washing was continued
until OD280 value was almost zero. Finally, DNA polymerase @ was gradually
eluted with Iml of SLIP buffer (protease inhibitors included) containing 50mM,
100mM, 150mM and 200mM ofimidazole. Aliquots from each fraction were taken
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and analyzed by SDS-PAGEfollowed by Brilliant Blue G staining and western
blotting.
2.10 Co-immunoprecipitation experiment
Co-immunoprecipitation is a technique used to identify proteins that exist in a
complex within a cell, without discrimination between direct and indirect interaction.
By using a specific antibody against the protein of interest it is possible to
immunoprecipitate complexes formed by proteins in vivo and identify other binding
partners forming the complex.
Buffers and reagents used:
SLIP buffer
- 50mM HEPES(pH 7.5) (Calbiochem)
- 150mM NaCl (VWR)
- 10% Glycerol (Sigma)
- 0.1% Triton X-100 (Sigma)
- 0.5mg/ml Bovine serum albumine (BSA) (Fluka)
Protein sample buffer
- 0.25M Tris (pH 6.8) (Calbiochem)
- 8% SDS (VWR)
- 40% Glycerol (Sigma)
- 4mg/ml Bromophenol Blue (Sigma)
- 1% B-Mercaptoethanol (Sigma)
- Aprotinin (2 g/ml) (Roche)
- Leupeptin (0.5 pg/ml) (Roche)
- Pepstatin (1 pg/ml) (Roche)
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- Soybean Trypsin Inhibitor (100 pg/ml) (Roche)
- Phenylmethanesulphony] fluoride (PMSF) (1mM)(Fluka)
- Protein G sepharose beads (Sigma)
Antibodies
- anti - DNA polymerase a (N-19) (2 yg)
- anti - HA (16B12) (2 yg)
- anti - DHFR (E-18) (2 pg)
- anti - DNA polymerase o (HP180-12) (300 pl)
- anti - DNA polymerase o& (SJK132-20) (300 pl)
- anti - CD20 (Leu16) (2 pg)
Cells were harvested 24 hours after transfection and resuspended in
appropriate volume of SLIP buffer supplemented with protease inhibitors, lysed on
ice for 10 minutes. Lysates were clarified by centrifugation at 14000 rpm at 4° C for
10 minutes and supernatants weretransferred to a fresh tube. Protein concentration in
the supernatants was measured using Bradford Assay, based on which 4 mg of each
sample was taken to be used for each immunoprecipitation reaction. In order to
minimize the amount of proteins that bind nonspecifically to Protein G beads,
samples were gently mixed on the Nutator with 50 pl of 50% slurry of Protein G
sepharose beads for 1 hour at 4°C. Afterwards, samples were briefly centrifuged and
pre-cleared supernatants transferred into fresh tubes, followed by addition of 2 pg of
either specific antibody or isotype control and incubation for 2 hours at 4°C with
gentle mixing on a nutator. In the next step 50 pl of Protein G 50% slurry was added
and samples were incubated for another 2 hours under the same conditions, to
capture the immuno complex on Protein G beads. Afterwards, Protein G beads were
washed three times with 0.5 ml of SLIP buffer containing protease inhibitors,
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resuspended in 40 pl of 1x protein samples buffer and stored at -80 °C for future
analysis by SDS-PAGEand western blotting.
2.11 Purification of GST-MDM2 and GST
Glutathione S-transferase (GST), a 26kDa enzyme with a high affinity to
glutathione, is commonly used as a protein tag. Expression and purification of GST
fusion proteins from bacterial cells allows to obtain large quantities of relatively pure
protein with preserved function since protein purification/elution is performed under
mild conditions.
Buffers and reagents used:
SLIP Buffer
- 50mM HEPES(pH7.5) (Calbiochem)
- 150mM NaCl (VWR)
- 10% Glycerol (Sigma)
- 0.1% Triton X-100 (Sigma)
- Aprotinin (2 pg/ml) (Roche)
- Leupeptin (0.5 g/ml) (Roche)
- Pepstatin (1 pg/ml) (Roche)
- Soybean Trypsin Inhibitor (100 pg/ml) (Roche)
- Phenylmethylsulphony! fluoride (PMSF) (1mM)(Fluka)
- L-Glutathione (Sigma)
- Glutathione Sepharose 4B (GE Healthcare)
- Isopropyl — B — D -thiogalactopyranoside (IPTG) (VWR)
- Ampicillin sodium salt (Sigma)
- Luria Bertani (LB) (Sigma)
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40 ul of pGEX2TK-GSTMdm2glycerol stock (or pGEX-6P-1 GST in case
of purification of GST) was inoculated into 100 ml of autoclaved LB media
supplemented with ampicillin and grown overnight at 37°C, shaking (250rpm) in the
incubator. The next day 100mlof the overnight culture was inoculated into 900 ml of
autoclaved LB medium containing ampicillin and grown until OD600 was between
0.6 — 0.8. To induce protein expression, IPTG wasadded to a final concentration of
0.5mM andbacterial culture was grown for additional 4 hours at the same conditions
as described above. Cells were then harvested by centrifugation for 5 minutes, at
8000 rpm at 4° C, supernatant was discarded andpellet stored at — 80° C overnight.
The next day pellet was resuspended in 40 ml of SLIP buffer and lysed onice for at
least 20 minutes. The lysate was transferred into 50 ml Sorvall centrifuge tubes and
sonicated three times for 30 seconds at power output of 25%, and then left on ice for
at least 10 minutes. Followingthis, bacterial debris was pelleted by centrifugation for
10 minutes, at 15000g at 4° C,the clarified lysate was transferred into 50 ml Corning
tube, glutathione beads were added to the lysate (0.5 ml of 50% slurry, washed three
times with SLIP buffer) and incubated for 2 hours at 4° C on the nutator. After
incubation the content of the tube was applied to Poly — Prep Chromatography
Column and allowedto drip through. The column was washedtwotimes with 15 ml
of SLIP buffer. Finally, 1ml of SLIP buffer containing 20 mM of L-Glutathione was
added and incubated for 10 minutes to elute protein from the column (beads).
Afterwards, a small fraction of eluted GST tagged protein (or GST) was subjected to
SDS-PAGEfollowed by Brilliant Blue G staining and western blotting in order to
confirm presence of protein of interest in the eluate. Remaining fraction of eluted
protein was used in DNA polymeraseassay.
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2.12 In vitro ubiquitylation assay with GST-MDM2
MDM2mediates ubiquitylation of manyofits interacting partners, as well as
its own ubiquitylation due to its E3 ubiquitin ligase activity (64). This enzymatic
activity of MDM2can betested in vitro by performing ubiquitylation assay, using
GST-MDM2purified under non-denaturing conditions.
Buffers and reagents used
 
  
Reaction buffer 10x Volume(p11)
Tris HCl (IM pH 7.5) 50
MgCl, (250mM) 2
ATP (80mM) 25
DTT (iM) 2
ZnCl (1omM) 2
HO 19
Final volume 100  
Table 2.12.1 Componentsofin vitro ubiquitylation assay reaction buffer.
SLIP Buffer
- 50mM HEPES(pH 7.5) (Calbiochem)
- 150mM Sodium chloride (NaCl) (VWR)
- 10% Glycerol (Sigma)
- 0.1% Triton X-100 (Sigma)
- Ubiquitin activating enzyme El (UBE1) (Boston Biochem)
- Ubiquitin conjugating enzyme E2 (UbcHSB) (Boston Biochem)
- Ubiquitin (Boston Biochem)
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In vitro ubiquitylation assay should be performed on the same day as
purification of GST-MDM2, used in the assay, in order to retain the E3 ligase
activity of MDM2.
Ubiquitylation reactions were set up in 1.5ml Eppendorftubes in a volume of 100 pl
in the following order:
1) SLIP buffer
2) 10x reaction buffer
3) substrate protein (this component is omitted when testing autoubiquitylation
ofMDM2)
4) GST-MDM2or GST (negative control) (approximately 200ng)
5) Either “ubiquitin mix”consisting of 100ng of El, 400ng of E2, and 10 pg of
ubiquitin or “no ubiquitin” control consisting of 100ng of El, 400ng ofE2,
and waterinstead of ubiquitin.
Reactions were incubated at 30°C overnight and stopped by adding sample buffer
and samples were subjected to SDS-PAGEfollowed by western blotting.
2.13 DNA polymerase assay
The DNA polymerase assay is used to measure of the enzymeactivity, based
on the incorporation of radiolabeled nucleotides e.g. 7H dTTP.It is possible to test
whether addition of other proteins has any effect on DNA polymerase enzymatic
activity using this assay.
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Reaction buffer Add(ul) Final concentration
°H dTTP (5.8 pmol/l) 33 1.91 pmol/l
dTTP (10 mM) 0.2 20 uM
Poly (dA) oligo (dT) 5 50 uM
(1pg/pl)
DTT (0.5M) 2 10mM
MgCl (1M) 1.5 15mM
HEPES-KOHpH7.5 (1M) 5 50mM
BSA (10mg/ml) Z 0.2 mg/ml
Glycerol (50%) 40 20%
Triton x-100 (1%) 3 0.03%
H20 8.3
Final volume 100 ul   
Table 2.13.1 Components of reaction buffer for DNA polymerase assay.
Assay buffer
- 50mM HEPES-KOH(pH 7.5) (Calbiochem)
- 10mM DLdithiothreitol (DTT) ( Sigma)
- 15mM Magnesium chloride (MgCl) (VWR)
- 10% Glycerol (Sigma)
- 0.03% Triton-X 100 (Sigma)
STOPsolution
- 10% Trichloroacetic acid (TCA) (BDH)
- 0.05M Sodium pyrophosphate tetrabasic decahydrate (Na4P207) (Sigma)
Washing buffer
- 1M Hydrochloric acid (HCl) (VWR)
- 0.1M Sodium pyrophosphatetetrabasic decahydrate (Na4P207) (Sigma)
- OSC Scintillation Cocktail (Amersham)
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A typical DNA polymerase assay reaction mix is assembled on ice and contains:
1) enzyme e.g. DNA polymerase a
2) protein ofinterest e.g. GST-MDM2or total volume
controlprotein e.g. GST of 10 ul
3) assay buffer
4) 90 ul of reaction buffer (components presented in Table 2.13.1)
Reaction mix (in quadruplicate per each condition) was incubated for one
hour at 37°C in a sealed 96-well plate. Afterwards, the plate was put on ice and
content of each well transferred into a 5 ml tube, followed by addition of 500 ul of
STOP solution terminate the reaction. Content of each tube was transferred onto
glass microfibre filter (Whatman GF/A 25mm (Fisher)) to collect acid - precipitable
(radioactive) products of reaction and the filter was then washed with ~20 ml of
washing buffer. The next day filters were put into the scintillation vials and after
addition of 5 ml OSC Scintillation Cocktail (to the vials) radioactivity was counted
using a Packard 1500 Tri-Carb liquid scintillation analyzer.
2.14 In vivo ubiquitylation/NEDDylation assay
In vivo ubiquitylation (/NEDDylation) assay is used for identification of
substrates for ubiquitin (/NEDD8) in the cell. This technique is based on usage of Ni-
NTA agarose beads to pull down the 6xHis-tagged ubiquitin (/NEDD8) covalently
attachedto its protein substrates.
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Buffers and reagents used
SLIP Buffer
- 50mM HEPES(pH 7.5) (Calbiochem)
- 150mM NaCl (VWR)
- 10% Glycerol (Sigma)
- 0.1% Triton X-100 (Sigma)
- 0.5mg/ml Bovine Serum Albumine (BSA) (Fluka)
Buffer A (pH 8.0)
- 6M Guanidine hydrochloride (Sigma)
- 0.1M NaH2PO, (Sigma)
0.01M Tris (Calbiochem)
- 5SmM Imidazole (VWR)
- 10mM £-mercaptoethanol (Sigma)
Buffer B (pH 8.0)
- 8M Urea (BDH)
- 0.1M NaH>PO,(Sigma)
- 0.01M Tris (Calbiochem)
- 10mM £-mercaptoethanol (Sigma)
Buffer C (pH 6.3)
- 8M Urea (BDH)
-  0.1M NaH»2PO, (Sigma)
0.01M Tris (Calbiochem)
10mM f£-mercaptoethanol (Sigma)
Protein sample buffer
- 0.25M Tris (pH 6.8) (Calbiochem)
8% SDS (VWR)
40% Glycerol (Sigma)
4mg/ml BromophenolBlue (Sigma)
1% B-Mercaptoethanol (Sigma)
75
 Materials and methods
- GeneJuice ® Transfection Reagent (Novagen)
- RPMI 1640 medium (Sigma)
- Aprotinin (2 g/ml) (Roche)
- Leupeptin (0.5 g/ml) (Roche)
- Pepstatin (1 pg/ml) (Roche)
- Soybean Trypsin Inhibitor (100 pg/ml) (Roche)
- Phenylmethylsulphonylfluoride (PMSF) (1mM) (Fluka)
- Ni— NTAagarose beads (Qiagen)
- Imidazole (VWR)
- 10mM N-Ethylmaleimide (NEM)
H1299 cells were transfected with 15 ug of His-Ubiquitin (or His-NEDD8-
pcDNA3 NEDD8&in case of NEDDylation assay) expression plasmid per 15cm dish
in addition to other expression constructs using GeneJuice transfection reagent.
Twenty four hours after transfection cells were split 1:2 and grown for an additional
24 hours after which cells were harvested into two aliquots: 10% for western blotting
(to check for the presence and possible degradation of transfected proteins of
interest) and 90% for the assay purpose (purification with Ni-NTA beads). In order
to perform the purification process, cell pellets (90%) were lysed in 2 ml of buffer A
(Iml per 15cm dish) supplemented with 10mM NEM in order to prevent
deubiquitylation. 200 ul of Ni-NTA beads (50% slurry) was added to the lysates and
samples were incubated for four hours on the nutator at room temperature. After
incubation Ni-NTA beads were washed with 1 ml of buffer A, 1ml of buffer B and
Iml of buffer C in order to remove proteins unspecifically bound to the beads.
Following washes,proteins bound to the Ni-NTA beads were eluted into 50 pl of 1 x
sample buffer supplemented with 200mM imidazole and analyzed by SDS-PAGE
followed by western blotting.
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2.15 Flow cytometry analysis
Buffers and reagents used:
- Ethanol (ice cold) 70% (VWR)
- Phosphate buffered saline (PBS), PBS Tween 20 (0.1%) (Sigma)
- Ribonuclease A (RNase A) (10 mg/ml) (Sigma)
- Propidiumiodide (PI) in PBS (1 mg/ml) (Sigma)
Typically, each sample prepared for analysis should contain between 0.5 —
1x10° cells in total. Mammalian cells were grown and harvested bytrypsinization
followed by centrifugation for 5 minutes at 173g at room temperature. Cellpellets
were then washed in PBS andcentrifuged twice. After last centrifugation PBS was
discarded and tubes containing the pellets were harshly flicked to resuspendthecells
and create a single cell suspension. Cells were gently vortexed while adding drop-
wise 5 ml of 70% ice cold ethanol. Samples wereleft on ice for at least 1 hour (or up
to two weeksin the fridge). During the next step cells were pelleted by centrifugation
and washed twice in PBS Tween 20, resuspendingcells each time. After pelleting the
cells for the final time, PBS Tween was removed, pellets resuspended in 100 pl of
RNase A andleft on ice for 5 minutes. Staining solution containing 850 pl of PBS
and 50 ul of propidium iodide was added to each sample to be analyzed andleft on
ice in the dark for 30 minutes.
Samples were analyzed using a Beckman Coulter Epics XL flow cytometer using
FL2 (propidium iodide) channel. Data were analyzed using WIN MDIsoftware
(Windows multiple document interface for flow cytometry; Scripps Research
Institute) and Cylchred software (developed at the University of Cardiff).
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2.16 Thymidine incorporation assay
Thymidine incorporation assay is used to measure cells proliferation rate
based on incorporation of [*H]-thymidineinto nucleic acid.
Buffers and reagents used:
- RPMI 1640 medium (Sigma) + 10% fetal bovine serum (FBS) (Sigma)
- (H]-thymidine (1mCi/ml)
- Phosphate Buffered Saline (PBS) (Sigma)
- 5% Trichloroacetic acid (TCA) (BDH)
- 0.1M Sodium hydroxide (NaOH) (VWR)
- OSC Scintillation Cocktail (Amersham)
Cells were plated at 5 x 10* per well (6 well plate) in 2 ml growth medium
and incubated for 24 hours in cell incubator at 37°C. (°H]-thymidine was added to
each well (apart from negative control wells) to final concentration of 1 wCi/ml and
samples were incubated for 2 hours in cell incubator. After incubation medium
containing [°H]-thymidine was discarded and cells were washedthree times with ice
cold PBS. 5% TCA was added to each well and incubated for 20 minutes in the
fridge, in orderto precipitate radioactive products. The TCA wasdiscarded and wells
washed two times with ethanol. 1m] of 0.1M NaOH wasadded to each well and
plates were put in the oven at 60°C for 1 hour. Following this 200 pl from each well
was added to 5ml of OSC Scintillation Cocktail in scintillation vials, the vials were
shaken well and radioactivity counted using a Packard 1500 Tri-Carb liquid
scintillation analyzer.
The assay wasperformedintriplicate.
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RESULTS
MDM2, in addition to its interplay with p53, interacts with several others
proteins and manyofthese are involved in crucial cell processes (2). One examples,
reported by members of our research group, appears to implicate MDM2 in some
way in the process of DNA replication and/or repair via interaction with DNA
polymerase € (58,59). During the course of studies on MDM2 and DNApolymerase
€, it was also discovered that MDM2interacts with DNA polymerase a.
Several experiments on MDM2 and DNApolymerase o interaction were carried
out by the former membersofour research group — Dr. Maria Maguire and Dr. Paul
Nield prior to the commencement of studies described in this thesis. These
experiments involved affinity chromatography based on which we concluded that
DNA polymerase & co-purified with 6xHis-tagged MDM2 from a nickel-charged
column (Figure 3.1.1). These findings were then additionally confirmed by the
results from immunoprecipitation experiments on untransfected HEK293 cells which
demonstrated that a protein complex exists containing both DNA polymerase a and
MDM2in these cells, as presented in Figure 3.2.1 of co-immunoprecipitation
experiments section (3.2).
These studies suggest that complexesexists that contains both DNA polymerase
a and MDM2but did not address the important question of whether MDM2 and
DNA polymerase © interact directly. To further examine the interaction of MDM2
with DNA polymerase ©, we first performed in vitro binding assay since these
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enables us to examine direct interactions between proteins. Next, we examined
protein complexes by co-immunoprecipitation with MDM2 deletion mutants to
determine which regions of MDM2 were required to incorporate MDM2into the
complex and finally examined whether MDM2 had any effect on the DNA
polymerase activity of DNA polymerase & or whether due to its E3 ligase activity
MDM2 mediated modifications of the catalytic subunit of DNA polymerase o
(p180).
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Figure 3.1.1 DNA polymerase « co-purifies with MDM2. Upper panel: elution
profile from the MDM2 coulmn; S5mg of MDM2 was bound to a HiTrap column
charged with Ni++ and then 12mg of BSA wasapplied to the column. After washing
the column extensively 12mg total protein lysate from HEK293 cells was passed
over the column and then again washed extensively. Ni++ binding proteins were then
eluted with an imidazole gradient from 0-1M. Lowerpanel: western blot of fractions
11-24 probed with the anti-p180 (N-19) antibody for detection of DNA polymerase o
and anti-MDM2(Ab1, clone IF2) (experiment was performed by Dr. Maria Maguire
and Dr. Paul Nield).
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3.1 Investigation of direct interaction between MDM2 and DNApolymerase a
Investigation of the potential direct interaction between MDM2 and DNA
polymerase & was performed using an in vitro binding assay. This method has been
used before in our laboratory (56,58) and enables one to determine whether two
proteins incorporated into the assay interact directly. For the assay oneofthe protein
partners is usually radiolabeled, while the other one is a 6xHis-tagged protein bound
to Ni-NTA beads. Therefore, in order to obtain radiolabeled proteins a TNT® T7
Coupled Reticulocyte Lysate System (Promega) with [°°S] methionine was used (as
described in Materials and methods, section 2.8.1.2). For the 6xHis-tagged proteins,
expression and purification was based on the QlAexpress® System (Qiagen), with a
set of pilot experiments performed to optimize conditions for expression and
purification ofproteinsofinterest.
3.1.1 Expression andpurification of 6xHis-tagged proteins
3.1.1.1 Determination of optimal induction time for 6xHis-tagged MDM2
As stated above, the QlAexpress® System (Qiagen) was used to produce
6xHis-tagged proteins in bacterial cells, since this allows us to obtain relatively high
level expression of fusion proteins compared to many other expression systemse.g.
insect or mammalian cells. In order to determine the optimal induction time for
expression ofproteins of interest, a pilot experiment was performed as described in
Materials and methodssection 2.8.1.1.
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Time course experiments for 6xHis—tagged human MDM2,amino (N)-terminal
half of MDM2 (246 aminoacids) and carboxy (C)-terminal half MDM2 (252 amino
acids) were carried out with sample collection at times 1, 2, 4, 6 and 8 hours after
induction with IPTG. All samples were then subjected to SDS — PAGEanalysis
followed by western blot performed using anti-MDM2antibodies: Ab1 (clone IF2)
for MDM2full length and amino (N)-terminal half MDM2, and Ab 6 (clone 5B10C)
for carboxy (C)-terminal half MDM2. Expected molecular weights of all MDM2
constructs were as follows: MDM2 - ~ 90kDa, amino (N)-terminal half MDM2 - ~
42 kDa, carboxy (C)-terminal half MDM2 - ~ 50 kDa. As shownin Figure 3.1.2 A
and B, 3.1.2 A represents a shorter exposure and 3.1.2 B a longer exposure of the
sameblot, levels of expression at 4, 6 and 8 hours upon induction are comparable.
Basedonthe signal strength displayed on blots (Figure 3.1.2), 4 hours induction with
IPTG waschosen as optimal for the future experiments since it confers high protein
expression levels but within a shorter period of time and this may result in less
toxicity and protein degradation than might arise at later time points; 4 hours
. . . . . . . TMinduction was also recommendedasa starting point in the QIAexpressionist manual
for the QIAexpress® System (Qiagen).
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Figure 3.1.2 Test of the time of induction of expression of 6xHis-tagged MDM2
using IPTG. Western blot of full length MDM2andits amino (N)- and carboxy (C)-
terminal halves expressed in XL — | Bluecells, harvested 1, 2, 4, 6 and 8 hoursafter
induction with IPTG. Time 0 also served as a noninduced control, C — purified
protein - represents positive control for each protein. Equal volumes of analyzed
samples represent 2% ofthe bacterial lysate; Ab1 (clone IF2) antibody was used for
detection of full length and amino-terminal half of MDM2, while Ab-6 (clone
5B10C) antibody was used to detect carboxy-terminal half of MDM2 (A — short
exposure, B — long exposure).
3.1.1.2 Optimization of wash buffer pH value for purification of 6xHis-tagged
MDM2
Purification of 6xHis-tagged proteins can be performed either under native or
denaturing conditions. The bacterial expression system used for this experiment
ensures high expression of proteins of interest, which may however lead to the
formation of insoluble protein aggregates. Hence, in order to solubilize these
potential aggregates, purification under denaturing condition was chosen (previous
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experience has shown that much lower levels of MDM2are produced undernative
conditions). Moreover, purification under denaturing conditions guarantees improved
binding of 6xHis-tagged protein to the Ni-NTA,since the tag is fully exposed, and
also there is reduced nonspecific binding of untagged proteins. To ensure optimal
purification of the protein of interest, other conditions need to be determined as well,
and oneparticularly important is the pH of the 8M urea buffers used throughout the
procedure. Urea buffer at pH 8.0 (buffer B) was used for bacterial cells lysis and
subsequent binding of fusion proteins to Ni-NTA, whereas for washing (removal of
nonspecifically bound proteins) and elution steps the buffer pH should be lower than
8.0 because at lower pH histidine (His) residues becomeprotonated thus reducing the
electrostatic attraction betweenhistidine and nickel (Ni) ions.
In order to determine the optimal buffer pH for washing and elution steps,
buffers with pH values of 6.3 (buffer C), 5.9 (buffer D) and 4.5 (buffer E) were
initially tested during small scale protein purification, as suggested in the
QlAexpressionist manual. As shown in figure 3.1.3 A and A’, when buffers with
pH 6.3 (C), 5.9 (D) and 4.5 (E) were applied to the column containing carboxy- and
amino-terminal halves of MDM2 bound to Ni-NTA beads, the proteins of interest
were eluted in almost every fraction, instead of being present only in fractions
collected from washes with buffer E. To decrease the stringency of the washes, the
pH of the buffers was increased to 6.8, 6.4 and 5.0 for C, D, and E buffers,
respectively. This improved the elution profile of the proteins and resulted in the
majority of recombinantprotein eluting in fractions El and E2, as shown in Figures
3.1.3B-B’.
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Figure 3.1.3 Optimization of buffer pH for purification of 6xHis-tagged
proteins. Western blot of carboxy (C)- and amino (N)- terminal halves of human
MDM2expressed in XL — 1 Blue cells. Numbers from | to 5 represent five washes
(0.5ml) with each buffer. A and A’) buffer pH: C — 6.3, D—5.9, E—4.5; B and B’)
buffer pH: C — 6.8, D — 6.4, E — 5.0. Equal volumes of analyzed samples represent
4% of the bacterial lysate; Abl (clone IF2) antibody was used for detection of the
amino-terminal half of MDM2, while Ab-6 (clone 5B10C) antibody was used to
detect carboxy-terminal half ofMDM2.
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3.1.1.3 Large scale purification of 6xHis-tagged MDM2
The small scale pilot experiments (described in sections 3.1.1.1 and 3.1.1.2)
allowed us to determine the optimal conditions for expression and purification of
6xHis-tagged MDM2 from bacterial cells (XL-1). Therefore, for large scale
expression and purification of 6xHis-tagged MDM2a 4 hour induction with IPTG
was performed, followed by purification of fusion proteins on Ni-NTA beads using
8M urea buffer at pH 6.8 (buffer C) and 6.4 (buffer D). In order to retain protein
bound to the beads the last wash — elution with buffer E was omitted. After washes
with buffer C and D,a fraction of the protein left on the beads was subjected to 15%
SDS — PAGEanalysis, followed by Brilliant Blue G staining (Figure 3.1.4) and
western blot analysis using appropriate antibodies (anti-MDM2: Ab 1, Ab 2 and Ab
6) (Figure 3.1.5) (expected molecular weights: MDM2 at ~ 90kDa, amino-terminal
half MDM2at ~ 42 kDa and carboxy-terminal half MDM2at ~ 50 kDa). A typical
purification result is shown in Figure 3.1.4 and it can be seen that the levels of
MDM2/MDM2-fragment expression were variable. The highest amount of protein
waspresent in the lane corresponding to the carboxy-terminal half of MDM2, while
the expression levels of full length MDM2, the amino-terminal half of MDM2, and
the control protein CPN60.1 are present at lower levels with the full length mouse
MDM2expressed at the lowest level. When the same fractions were analyzed by
western blotting, this analysis confirmed the presence of MDM2proteins on the
beads (Figure 3.1.5).
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Figure 3.1.4 Brilliant Blue G staining of 6xHis-tagged CPN60.1, MDM2, amino-
and carboxy-terminal halves of MDM2. 6xHis-tagged proteins were bound to the
Ni-NTA beads after purification procedure and then separated on 15%
polyacrylamide gel. Main protein bands are indicated by arrows: CPN60.1 at ~ 27
kDa, MDM2at ~ 90kDa, amino (N)-terminal half MDM2at ~ 42 kDa and carboxy
(C)-terminal half MDM2 at ~ 50 kDa; M — indicates protein molecular weight
marker.
 
Figure 3.1.5 Western blot analysis of 6xHis—tagged MDM2proteins bound to
the Ni-NTA beadsafter purification procedure. Proteins were separated on 15%
polyacrylamide gel. Equal volumes of analyzed samples represent 3% ofthe total
protein bound to the Ni-NTA beads; Abl, Ab6 and Ab2 antibodies were used for
detection of MDM2proteins as indicated at the bottom of the figure. Main protein
bands are indicated by arrows: MDM2at ~ 90kDa, amino (N)-terminal half MDM2
at ~ 42 kDa and carboxy (C)-terminal halfMDM2at ~ 50 kDa.
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3.1.2 In vitro binding assay — 6xHis-tagged p53 protein binds to p180 in vitro
After establishing the conditions for purification of 6xHis-tagged MDM2
proteins (sections 3.1.1.1-3) we decided to perform a pilot in vitro binding assay
utilising well known and acknowledged binding partners, in order to examine the
specificity of the assay.
Since p53 is the best established and most widely studied MDM2 interacting
protein, with a proven profound effect on cell function (section 1.4) it was an
obvious candidate for the pilot experiment. The assay wascarried out, as described in
Materials and methods (section 2.8), with 6xHis-tagged p53 (Figure 3.1.6B) and
CPN60.1 (Figure 3.1.6A) proteins purified by binding to the Ni-NTA beads and
incubated with in vitro translated MDM2protein for 3 hours at 30°C and then
washedextensively to remove non-specific interactions. Samples were then analyzed
by SDS-PAGE and fluorography. Results presented in Figure 3.1.7 show, as
expected,that in vitro translated MDM2bindsdirectly to 6xHis-tagged p53 and does
not bind to CPN60.1 protein.
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Figure 3.1.6 Brilliant Blue G staining of 6xHis-tagged CPN60.1, MDM2, amino-
and carboxy-terminal halves of MDM2 and p53. Brilliant Blue G staining of
6xHis-tagged proteins bound to the Ni-NTA beads after purification procedure,
separated on 15% polyacrylamide gel (A) and 10% polyacrylamide gel (B). Main
protein bandsare indicated by arrows: CPN60.1 at ~ 27 kDa, MDM2at ~ 90kDa,
amino (N)-terminal half MDM2 at ~ 42 kDa, carboxy (C)-terminal half MDM2at ~
50 kDa and p53 at ~ 53 kDa; M indicates protein molecular weight marker.
IVT  CPN60.1 p53
MDM2
Figure 3.1.7 In vitro binding assay of in vitro translated MDM2 mixed with
6xHis-tagged p53 and CPN60.1 protein. CPN60.1 protein served as a negative
control. IVT indicates 10% of the input in vitro translated protein. Assay was
performed in duplicate as shown.
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Reports on interaction between p180 and p53 have been published, showing
binding of these two proteins by surface plasmon resonance analysis (13, 14). Since
it has not been confirmed that p53 interacts exclusively or directly with the catalytic
subunit (p180) of DNA polymerase o (13) we wanted to examinethe potential direct
p53 binding to p180 by performingin vitro binding assay.
In vitro translated full length catalytic subunit (p180) of DNA polymerase a
was incubated with 6xHis-tagged proteins: CPN60.1, p53, MDM2andin thefirst
instance with only the amino-terminal half of MDM2.After 3 hours incubation at 30°
C, samples were analyzed by SDS-PAGEandfluorography.
CPN60.1 p53 MDM72N-half
IVT MDM2
 
 
  pol c.(p180)
|
‘me
Figure 3.1.8 In vitro binding assay of in vitro translated catalytic subunit (p180)
of DNA polymerase & mixed with 6xHis-tagged p53, MDM2, amino-terminal
half of MDM2 and CPN60.1 protein. CPN60.1 protein served as a negative
control. IVT indicates 10% of the input in vitro translated protein. Assay was
performed in duplicate as shown.
Fluorography analysis, presented in Figure 3.1.8, revealed that the catalytic
subunit of DNA polymerase o (p180) bindsdirectly to p53, as well as to MDM2and
the amino-half of MDM2. However, comparing signals for p53 and MDM2orp53
and the amino-terminal half of MDM2 andtaking into account the amount of p53
protein present on the Ni-NTA beads(Figure 3.1.6B), it seems that p53 does not bind
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to p180 as well as it does to MDM2orthe amino-terminal half of MDM2 (Figure
3.1.8).
3.1.3 In vitro binding assay — p180 bindspreferentially to full length and amino-
terminal half of MDM2
In order to test direct interactions between p180 and MDM2proteins and
identify regions involved in these interactions an in vitro binding assay was
performed. The binding partners for the in vitro binding assay are presented in Table
3.1.1.
 In vitro translated pol a
(p180)
pola full length
6xHis — tagged proteins
 
0iene. pol a N-terminalhalf
. pol a C-terminal half
Human MDM2 pol a full lengthpol a N-terminalhalf
pol o C-terminal half
pol a full length
pol a N-terminalhalf
pol a C-terminal half
pol o full length
CPN60.1 pol a N-terminalhalf
pol a C-terminal half
 amino-terminal half
 
Human MDM2
carboxy-terminalhalf
    
Table 3.1.1 Jn vitro binding assay pairingstested.
For these experiments p180 proteins were generated using TNT® T7 Coupled
Reticulocyte Lysate System (Promega) with (°°S] methionine to radiolabel the
proteins (as described in Materials and methods, section 2.8.1.2), while the
purification of 6xHis-tagged MDM2 proteins was performed based on pilot
experiments (3.1.1.1 and 3.1.1.2). Controls for the assay were included,as follows:
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in vitro translated, radiolabeled fragment of DNA polymerase e€ (clone 65, described
in section 2.1) served as positive control for binding to MDM2 (58), while as
negative control for binding to 6xHis-tagged proteins a CPN60.1 fusion protein was
used (described in Materials and methods, section 2.1). Prior to use in the in vitro
binding assay, the presence of 6xHis-tagged proteins on the beads was confirmed by
Brilliant Blue G staining and western blot analysis, an example is shownin Figures
3.1.4, 3.1.5, respectively.
Based on Brilliant Blue G staining of 6xHis-tagged proteins bound to Ni-NTA
beads, the carboxy-terminal half of MDM2 protein was found to be present at a
higher level than the rest of the 6 x His-tagged proteins used for the assay, as shown
in Figure 3.1.4. In order to have comparable amounts of input proteins in the assay,
purified 6xHis-tagged carboxy-terminal half of MDM2protein bound to the Ni-NTA
beads was diluted using “empty” Ni-NTA beads suspended in Buffer B, pH 8.0 (1:1
ratio). The effect of this was verified by SDS-PAGE followed by Brilliant Blue G
staining, and as shown in Figure 3.1.9 more comparable amounts of proteins were
thus available for the assay. It is noteworthy that for the in vitro binding assay, two
variants in terms of amount of 6xHis-tagged carboxy-terminal half of MDM2input
were examined(as presented in Figures 3.1.4 and 3.1.9), and the results obtained for
both variants were the same (an example is presented in Figure 3.1.10).
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CPN60.1 MDM2 N-half C-half M
MDM2 MDM2
 
 
 
Figure 3.1.9 Brilliant Blue G staining of 6xHis-tagged proteins boundto the Ni-
NTA. Proteins were separated on 15% polyacrylamide gel. Main protein bands are
indicated by arrows: CPN60.1 at ~ 27 kDa, MDM2 at ~ 90kDa, amino (N)-terminal
half MDM2at ~ 42 kDa and carboxy (C)-terminal half MDM2at ~ 50 kDa; M —
indicates protein molecular weight marker. Amount of carboxy (C)-terminal MDM2
protein has been adjusted to be at a comparable level to other 6xHis-tagged proteins
as shown.
Anin vitro binding assay was performed with protein partners as presented in
Table 3.1.1 (including controls) in duplicate, according to the standard protocol
described in Materials and methods, section 2.8.2. Samples were analyzed by SDS-
PAGEfollowed by fluorography and exposure of the X-ray film. Signal strength
obtained on the X-ray film is an indication of the amount of direct interaction
between proteinsin the assay.
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IVT MDM2 MDM2
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Figure 3.1.10 In vitro binding assay between p180 and MDM2.In vitrotranslated,
radiolabeled: A) full length DNA polymerase catalytic subunit (p180), B) amino
(N)-terminal half of DNA polymerase o catalytic subunit (p180), C) carboxy (C)-
terminal half of DNA polymerase « catalytic subunit (p180), D) carboxy (C)-
terminal half of DNA polymerase € as a positive control (clone 65), mixed with
6xHis-tagged full length mouse MDM2, amino (N)-terminal half of human MDM2,
carboxy (C)-terminal half of human MDM2 and CPN60.1 protein as a negative
control. IVT indicates 10% of in vitro translated protein input. Assays were
performed in duplicate as shown.
Comparing signals obtained from the fluorographs of in vitro binding assays,
taking into accountthe amountofinput proteins boundto the beads for each sample,
in particular the high amount of 6xHis-tagged carboxy-terminal half of MDM2
(Figure 3.1.4), it appears that the full length (FL) DNA polymerase catalytic
subunit (p180), and its amino (N)-terminal and carboxy (C)-terminal halves bind
preferentially to the full length mouse MDM2and amino(N)-terminal half of human
MDM2.Despite the fact that the human carboxy (C)-terminal half of MDM2 seems
to be present at the highest levels on the beads, it does not bind DNA polymerase a
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catalytic subunit (p180) as well as mouse full length MDM2 or human amino(N)-
terminal half of MDM2,as Figure 3.1.10 shows. Moreover, 6xHis-tagged CPN60.1,
which served as a negative control does not seem to bind to p180orits halves, while
the positive control — a carboxy-terminal fragment of DNA polymerase € (clone 65)
previously shownto bind to MDM2,as expected, binds to 6xHis-tagged MDM2and
to the amino-terminal half of MDM2(58) (Figure 3.1.10).
The results show that full length p180 as well as its amino- and carboxy-terminal
halves binds directly to full length MDM2 and its amino-terminal half. To further
verify these findings another in vitro binding assay was designed.
3.1.4 In vitro binding assay with A166 MDM2
Results obtained from in vitro binding assays (section 3.1.3) indicate that
MDM2interacts directly with p180, and moreover the amino-terminal half of
MDM2seemsto beselectively engaged in the interaction with p180. In orderto test
whether the amino-terminal region of MDM2is indispensable for direct binding with
catalytic subunit of DNA polymerase a (p180) an in vitro binding assay was
performed with a mutant of MDM2: A166 MDM2lacking the amino-terminal 166
aminoacids.
An in vitro binding assay was performed with proteins as presented in Table
3.1.2. In addition to A166 MDM2,full length and the amino-terminal half of MDM2
were used, as well as CPN60.1 as a negative control.
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 pola full length
 
flllength2 pol a N-terminal halfpol a C-terminal half
Human MDM2 pol a full length
amino-terminal half pol a N-terminalhalf pol a C-terminal half
pol a full length
Results
 
 
seeNe pol a N-terminal half
pol a C-terminal half
pol ao full length
CPN60.1 pol a N-terminalhalf   pol a C-terminal half
Table 3.1.2 Jn vitro binding assay pairings tested.
Prior to the use of 6xHis-tagged proteins for the in vitro binding assay, their
presence on the Ni-NTA beads was confirmed by SDS-PAGEanalysis followed by
Brilliant Blue G staining, an example is shown in Figure 3.1.11 A. It is noteworthy
that based on the staining, A166MDM2waspresentat a higher level than the other
6xHis-tagged proteins used for the assay. Therefore, an attempt to normalize the
level of 6xHis-tagged proteins put into the assay was made, by diluting the
A166MDM2bound to Ni-NTA beads with “empty” Ni-NTA. The effect of this was
verified by SDS-PAGE followed by Brilliant Blue G staining, and as shown in
Figure 3.1.11 B the amounts of proteins were found to be at comparablelevels. For
the in vitro binding assay, two variants in terms of amount of Al66MDM2input
were examined(as presented in Figures 3.1.11A and B), and the results obtained for
both variants were the same (an example is presented in Figure 3.1.12).
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MDM2 MDM2 MDM2 MDM2
 
  
 
Figure 3.1.11 Brilliant Blue G staining of 6xHis-tagged CPN60.1, MDM2,
amino-terminal half of MDM2 and A166MDM2.Brilliant Blue G staining of
6xHis-tagged proteins bound to the Ni-NTA beads after purification procedure,
separated on 15% polyacrylamide gel. Main protein bandsare indicated by arrows:
CPN60.1 at ~ 27 kDa, MDM2at ~ 90kDa, amino (N)-terminal half MDM2at ~ 42
kDa and A166MDM2at ~ 75 kDa; M — indicates protein molecular weight marker;
A) represents amounts of 6xHis-tagged proteins after purification, B) represents
adjusted amount of carboxy (C)-terminal MDM2protein to be on comparable level
to other 6xHis-tagged proteins.
Anin vitro binding assay was performed with protein partners as presented in
Table 3.1.2 (including controls) in duplicate, according to the standard protocol
described in Materials and methods, section 2.8.2. Samples were analyzed by SDS-
PAGEfollowed by fluorography and exposure of the X-ray film.
Based on results from fluorography analysis, presented in Figure 3.1.12, it
appears that binding of p180 and its amino- and carboxy-terminal halves to
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A166MDM2is much weaker when comparing this to binding to the full length and
the amino-terminal half of MDM2. This conclusion is also supported by the fact that
the amount of A166MDM2usedin the assay was greater than the other 6xHis-tagged
proteins used (Figure 3.1.11A). Preferential binding of p180 to MDM2andits
amino-terminal half confirmed previous observations (Figure 3.1.10) as did lack of
binding to 6xHis-tagged CPN60.1 of p180 and its halves. Moreover, as expected the
positive control for the binding assay, a fragment of DNA polymerase e (clone 65)
binds to both 6xHis-tagged MDM2 and the amino-terminal half of MDM2 (58)
(Figure 3.1.12).
CPN60.1 MDM2 N-half A166
IVT MDM2 MDM2
B pol a (p180) |N-half
C pol «(p180) |.C-half |
Figure 3.1.12 In vitro binding assay between p180 and A166MDM2. In vitro
 
translated, radiolabeled: A) full length DNA polymerase o catalytic subunit (p180),
B) amino (N)-terminal half of DNA polymerase © catalytic subunit (p180), C)
carboxy (C)-terminal half of DNA polymerase a catalytic subunit (p180), D)
carboxy (C)-terminal half of DNA polymerase € as a positive control (clone 65),
mixed with 6xHis-tagged full length mouse MDM2, amino (N)-terminal half of
human MDM2, mouse A166MDM2and CPN60.1 protein as a negative control. IVT
indicates 10% of the input in vitro translated protein. Assays were performed in
duplicate as shown.
98
 Results
In summary, it can be concluded that since p180 does not seem to bind to
A166MDM2in vitro, therefore, the region of the amino-terminal 166 amino acids of
MDM2mightbe indispensable for direct interaction between MDM2and p180. Thus
the region of MDM2to which catalytic subunit of DNA polymerase a binds appears
to be contained between aminoacids | and 166.
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3.2 DNA polymerase & forms a complex with MDM2inthecells
As mentioned at the beginning of the Results chapter prior to the studies
described in this thesis, several experiments on MDM2 and DNA polymerase
interaction were carried out by former members of our research group — Dr. Maria
Maguire and Dr. Paul Nield. One of these experiments was an immunoprecipitation
assay performed on untransfected HEK293 cells showing that endogenousproteins
DNApolymerase a and MDM2forms a complexin these cells (Figure 3.2.1).
 
p180DNApol a p180
IB antibody
MDM2      MDM2 © ps0
 
IP antibody
Figure 3.2.1 Co-immunoprecipitation of endogenous MDM2 with p180 from
HEK293 cells. MDM2 co-precipitates endogenous DNA polymerase o and vice
versa (lysates from HEK293 cells). Note that for immunoprecipitation (IP), N-19
polyclonal antibody was used for DNA polymerase © catalytic subunit, and SMP14
monoclonal antibody was used for MDM2. For immunoblot (IB) detection Ab-1
(clone IF2) monoclonal antibody was used for MDM2 and N-19 was used for DNA
polymerase © catalytic subunit; C — isotype control (experiment was performed by
Dr. Maria Maguire).
100
 Results
3.2.1 Co-immunoprecipitation experiments with MDM2deletion mutants
Results from experiment performed by Dr. Maguire indicate that endogenous
MDM2forms a complex with DNA polymerase @ in cells, as presented in Figure
3.2.1. In addition, experiments carried outin vitro (sections 3.1.3 and 3.1.4) revealed
that amino-terminal fragment of MDM2 binds directly to p180 and region of the
amino-terminal 166 amino acids of MDM2appearsto be required for that interaction
with p180 (section 3.1.4). In order to determine whether such an interaction could be
detected in cells in culture a series of co-immunoprecipitation (Co-IP) experiments
were performed. Co-immunoprecipitation is a routinely used laboratory technique,
that enables one to detect protein-protein interactions based on purification of protein
complexes using a specific antibody against one of the suspected partner proteins. A
weakness of this approach, howeveris that it cannot distinguish between direct or
indirect interactions. Since we have already confirmed direct interaction between
p180 and MDM2byinvitro binding assay (sections 3.1.3 and 3.1.4), we were not
primarily concerned in these experiments with the question of whether interactions
were direct, rather we wanted to examine the regions of MDM2 required for
interaction with p180 in live cells. To facilitate these studies we used N-terminal
HA-tagged MDM2 carboxy-terminal deletion mutants and a schematic
representation of these is shownin Figure 3.2.2.
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Figure 3.2.2 Schematic representation of N-terminal HA-tagged carboxy-—
terminal deletions MDM2 mutants used for co-immunoprecipitation
experiments. Location of different domains and motifs indicated by coloured boxes;
NLS — nuclear localization signal, NES — nuclear export signal, NoLS — nucleolar
localization signal. Constructs were made by a former memberofour research group
- Dr. Tim Devling.
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3.2.1.1 An examination of the expression levels of HA-MDM12carboxy-terminal
deletion mutants
Prior to performing a Co-IP experiment with HA-MDM2 mutants (Figure
3.2.2), an examination of their expression levels was carried out. It is desirable that
the constructs used for transient tranfection in Co-IP experiments express proteins at
comparable levels in order to be able to properly analyze obtained results, since Co-
IP results obtained for each construct are then compared against each other.
Therefore, H1299 cells were transfected, using GeneJuice™ (at a 3:1 v:w ratio to
DNA), with 10 pg of plasmid DNA from each of the HA-MDM2 mutantconstructs.
24 hours after transfection cells were harvested, lysed in SLIP buffer and protein
concentration in the lysates was measured using the Bradford method (as described
in section 2.6). Normalized amounts of proteins from each transfection were
separated by 12% SDS-PAGE followed by western blot analysis. Anti-MDM2
antibody (Ab1, clone IF2) was then used to detect MDM2 carboxy-terminal deletion
mutants.
Based on the results obtained from western blot analysis, all the constructs
express MDM2 proteins (Figure 3.2.3B). Comparing signals amongst MDM2
carboxy-terminal deletion mutants it was apparent that the mutant protein consisting
of the amino terminal 335 amino acids was expressed at lower levels than the other
mutants. Examination of the Ponceau S stained membrane (Figure 3.2.3A), which
served as a loading control, demonstrated no obvious difference in loading of the
samples on the gel. The transfection efficiency based on western blot analysis
(Figure 3.2.3C), was also comparable for each construct. Thus it appears that mutant
335 possessesanintrinsically reduced ability to produce protein.
103
 Results
Nevertheless, since all the constructs detectably express MDM2 mutant
proteins the next stage of the experiment could be performed.
HA-tagged MDM2 HA-tagged MDM2
DELETION MUTANTS DELETION MUTANTS
a e
kDa kDaUNT 166 205 230 280 335 175 UNT 166 205 230 280 335 17.
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58 58
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Figure 3.2.3 Test of expression of HA — tagged MDM2 carboxy-terminal
deletion mutants. Proteins were separated on 12% polyacrylamide gel: A) Ponceau
—S staining, B) western blot with anti-MDM2antibody (Ab1, clone IF2), C) western
blot with anti-B-galactosidase antibody (Ab1, clone 200-193), D) western blot with
anti-actin antibody (C-2) (loading control for B-galactosidase).
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3.2.1.2 Determination of conditions for immunoprecipitation experiments with
HA-MDM2carboxy-terminal deletion mutants
After testing expression levels of HA-MDM2 carboxy-terminal deletion
mutants another experiment was performed in order to establish conditions for the
immunopreciptation procedure. Two different antibodies were examined — anti-HA
tag (16B12) and anti-DNA polymerase o catalytic subunit p180 (N-19) in order to
be used in subsequent immunoprecipitation experiments.
Therefore, H1299 cells were transfected with expression vectors for p180 — the
catalytic subunit of DNA polymerase a, B-galactosidase and either the 166 or 335
amino acids fragment of HA-tagged MDM2 mutant. Immunoprecipitation was
carried out as described in Materials and methods (section 2.10) and two antibodies
were tested: an antibody recognizing HA tag (16B12) was usedfor oneset of lysates,
while an antibody recognizing the DNA polymerase @ catalytic subunit p180 (N-19)
was used on the other set. Appropriate antibodies were also included as
isotype/antibody controls: anti-CD20 (Leu16) and anti-DHFR(E-18), respectively.
Samples from immunoprecipitation experiments were analysed by SDS-PAGE
followed by western blotting with anti-p180 (N-19) and anti-MDM2 (AbI1, clone
IF2) antibodies (Figure 3.2.4A-E). Based on the results from western blot analysis,it
is clear that immunoprecipitation with an anti-p180 antibody resulted in co-
precipitation of p180 with both 166 and 335 HA-MDM2 mutants,as presented in
Figure 3.2.3C. However, when anti-HA tag (16B12) antibody was used for
precipitation, only HA-tagged MDM2 mutants were immunoprecipitated and p180
could not be detected (Figure 3.2.4B).
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Figure 3.2.4 Co-immunoprecipitation experiment of p180 with 166 and 335 HA-
tagged MDM2. H1299cells were transfected with p180 (30 yg), B-galactosidase (6
wg) and either 166 HA-MDM2or 335 HA-MDM2 (30 1g) (A). Two 15 cm dishes
of H1299 cells per each condition were transfected with GeneJuice™ reagentat a 3:1
ratio. For each immunoprecipitation 3 mg of protein lysate were used. For
immunoprecipitation the antibodies used were: B) anti-HA (16B12) antibody (2pg);
C) anti-p180 (N-19) antibody (2g); D) anti-CD20 (Leu16) (2g) - antibody control
for anti-HA (16B12) antibody; E) anti-DHFR (E18) (21g) - antibody control for anti-
p180 (N-19) antibody; F) Ponceau-S stained membrane presented as a loading
control. Mutant MDM2proteinsare indicated by arrows: 166 ~ at 22 kDa, 335 ~ at
54 kDa (A, B,C).
106
 Results
Based on results presented in Figure 3.2.4 we concluded that the anti-p180
antibody could be used for further immunoprecipitation experiments with p180 and
HA-tagged MDM2 mutantproteins, while the anti-HA tag (16B12) antibody was not
suitable for this purpose. Furthermore, as shownin Figure 3.2.4B, 166 and 335 HA-
tagged MDM2 were co-immunoprecipitated with p180 protein, thus it appears that
these proteins form complexes with DNA polymerase o in cells.
3.2.1.3 Co-immunoprecipitation of p180 with A 1-49, 166, 230, 280 MDM2
The experiment described in section 3.2.1.2 demonstrated that the anti-p180
antibody (N-19) was suitable for Co-IP experiments with DNA polymerase
catalytic subunit (p180) and MDM2 mutants, thus we decided to use that antibody to
further examine p180-MDM2interactions in cells in culture. In addition to the HA-
tagged MDM2 mutants (presented in Figure 3.2.2) another MDM2deletion mutant
(Al-49 MDM2) lacking the first 49 amino acids of MDM2 (see schematic
representation in Figure 3.2.5) was available in our laboratory (described in more
detail in reference no. 57) and therefore we decided to include that mutant in our
immunoprecipitation experiment.
50 NLS NES NoLS 491
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Figure 3.2.5 Schematic representation of MDM2 mutantlacking the amino-
terminal 49 amino acids. Construct was made by former memberof our research
group - Dr. Mark Brady (57).
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As with the other mutants, prior to using the Al-49 MDM2 construct in
immunoprecipitation experiments, the expression levels of Al-49 MDM2and 166
HA-MDM2were comparedin cell lysates of transiently transfected H1299 cells by
SDS-PAGEand western blot. As shown in Figure 3.2.6 the expression level of both
constructs was comparable, hence the Al-49 MDM2construct was deemed to be
suitable to use alongside 166 HA-MDM2and other HA-MDM2 carboxy-terminal
deletion mutants in subsequent immunoprecipitation assays.
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Figure 3.2.6 Test of expression of 166 and A49 MDM2 mutants. H1299 cells
were transfected with 10 yg of the appropriate MDM2 plasmid DNA and2 yg of B-
galactosidase plasmid using GeneJuice™; A) western blot with anti-MDM2antibody
(Ab1, clone IF2), B) western blot with anti-B-galactosidase antibody (Ab1, clone
200-193) (transfection efficiency control), C) western blot with anti - actin antibody
(C-2) (loading control); M — indicates protein molecular weight marker.
H1299 cells were transfected with expression vectors for p180, f-
galactosidase and either Al-49, 166, 230 or 280 MDM2per each condition. Cells
were then processed as described in Materials and methods (section 2.10) and
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samples analysed by SDS-PAGE followed by western blot analysis with anti-p180
(N-19) and anti-MDM2(Ab1, clone IF2) antibodies (Figure 3.2.7).
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Figure 3.2.7 Co-immunoprecipitation of p180 with A49, 166, 230 and 280
MDM2. H1299cells were transfected with p180 (30 pg) and either A49MDM2 (30
ug) (lane L, panel A), 166HA-MDM2(30 pg)(lane L, panel B), 230HA-MDM2 (30
ug) (lane L, panel C) or 230HA-MDM2(30 pg) (lane L, panel D). Experiment was
carried out using 3mgof protein, immunoprecipitation was performed with anti-p180
(N-19) antibody (lanes marked: IP) and anti-DHFR (E18) as an antibody control
(lanes marked: AC). For western blot analysis p180 (N-19) and MDM2(AbI1, clone
IF2) antibodies were used.
Results obtained after immunoblot analysis confirmed that p180 can be co-
immunoprecipitated with 166 HA-MDM2 mutant (Figures 3.2.4C and 3.2.7B). In
addition, Al-49, 230 and 280 MDM2 mutants were also co-immunoprecipitated with
p180 (Figure 3.2.7 A,C,D).
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Based on these findings, it appears that the MDM2 region involved in
forming a complex in the cell with p180 lies between amino acids 50 and 166 of
MDM2.In orderto further test this conclusion, an MDM2 mutant lacking the amino-
terminal 166 amino acids was generated that could be used to drive expression in
mammalian cells, and subsequently examinedforthe ability of the mutant MDM2to
co-immunoprecipitate with p180.
3.2.1.4 The amino terminal 166 amino acids fragment of MDM2is dispensable
for forming a complex with p180 in cells in culture
Immunoprecipitation experiments performed thus far revealed that p180
forms complexes in cells with MDM?deletion mutants, as presented in Figures 3.2.4
and 3.2.7. Based on the immunoprecipitation data, the region between aminoacids
50 and 166 of MDM2 seems to mediate the interaction with p180. To further
examine this possibility, an MDM2 mutant lacking the amino-terminal 166 amino
acids (A166MDM2) wascreated as described in Materials and methods(section 2.1);
schematic representation of A166MDM2is presented in Figure 3.2.8.
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Figure 3.2.8 Schematic representation of MDM2 mutantlacking of the amino-
terminal 166 amino acids. Location of different domains and motifs indicated by
coloured boxes; NLS — nuclear localization signal, NES — nuclear export signal,
NoLS — nucleolarlocalization signal.
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Figure 3.2.9 Test of expression of A166, 166 and 280 MDM2 mutants. H1299
cells were transfected with 10 pg of appropriate MDM2plasmid DNA and 2 pg of B-
galactosidase using GeneJuice™ and separated along untransfected H1299 cells
lysate (Unt.); A) western blot with anti-HA antibody (16B12), B) western blot with
anti-B-galactosidase antibody (Ab1, clone 200-193) (transfection efficiency control),
C) western blot with anti-actin antibody (C-2) (loading control for B-galactosidase);
M — indicates protein molecular weight marker.
Before using the A166MDM2construct in immunoprecipitation experiments,
the expression levels of A166MDM2and for comparison the existing 166 and 280
HA-MDM2mutants were comparedin transiently transfected H1299 cells analyzed
by SDS-PAGEand western blot. As shown in Figure 3.2.9 the expression level of
constructs was at comparable levels, hence the Al66MDM2construct was deemed
suitable to use alongside the 166, 280 HA-MDM2and other MDM2deletion mutants
in subsequent immunoprecipitation assays.
H1299 cells were transfected, using Genejuice, with expression vectors for
p180, B-galactosidase and either A1-49, A166, 166, 230, 280 or 335 MDM2mutants.
Immunoprecipitation was carried out as described in Materials and methods(section
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2.1), then samples were analysed by SDS-PAGEfollowed by western blot analysis
with anti-p180 and either anti-MDM2 (Ab1, clone IF2) (Figure 3.2.10A) or anti-HA
(16B12) (Figure 3.2.10B).
As shownin Figure 3.2.10A, results for already tested MDM2 mutants were
in agreement with previous findings with Al-49, 166, 230, 280 and 335 MDM2 were
all found to immunoprecipitate with p180 (c.f. Figures 3.2.4C, 3.2.7). However, the
A166 MDM2 wasalso found to immunoprecipitate with p180 (Figure 3.2.10B, IP
panel). This observation suggests that whilst the region of amino-terminal 166 amino
acids of MDM2is required for direct interaction with p180 in vitro, it is dispensable
for complex formation with p180 in the cell. Co-immunoprecipitation assays cannot
distinguish between direct and indirect interaction between proteins and thus these
results may be due to MDM2 and p180 interacting with other proteins in a complex
in thecell.
Results from in vitro binding assay (sections 3.1.3, 3.1.4) indicated that p180
and MDM2interact directly, with the amino-terminal 166 amino acids of MDM2
being required for in vitro interaction. However, in vivo experiments have not
confirmed an essential role of this amino-terminal 166 amino acids of MDM2 in
mediating interaction with p180 in cells, albeit that the existence of a protein
complex involving p180 and MDM2in cells was observed. Based on the results
obtained, we conclude that p180 and MDM2interact directly and that the amino-
terminal 166 amino acids of MDM2are required for direct interaction with p180 in
vitro. In addition, p180 and MDM2interact in cells in culture, but incorporation of
MDM2into this complex does not depend upon the amino-terminal 166 aminoacids
of MDM2and maywell depend uponotherprotein/s.
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Figure 3.2.10 Co-immunoprecipitation of p180 with MDM2 mutants. H1299
cells were transfected with p180 (30 pg) and either A49, A166, 166, 230, 280, 335
MDM2 (30 pg) using GeneJuice™ reagent, as presented in Lysates panel.
Immunoprecipitation was performed on 3mgoftotal protein with anti-p180 (N-19)
antibody (IP panel) and anti-DHFR (E18) as an antibody control (AC panel). For
western blot analysis anti-p180 (N-19) and anti-MDM2 (Abl1, clone IF2) antibodies
were used in section A, in section B anti-p180 (N-19) and anti-HA (16B12). Main
MDM2 mutants bandsindicated by arrows(IP panel): A49 at ~ 77 kDa, 166 at ~ 22
kDa, 230 at ~ 30 kDa, 280 at ~ 42 kDa, 335 at~ 55 kDa, A166 at ~ 65 kDa.
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3.3 Examining the effect of MDM2 on DNApolymerase © activity
Results obtained from in vitro binding assay and immunoprecipitation
experiments revealed that MDM2 interacts with the catalytic subunit of DNA
polymerase ©, both in vivo and in vitro (sections 3.1, 3.2). When studies on
interaction between MDM2 and DNApolymerase € were performed by the members
of our research group (58, 59) they revealed that the polymerase activity of DNA
polymerase € was stimulated by MDM2in vitro (59). Encouraged by these findings
we decided to perform similar experiments in order to test whether MDM2 may
stimulate or otherwise modify the catalytic activity ofDNA polymerase a.
3.3.1 Purification of the catalytic subunit (p180) of DNA polymerase a
In order to perform DNA polymerase assays to examine DNA polymerase a
activity upon addition of MDM2wefirst needed to produce and purify the catalytic
subunit (p180) of DNA polymerase o. The purification of 6xHis-tagged p180 was
performed using Ni-NTA agarose beads under native conditions in order to retain
p180 enzymaticactivity.
DNA polymerase © catalytic subunit (p180) was expressed in and purified from
insect cells using procedures described in Materials and methods (section 2.9). Cells
lysates, after infection with pBlueBacHis2p180, were incubated with Ni-NTA beads,
the lysate-Ni-NTA bead mixture was then applied to a column.In orderto determine
the amountofthe specific protein that has not boundto the beads, the column flow-
through fraction was collected. The beads on the column were extensively washed
with SLIP buffer containing 20mM imidazole, to remove proteins nonspecifically
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bound to Ni-NTA beads. After washing, the catalytic subunit (p180) of DNA
polymerase & was gradually eluted using SLIP buffer containing increasing amounts
of imidazole: 50, 100, 150 and 200 mM imidazole.
 1 2 3 FT 50 100 150 200 M
> 175
send
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Figure 3.3.1 Brilliant Blue G staining and western blot analysis of fractions
collected during p180 purification from the insect cells. Lanes marked 1-3
represent fractions of 0.03% of raw lysates from insect cells cultures; FT represents
0.03% of flow through from the column; 50 — 200 lanes represent 2% of
elution/imidazole (mM) fractions. Fractions were separated on 6% polyacrylamide
gel, followed by: A) staining with Brilliant Blue G, arrows indicate 6xHis-tagged
catalytic subunit (p180) of DNA polymerase © location on the gel at ~ 180kDa, B)
western blot analysis using anti DNA polymerase a (N — 19) antibody; M — indicates
protein molecular weight marker.
Fractions obtained during p180 purification (including raw lysates of insect
cells, column flow- through and elution fractions) were subjected to 6% SDS-PAGE
followed by Brilliant Blue G staining and western blot analysis. As shown in Figure
3.3.1 A and B, DNA polymerase o protein is present in fractions from raw lysates,
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which indicate successful infection of the insect cells with virus from
pBlueBacHis2p180 transfected insect cells. In addition, the amount of p180 in the
flow through fraction indicating the amount of unboundprotein wasrelatively low,
which suggested that majority of protein of interest has bound to the Ni-NTA beads.
Finally, the presence of p180 in elution fractions with 100 and 150 mM imidazole, is
also indicative of successful purification.
 
p180 BSA
100 150 20 50 100
fractions M (ng/L)
 
  
Figure 3.3.2 Brilliant Blue G staining of 100 and 150 mM imidazole fractions of
p180 fractions. Fractions represent 100 and 150 mM imidazole eluents collected
during DNA polymerase a purification process separated along with increasing
amount of BSA; arrow indicates DNA polymerase © location on the gel at ~ 180kDa;
M — indicates protein molecular weight marker.
After purification of DNA polymerase © catalytic subunit (p180), we wanted
to estimate the amount of p180 protein present in 100 and 150 mM imidazole
fractions, thus both samples along with increasing amount of BSAas a standard were
separated on 8% polyacrylamide gel and stained with Brilliant Blue G (Figure
3.3.2). Based on the Brilliant Blue G staining, the amount of protein of interest
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recovered was compared to a BSA standard and although the standard appeared to be
overloaded, it was estimated that 100 mM fraction contains approximately 5 ng per
ul, whereas 150 mM about 10 ngperul. For the further experiments p180 from the
150 mM fraction were used, since the amountof protein was greater than in 100 mM
fraction.
3.3.2 Examination of p180 enzymatic activity
Pilot DNA polymerase assays were performed in order to test whether the
enzymatic activity of p180 was retained after purification from insect cells. The
assay in general enables one to measure polymerase activity based on incorporation
of radiolabeled nucleotides e.g. [7H] dTTPs.
The time course experiment was performed with different amounts of catalytic
subunit of DNA polymerase & (p180) from 150 mM imidazole elution fraction
(Table 3.3.1) assayed as described in Materials and methods (section 2.13) and then
collected at several time points as specified in Table 3.3.1.
 Amount of p180 (ng) Time points (minutes)
10
20 0, 15, 30, 60, 120
40    
Table 3.3.1 Conditions for DNA polymerase assay — time course. Amounts of
p180 used andthe time points at which samples werecollected are indicated.
Reaction products were TCA-precipitated ontofilters, air-dried, suspendedin
scintillant and counted. Results are shown in Figure 3.3.3 which demonstrates that
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that p180 purified from the insect cells retains enzymatic activity in this assay. The
rate of product formation is almost linear during the first 15 minutes, then decreases,
however the enzymeretains detectable activity up to 2 hours. The figure also
demonstrates that there is a dose-dependent incorporation of [3H]dTTPs.
Based on these results, we conclude that the enzymatic activity of DNA
polymerase © catalytic subunit (p180) purified from insect cells has been retained,
and that by performing assays for 1 hour should provide a good compromise between
a stable linear reaction rate and assay sensitivity.
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Figure 3.3.3 Enzymatic activity of purified 6xHis-tagged human DNA
polymerase © catalytic subunit - p180 expressed in baculovirus infected insect
cells. Three different amounts of p180 (10, 20 and 40 ng) were assayed and collected
at certain time points (0, 15, 30, 60, 120 minutes). Incorporation of [3H]dTTP
(picomoles) was measured by scintillation counting. Data are shown as mean +
standard error of the mean.
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3.3.3 DNA polymerase assay with MDM2purified from theinsectcells
Once the enzymatic activity of purified p180 was confirmedin the pilot assay
(section 3.3.2), other tests were performed in order to investigate whether MDM2
influences p180 polymeraseactivity.
For these experiments MDM2 from insect cells purified by a former member
of our research group - Dr. Eider Larrarte was used. Aliquots of MDM2werestored
at —80°C and each contained approximately 60 ng per pl of MDM2protein. The
MDM2wasproducedin insect cells after infection with a baculovirus vector and the
purification procedure was conducted in the same way as described for p180 in
Materials and methods(section 2.9).
 
Amount/ volume Volumeof
Amount of p180 of MDM2 assay buffer
1 ng
 3 ng - 9 pl
10 ng
lng
3 ng 540 ng/9 pl -
10 ng
     
Table 3.3.2 Conditions for DNA polymerase assay with MDM12purified from
insect cells. Different amounts of pl80 were assayed with either specified
amount/volume ofMDM2orassay buffer as indicated.
To examine any putative MDM2effect on polymerase activity of p180, a
DNApolymerase assay was performed, with p180titrated in the presence of either
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MDM2orthe assay buffer, as presented in Table 3.3.2. After one hour incubation at
37°C, samples were transferred to filters, washed and counted in the scintillation
counter.
The results shown in Figure 3.3.4 demonstrate that amount of incorporated
[3H]dTTPsis higher when p180is assayed in the presence of MDM2than for p180
assayed with only the buffer. For each of three different amounts of p180 used, there
is a noticeable difference ranging from approximately two-fold higher values for 10
ng of p180 to almost 3.5 fold higher activity for 3 ng of p180.
 
 
  
Yn2°£22°o=o
keKk5x=
oO
0 2 4 6 8 10 12
p180 (ng)
—e— p180+buffer —m— p180+MDM2 | 
Figure 3.3.4 Enzymatic activity of purified 6xHis-tagged p180 upon addition of
MDM2purified from insect cells. DNA polymerase © catalytic subunit - p180
expressed in baculovirus infected insect cells mixed with either assay buffer
(p180+buffer) or MDM2 (p180+MDM2).Three different amounts of p180 (1, 3 and
10 ng) were assayed with buffer/MDM2 and collected after 60 minutes.
Incorporation of [3H]dTTP (picomoles) was measuredbyscintillation counting. Data
are shown as mean + standard error of the mean.
120
 Results
These observations, based on results presented in Figure 3.3.4, suggest that
addition of MDM2stimulates the polymerase activity of p180 in vitro. However, the
possibility exists that MDM2 expressed and purified from the insect cells might
either possess or co-purify with DNA polymeraseactivity.
During the protein purification process there is the possibility that
contaminants that possess DNA polymeraseactivity or other proteins that may affect
activity of assayed enzymebind to the resin/protein and then are eluted with the
protein of interest, we were concerned about the purity of MDM2protein purified
from the insect cells and by the possibility of such contaminating enzymaticactivity.
In order to address these questions, we prepared equivalent fractions of protein from
uninfected insect cells, grown and processed in exactly the same manneras used for
MDM2protein purification procedure (Figure 3.3.5). The presence of p180 and
MDM2in uninfected cells fractions was verified by western blot with anti-DNA
polymerase & and anti-MDM2antibodies, respectively (Figure 3.3.6).
150 200 M
| cemcd sea
  
  
Figure 3.3.5 Brilliant Blue G staining of fractions collected during purification
process of uninfected insect cells. Lanes marked: RL represents 0.03% raw lysate
from insect cells culture; FT represents 0.03% of flow through from the column; 50 —
200 lanes represent 2% of elution/imidazole (mM)fractions; M — indicates protein
molecular weight marker.
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Figure 3.3.6 Western blot analysis of 150mM elution fraction collected during
purification process of uninfected insect cells. Presence of MDM2and p180 was
verified in fraction as indicated: A) lane marked: S represents sample of 150mM
imidazole/elution fraction from uninfected insect cells culture and lane C MDM2
represents MDM2purified from insect cells in 150mM imidazole/elution fraction
which served as a positive control, anti-MDM2(Ab1, clone IF2) antibody was used
for western; B) lane marked: S represents sample of 150mM imidazole/elution
fraction from uninfected insect cells culture and lane C p180 represents p180 purified
from insect cells in 150mM imidazole/elution fraction which served as a positive
control, anti-p180 (N-19) antibody was used for western. Main protein bands are
indicated by arrows: MDM2at ~ 90kDa, p180 at ~180kDa.
Results from the purification process, visualized by Brilliant Blue G staining
(presented in Figure 3.3.5), suggest that many endogenousinsect proteins bind to the
Ni-NTAbeads and are subsequently eluted with increasing imidazole gradient, with
the majority of proteins being eluted in 100mM and 150mM imidazole fractions. The
fact that many endogenousinsectproteins bind to Ni-NTA beads, and thenare eluted
in the same condition as MDM2protein, confirm our concerns aboutother proteins
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being present in MDM2 150mM imidazole elution fraction, which may mediate
stimulatory effect on p180 enzymaticactivity.
The approximate amount of proteins present in MDM2 150mM imidazole
fraction purified from the insect cells and 150mM imidazole fraction obtained from
uninfected insect cells, were compared in order to try to determine equivalency for
the further assays. Therefore, both samples were separated by SDS-PAGE and
stained with Brilliant Blue G (Figure 3.3.7). Based on the staining, it was estimated
that the level of background proteins in MDM2fraction was at least three times
greater than in an equivalent volumeofthe uninfected cells fraction (Figure 3.3.7).
MDM2 Uninfected insectcells
 10ul 20. 15 10 Spl
 
  
Figure 3.3.7 Brilliant Blue G staining of 150mM imidazole fraction of uninfected
insect cells and MDM2 purified from the insect cells. MDM2 from 150 mM
imidazole fraction (101 run on the gel) and 150mM imidazole fraction of uninfected
insect cells (different volumesrunon the gel from 20 to 51) were separated by SDS-
PAGE followed by Brilliant Blue G staining in order to compare amounts of
background proteins in these fractions. Main MDM2protein band is indicated by
arrow: at ~ 90kDa.
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Since many endogenous insect proteins were eluted from uninfected insect
cells, but also were present with MDM2 from MDM2expressinginsect cells (Figure
3.3.7) we wanted to examine, prior to the assay with p180, whether any of these
fractions displays DNA polymeraseactivity. Samples were assayed along with p180
and assay buffer for comparison. As presented in Figure 3.3.8, the value obtained for
p180 sample was two-fold higher than both the uninfected insect cells or MDM2
fraction, with the latter both being comparable to background value from the assay
buffer alone. Based on these observations it was concluded that fractions obtained
following the purification procedure from either uninfected insect cells or from
MDM2expressinginsect cells do not possess intrinsic DNA polymeraseactivity.
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Figure 3.3.8 Examination of intrinsic polymerase activity of MDM2 and
uninfected cells fractions. Polymerase activity was measured for the assay buffer
(Buffer); 3 ng of p180 - 150 mM imidazolefraction purified from insect cells (p180
(3ng)); 180 ng of MDM2 - 150 mM imidazole fraction purified from insect cells
(MDM2(180ng/3p1)); 9p1 of 150 imidazole fraction purified from uninfected insect
cells (Ctrl (9y1)). Incorporation of [3H]dTTP (picomoles) was measured by
scintillation counting. Data are shown as mean + standard error of the mean.
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Having tested that neither the purified MDM2fraction nor those from the
uninfected insect cells possess intrinsic DNA polymerase activity we examined the
effect of purified MDM2along with fractions of proteins from uninfected insect cells
on p180 activity. Since the estimated level of background proteins in the MDM2
fraction was at least three times greater than in an equivalent volume of the
uninfected cells fraction, for the DNA polymerase assay, the volumeof the control
fraction from uninfected insect cells was adjusted to exceed three times the volume
ofMDM2fraction, as presented in Table 3.3.3.
 
Volumeof control
Amount / volume
 
 
Amountof p180 fractionof MDM2 (uninfected insectcells)
- 1 pl
3 ng - 3 pl
- 9 pl
60 ng/1 pl -
3 ng 180 ng/3 pl -
540 ng/9 pl -     
Table 3.3.3 Conditions for DNA polymerase assay with MDM2purified from
insect cells and control uninfected cells. Different amounts/volumes of MDM2
were put into the assay with corresponding amount of background protein/volumes
of uninfected insect cells fraction as indicated.
Accordingly, p180 was mixed with varying amounts of either MDM2 or
corresponding amounts of control uninfected insect cells fraction e.g. 60ng/1}11 of
MDMI2was compared with 31 of control uninfected cells (Table 3.3.3). In addition,
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since the quantification of protein in these fractions was based on estimates we also
compared equivalent volumes of MDM2andthe control fraction in the assay i.e. 1pl
of MDM2fraction was compared with | yl of control uninfected cell fraction. After
one hour incubation at 37°C samples weretransferred onfilters, washed and counted
in the liquid scintillation counter. The results using equivalent volumesare presented
in Figure 3.3.9 and those from the equivalent amounts of backgroundproteins are
presented in Figure 3.3.10.
Comparing activity of p180 upon addition of equal volumes of control from
uninfected insect cells and MDM2, it was observed that the activity of p180 was
approximately 1.6 fold higher with addition of MDM2 comparedto addition of the
uninfected cell fraction. However, when these results were analysed taking into
account that the volume of the control should exceed the volume of MDM2 by
roughly three-fold (in order to have comparable amounts of backgroundproteins), no
obvious difference in p180 activity with either MDM2or uninfected cells fraction
was observed, as shownin Figure 3.3.10.
Based on these data it is difficult to conclude whether or not the evidence
presented to date demonstrating that MDM2apparently stimulates p180 activity is a
real and specific effect or whether it might be the result of an artifact. It is certainly
possible that the purified MDM2present in the fraction from insect cells is not
responsible for stimulatory effect on p180, while other protein/proteins present along
with MDM2 or without MDM2 in the fraction from uninfected insect cells may
mediate this effect.
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Figure 3.3.9 Enzymatic activity of p180 mixed with either control fraction from
uninfected insect cells or MDM2. (p180+C) - 3 ng ofp180 were assayed with either
different volumes of control fraction (1, 3 and 9ul) or (p180+MDM2) different
amounts of MDM2 (60ng - ll, 180ng - 31, 540ng — Spl). Effects of equivalent
volumes of control and MDM2added to p180 were compared alongside (A — line
chart, B — column chart). Data are shown as mean + standarderror of the mean.
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Figure 3.3.10 Enzymatic activity of p180 mixed with either control fraction from
uninfected insect cells or MDM2. (p180+C) - 3 ng of p180 were assayed with
different volumes of control fraction (3 and 9ul) or (pl180+MDM2) - different
amounts of MDM2 (60ng - ll, 180ng - 3y1). Effects of three times greater volumes
of control fraction in comparison to volume of MDM2 addedto p180 (A — line chart,
B—column chart). Data are shown as mean + standard error of the mean.
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3.3.4 Investigating the specificity of the stimulatory effect of MDM2 on p180
activity: use of MDM?2-specific antibodies to try to block the effect
Based on the experimental results presented in section 3.3.3, it seems that
MDM2 may not stimulate the polymerase activity of the catalytic subunit of DNA
polymerase a (p180), but since the controls for these experiments are imperfect, we
therefore wanted to try another approachto investigate this matter.
Therefore, we performed DNA polymerase assays in which MDM2 was
added in the presence and absenceofvarious anti-MDM2antibodies. The idea being
to attempt to block MDM2stimulation by mixing the protein with antibodies mainly
recognizing epitopes on its amino — terminal half, which as shownin sections 3.1.3
and 3.1.4 ofthis thesis is involved in mediating interaction with p180. By using such
an approach we predicted two possible outcomes. If an antibody inhibited
stimulatory effect of MDM2 on p180 activity, then this would suggest that MDM2
specifically mediates this effect. In the event that no inhibitory effect was observed,
the conclusion would be more ambiguous since either the antibody binding to
MDM2hasnoeffect on the ability of MDM2 to stimulate p180 activity or another
protein that co-purifies with MDM2 must be responsible for stimulating p180
activity.
Anti-MDM2antibodies used for the experiment were as follows: Ab1 (clone
IF2) — recognizes an epitope within amino acids 26 — 169; SMP14 — raised against
amino acids 154 — 167; N-20 — recognizes an epitope at the amino-terminus; in
addition anti-MDM2 (C-18), which recognizes an epitope at the carboxy-terminus
and anti-p53 (2433) antibodies were used as negative/specificity controls. All the
antibodies were mixed with MDM2 and incubated on ice for 15 minutes prior to
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adding p180, followed by additional 15 minutes incubation on ice with the enzyme
(Table 3.3.4). After one hour incubation at 37°C, samples weretransferredto filters,
washedand countedin the liquid scintillation counter.
 
  
 
  
Amount Amount Antibody usedof p180 of MDM2
anti-MDM2(Ab1) (lpg)
anti-MDM2 (SMP14) (1g)
3 ng 60 or 180 ng anti-MDM2 (N-20) (lpg)
anti-MDM2(C-18) (lpg)
anti-p53 (2433) (lug)  
Table 3.3.4 Conditions for DNA polymerase assay with MDM2purified from
insect cells and various antibodies. Varying amounts of MDM2 were addedto the
assay together with the indicated amounts of antibodies recognising MDM2or p53
(as a control).
As presented in Figure 3.3.11, the activity of p180 assayed with MDM2 was
considerably greater than activity of p180 assayed in the buffer. Upon addition of
antibodies, the activity of p180 was not substantially changed. Therefore, as argued
above, these results do not shed additional light on the nature of the potential
stimulation of p180 activity by MDM2.
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Figure 3.3.11 Enzymatic activity of p180 incubated either with assay buffer,
MDM2or MDM?pre-incubated with the indicated antibodies. 3 ng of p180 were
assayed with the indicated amounts of MDM2 (60 or 180ng) in the presence or
absence of indicated antibody. Incorporation of [3H]dTTP (picomoles) was
measured by scintillation counting. Data are shown as mean + standard errorofthe
mean.
3.3.5 DNA polymeraseassay with bacterially expressed GST-MDM2
DNA polymerase assays performed with MDM2 purified from insect cells,
revealed that p180 activity was stimulated, but we could not determine whether or
not this was due to the presence of other protein/proteins in addition to the MDM2
addedto the assay (section 3.3.3). To try to resolve this uncertainty we have pursued
another approach in which MDM2is producedin a heterologous system. We chose
to test the effect of MDM2 expressed in bacterial system for a numberofreasons.
Firstly, in other studies (134) we had found that expression and purification of
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glutathione S-transferase (GST) tagged MDM2 protein allowed us to obtain
relatively large amounts of fairly pure MDM2 and moreover, this would probably be
contaminated with a different set of contaminant proteins than were present in the
insect cells. Perhaps more significant, MDM2 purified in this mannerretains its E3
ligase activity for up to 24 hours (134), and this can be verified by performing in
vitro ubiquitylation assays. By using freshly prepared GST-MDM2 versus GST-
MDM2protein from frozen aliquots, it would be possible for us to compare an effect
of enzymatically active and inactive MDM2on p180 polymeraseactivity.
3.3.5.1 DNA polymerase assay with frozen (enzymatically inactive) aliquots of
bacterial GST-MDM2
In order to perform DNA polymerase assays with GST-MDM2,the protein
was purified from Escherichia coli, as described in Materials and methods (section
2.11). Since glutathione S-transferase (GST), used to facilitate purfication of MDM2
can be readily purified in the absence of a fusion partner, we could use purified GST
as an appropriate control. For these experiments the purified GST was purified by a
former member of our research group Dr. Tim Devling. In order to estimate the
amount of GST-MDM2 and GST present in elution fractions, samples were
subjected to SDS-PAGE followed by Brilliant Blue G staining with BSAtitrated
providing a standard (Figure 3.3.12). Based on the Brilliant Blue G staining, it was
estimated that elution fractions contained approximately 20 ng per pl of GST-
MDM2,whereasthe elution fraction of GST approximately ten times more protein
(200ng/ul).
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Figure 3.3.12 Brilliant Blue G staining of GST and GST-MDM2proteins
purified from E.coli. GST and GST-MDM2proteins purified from E.coli were
separated by SDS-PAGEfollowed by Brilliant Blue G staining, BSA wasused as a
protein amount standard. Main protein band are indicated by arrows: GST at ~
26kDa, GSTMDM2at ~ 120kDa.
In the first instance we tested whether excess GST-MDM2could stimulate a
range of p180 concentrations with GST as a control normalized either for matched
volumeorprotein concentration (based upon ourearlier estimates) (Table 3.3.5)
 
 
 
Amount Amount Amount
of p180 of GST-MDM2 of GST
3ng
10ng - 180ng or
20ng 1.8pg/9 pl
3ng
10ng 180ng/91 -
20ng     
Table 3.3.5 Conditions for DNA polymerase assay with GST-MDM2 and GST
purified from E.coli. Different amounts of p180 were put into the assay with GST-
MDM2and GSTas controlas indicated.
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Based on the results presented in Figure 3.3.13 it can be observed that neither
GST nor GST-MDM2possessintrinsic polymerase activity. Moreover, the activity
of p180 wasnotaltered upon addition of either GST-MDM2or GSTasFigure 3.3.13
illustarates.
GST-MDM2purified from E.coli and stored frozen in —80°C does not
stimulate the activity of DNA polymerase o catalytic subunit. These findings support
earlier observations suggesting that the stimulatory effect on p180 polymerase
activity was not mediated by MDM2protein (Figure 3.3.10).
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Figure 3.3.13 Enzymatic activity of p180 assayed with enzymatically inactive
MDM2.Different amounts of p180 (A-3ng, B-10ng, C-20ng) mixed with either
assay buffer, GST or GST-MDM2(frozen batch) purified from £.coli. Incorporation
of [3H]dTTP (picomoles) was measuredbyscintillation counting. Data are shownas
mean + standard error of the mean.
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3.3.5.2 Assay of DNA polymerase o activity in the presence of freshly purified
(i.e. E3 ligase active) GST-MDM2
MDM2possesses an E3 ligase activity (64) that might alter DNA polymerase
© activity and which is lost when the enzymeis stored frozen or within 24 hours
when stored at 4°C. We therefore decided to test freshly prepared GST-MDM2
protein, which retain its E3 ligase activity, in order to examine whether
enzymatically active GST-MDM2mayalter p180 activity.
Both GST and GST-MDM2were purified from £.coli and immediately after
purification proteins were subjected to SDS-PAGE followed by staining with
Brilliant Blue G in order to confirm the presence and estimate the yield of proteins of
interest (Figure 3.3.14). Based on the Brilliant Blue G staining, compared to a BSA
standard, it was estimated that elution fractions contains approximately 20 ng perpl
of GST-MDM2, whereaselution fraction of GST yielded approximately ten times
more protein (200ng/ul).
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Figure 3.3.14 Brilliant Blue G staining of purified GST and GST-MDM2
proteins. GST (A) and GST-MDM2(B) were separated by SDS-PAGEfollowed by
Brilliant Blue G staining. BSA wasusedas a protein amount standard. Mainprotein
band are indicated by arrows: GST at ~ 26kDa, GST-MDM2at ~ 120kDa.
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In vitro ubiquitylation assays were performed to test whether purified GST-
MDM2wasable to mediate auto-ubiquitylation in vitro, thus confirming whether
MDM2retained its E3 ligase activity. GST-MDM2 wasincubated in the presence
and absence of ubiquitin (Ub) at 30°C overnight. After incubation samples were
subjected to SDS-PAGE and western blotting (Figure 3.3.15). As shown in Figure
3.3.15, in the presence of ubiquitin, purified GST-MDM2 catalyzed an auto-
ubiquitylation reaction, which confirmed its enzymaticactivity.
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Figure 3.3.15 GST-MDM2 in vitro ubiquitylation assay. In the presence of
ubiquitin (Ub) GST-MDM2catalyzes autoubiquitylation reaction in vitro. Samples
were subject to SDS-PAGEfollowed by western blotting with anti-MDM2antibody
(Ab1, clone IF2).
For the DNA polymerase assay p180 wastitrated with either 180 ng of GST-
MDM2or GST,or 1.8 pg of GST thus comparing either equal estimated protein
concentrations or eluate volumesrespectively, as presented in Table 3.3.5.
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Based on the results presented in Figure 3.3.16 it can be observedthat neither
GST nor GST-MDM2possess intrinsic polymerase activity. Moreover, the activity
of p180 was notaltered upon addition of either enzymatically active GST-MDM2or
GSTas presented in Figure 3.3.16.
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Figure 3.3.16 Enzymatic activity of p180 assayed with enzymatically active
MDM2.Enzymatic activity of different amounts of p180 (A-3ng, B-10ng, C-20ng)
mixed with either assay buffer, GST or freshly purified GST-MDM2from E.coli.
Incorporation of [3H]dTTP (picomoles) was measuredby scintillation counting. Data
are shown as mean + standarderror of the mean.
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In summary, results presented on the involvement of MDM2inaltering
p180 enzymatic activity do not provide clear evidence for such an effect, since the
activity of DNA polymerase & was not altered upon addition of bacterially purified
GST-MDM2either enzymatically active or inactive, whilst results from assays with
MDM?purified from insect cells seem to be ambiguous.In the latter experiments,in
which we observed stimulation of polymerase activity of p180 upon addition of
MDM?2-enrichedfractions, our main concern was the purity of used MDM2protein,
and subsequent experiments with equivalent fractions from uninfected insect cells
provided further support for this concern. Hence, to overcome the problem of impure
MDM2, we collaborated with Stuart Linn at U.C. Berkley, who has shown
previously a stimulatory effect of MDM2 on DNA polymerase € activity, where
exceptionally pure MDM2wasused (59). To examine MDM2effect on polymerase
activity of DNA polymerase a, an assay with MDM2 expressedin insect cells (59)
and DNA polymerase @ holoenzyme purified from HeLa cells was performed. As
observed in Figure 3.3.17A polymerase activity of DNA polymerase & was increased
substantially upon addition of MDM2, whilst this effect of MDM2 was inhibited
when anti-DNA polymerase @ antibody was added (Figure 3.3.17B). Hence, these
findings provide more convincing though not unequivocal evidence that DNA
polymerase © activity is stimulated by MDM2.
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Figure 3.3.17 Enzymatic activity of DNA polymerase a holoenzyme purified
from HeLa cells. A) MDM2 purified from insect cells (59); B) anti-DNA
polymerase & antibody (experiment was performed by Prof. S. Linn).
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3.4 Examinationof ability of MDM2 to mediate modifications of p180
Results presented in this thesis thus far indicate that MDM2interacts with
p180 both in vitro and in vivo. In addition, work from our collaboration with Stuart
Linn at U.C. Berkley suggests that MDM2 maystimulate the catalytic activity of the
DNA polymerase & holoenzyme (as Figure 3.3.17 shows). Since many MDM2
interacting proteins are subject to ubiquitylation (and often therefore to subsequent
degradation in proteasomes) mediated by MDM2 E3ligase activity (64,151), we
decided to test whether MDM2 might also modify p180. To the best of our
knowledge, there are no reports linking p180 with the ubiquitin/proteasome pathway.
Therefore, we first wanted to examine whether inhibition of the 26S proteasome
complex might have an effect on p180 levels in cells and might therefore suggest,
that p180 was subject to proteasomal degradation with the possibility that MDM2
might be involved in this.
3.4.1 MG132 addition to MCF-7, H1299 and Clone9 cells
In order to test whether p180 levels were changed upon addition of a well
known inhibitor of 26S proteasomes - MG132,the inhibitor was applied to MCF-7,
H1299 and Clone 9 (H1299)cells in culture. H1299 and Clone 9 cells are routinely
grown in our laboratory, (Clone 9 cells are derived from H1299 cells but express
high levels of MDM2 since the cells were stably transfected with
pCMVNeoBamMdm2)anddo not express p53; whilst MCF-7 cells were includedin
the experiment because Dr. Claire Gibney wastesting the effect of MG132 on MCF-
7 cells as part of a different study and kindly provided samples used in this
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experiment. Cells were treated with 10014.M MG132 andincubatedfor 0, 2, 4, and 6
hours before harvesting and then being subjected to SDS-PAGEand analysed by
western blotting.
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Figure 3.4.1 Effect of MG132 addition to MCF-7 cells. MCF-7 cells in culture
were treated with MG132 to a final concentration of 100M and harvested by
trypsinization at indicated time points: 0, 2, 4 and 6 hours; SOyg of total protein,
from each sample was subjected to SDS-PAGEfollowed by western blot using anti-
p180 (N-19) and anti-actin (C-2) antibodies as indicated; A) western blot analysis
performed on the samples separated on 6% polyacrylamide gel; B) western blot on
samples separated on 10% polyacrylamide gel (samples were provided by Dr. C.
Gibney).
In Figure 3.4.1, we can see that the level of p180 after 4 hours of treatment
with MG132is considerably higher than for 0, 2 or even 6 hours treatment. However,
the sample loading (indicated by the actin level) maybeslightly higher for this lane
(Figure 3.4.1B, lower panel).
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Figure 3.4.2 Effect of MG132 addition to Clone 9 and H1299 cells. Cells in
culture were treated with MG132to a final concentration of 100M and harvested by
trypsinization at the indicated time points; 5Oug of total protein, from each sample
was analyzed by SDS-PAGE followed by western blot; A) western blot with anti-
p180 (N-19) and anti-actin (C-2) antibodies as indicated; B) Ponceau S staining of
the blot as an indicator of samples loading.
The results for Clone 9 partly confirmed results for MCF-7 cells with
stabilization of p180 being observed after treatment for 2, 4 and 6 hours with MG132
(Figure 3.4.2A). In this case sample loading appears equal as indicated by actin
levels although Ponceau S staining suggests that the 6h time point sample was
overloaded (Figure 3.4.2B).
Based on the western blot analysis of samples from H1299 cells treated with
MG132,it was not obvious whether stabilization of p180 occurred (Figure 3.4.2A).It
appeared that loading was not equal, samples for time points 2 and 6 hours were
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overloaded (Figure 3.4.2A-actin, 3.4.2B). Nevertheless, the levels of p180 were not
considerably higher for these two time points suggesting that stabilization did not
take place.
In summary, results obtained for MCF-7 and Clone 9 cells, suggested that
p180 might be subject to regulation by the ubiquitin/proteasome pathway, whilstthis
was not observed in H1299 cells expressing relatively low levels of MDM2,
especially when compared to Clone 9 cells, which might suggest involvement of
MDM2in that process. However, in general data presented do not provide strong
evidence for p180 being subject to ubiquitin/proteasome degradation pathway,
especially in the light of findings presented in report from Wong SW et al. 1986
(109) which shows noevidence for intracellular degradation of p180, and estimates
half life of [15 hours for p180. Despite this we were determined to examine p180
ubiquitylation in cells, encouraged by the findings that proteins involved in DNA
replication such as Cde45 or PCNA are subject of that modification as well
(197,198). Moreover, westill wanted to test the potential involvement of MDM2in
mediating modification of p180, since MDM2 mediates ubiquitylation of many ofits
interacting proteins (reviewed in 151). Therefore, we decided to utilize an in vivo
ubiquitylation assay which enables us to address these issues.
3.4.2 In vivo ubiquitylation assay to examine MDM2involvement in mediating
p180 modification
To examine whether MDM2 might modify p180 by ubiquiltylating it we
performed an in vivo ubiquitylation assay based upon purification of ubiquitin-
conjugates by affinity chromatography. The in vivo ubiquitylation assay we used
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enablesidentification of substrates that are covalently modified by addition of 6xHis-
tagged ubiquitin moieties expressed in the cell that can be purified by binding of
these to Ni-NTA agarose beads.
H1299 cells were transfected with constructs expressing variously 6xHis-
tagged ubiquitin, MDM2 and/or p180, as described in Figure 3.4.3 lanes 2-8. We
wanted to examine whether p180 could be pulled down(1.e. affinity purified) along
with 6xHis-tagged ubiquitin, in either the absence or presence of transiently
transfected MDM2 (Figure 3.4.3 lanes 3 and 5 respectively). An increase in the
amount of p180 affinity purified in the presence of transfected MDM2 would suggest
MDM2involvementin p180 ubiquitylation. In addition, cells transfected solely with
6xHis-tagged ubiquitin provided an indication of endogenous ubiquitylation levels of
the proteins of interest (Figure 3.4.3 lane 2). Lanes 1, 4, 6 and 8 serve as specificity
controls for the assay, since 6xHis-tagged ubiquitin was not transfected and any
proteins pulled downarethe result of non-specific interactions of these proteins with
Ni-NTA agarose beads. Finally, the samples in lanes 5 and 7 from cells transfected
with MDM2and 6xHis-tagged ubiquitin which should (and do) display detectable
MDM2 £3ligase activity, and thus act as a positive controls for the assay (Figure
3.4.3).
Transfected cells were processed as described in Materials and methods
(section 2.14), and harvested after 48 hours and then divided into two aliquots: one,
aliquot consisting of 10% of harvested cells was used for western blot analysis, a
second aliquot consisting of 90% of the sample was processed for the in vivo
ubiquitylation assay. In order to purify proteins conjugated to 6xHis-tagged
ubiquitin, lysates from 90% aliquots were incubated with Ni-NTA beads for 4 hours,
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washed and eluted with sample buffer supplemented with 200mM imidazole. Eluted
samples along with cells lysates were subjected to SDS-PAGE followed by western
blot analysis with antibodies against p180 (N-19) and MDM2 (Abl, clone IF2)
(Figure 3.4.3).
Results presented in Figure 3.4.3 show, as expected, that MDM2is detected
as ubiquitylated in the presence of 6xHis-tagged ubiquitin and un-surprisingly this
was unaffected by co-transfection of p180 (lanes 5 and 7). Although, the signal
obtained for p180 in lanes 3 and 5 seemsto bethe strongest, it is difficult to assess
whether this is an indication of p180 ubiquitylation since a slightly weaker bandis
also present in lane 4 which suggests that p180 binds non-specifically to the Ni-NTA
beads. It is known that p180 is capable of binding to metal ions such as Mn++ or
Mg++ during catalysis (199), in addition p180 possesses a Zn finger motif (9) and
this may form the basis for the observedresult.
147
 Results
 
 
 
 
1 23 45 6 7 8
His-Ub~ - + + t+ - + -
MDM2 - M - - - + + + +
p180 - - t+ + + - - +
p180
Ni-NTApurified
oe MDM2
6
p180
MDM2
Lysates
er
& B-gal
Actin   
Figure 3.4.3 Jn vivo ubiquitylation assay with 6xHis-tagged ubiquitin, p180 and
MDM2. H1299 cells were transfected 6xHis-tagged ubiquitin (15 pg), p180 (30 pg)
and MDM2(30 pg) transfected using GeneJuice™ reagent in several combinations,
as indicated. Ni-NTA purified section (upper panels as indicated) presents data for
proteins purified with 6xHis-tagged ubiquitin on Ni-NTA agarose beads; Lysates
section (lower panels as indicated) illustrate the steady-state levels of the indicated
proteins with or without transfection. Note that all transfected samples included a
plasmid that expresses B-galactosidase (6g) to enable comparison of transfection
efficiency and also actin provides loading information. Western blots were
performed with anti -p180 (N-19), -MDM2 (Abl, clone IF2), -actin (C-2) and -B-
galactosidase (Ab1, clone 200-193) antibodies.
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Despite these issues with binding of p180 to Ni-NTA beads, we attempted to
perform another assay to clarify whether p180 might be ubiquitylated and also
determine whether MDM2is engaged in that process. A RING finger mutant of
MDM2 (Cys464Ala), which lacks the ability to mediate ubiquitylation and a mutant
of 6xHis-tagged ubiquitin (Lys29,48,63Arg) incapable of forming ubiquitin chains
were included in the experiment. By using the RING finger mutant we were hoping
to overcome potential endogenous effect of wild type MDM2 promoting p180
ubiquitylation (as suggested by lane 3 in Figure 3.4.3), while 6xHis-tagged ubiquitin
(Lys29,48,63Arg) was used in order to detect only monoubiquitylation of p180.
H1299 cells were transfected with combinations of p180, MDM2, MDM2
RING finger mutant, 6xHis-tagged ubiquitin and 6xHis-tagged ubiquitin mutant, as
described in Figure 3.4.4 lanes 2-7. Transfected cells were then processed as
described in Materials and methods (section 2.14) and proteins purified on Ni-NTA
beads, along with cells’ lysates were subjected to SDS-PAGEanalysis followed by
western blot (Figure 3.4.4).
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Figure 3.4.4 In vivo ubiquitylation assay with 6xHis-tagged ubiquitin, 6xHis-
tagged mutant ubiquitin (K29,48,63R), p180, MDM2 and mutant MDM2
(C464A). H1299 cells were transfected with 6xHis-tagged ubiquitin (15 pg), 6xHis-
tagged mutant ubiquitin (K29,48,63R) (15 pg), p180 (30 wg), MDM2 (30 pg) and
mutant MDM2 (C464A) (30 pg) using GeneJuice™ reagent in several combinations,
as indicated. Ni-NTA purified section presents proteins purified with 6xHis-tagged
ubiquitin on Ni-NTA agarose beads; Lysates section show effect of cell’s
transfection, with B-galactosidase (61g) as an transfection efficiency control and
actin as an loading control. Western blot was performed with anti -p180 (N-19),
-MDM2(AbI1, clone IF2), -actin (C-2) and -B-galactosidase (Ab1, clone 200-193)
antibodies. ECL Advance Western Blotting Detection System was used in the
indicated panels to provide greater sensitivity (GE Healthcare).
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As expected, MDM2 was ubiquitylated in the presence of 6xHis-tagged
ubiquitin (lane 5) and also MDM2 ubiquitylation was inhibited in cells transfected
with an MDM2 RINGfinger mutant (lane 6). In addition, MDM2 was detectably
monoubiquitylated in the presence of 6xHis-tagged ubiquitin mutant
(Lys29,48,63Arg) (lane 7). In order to enhance the signal obtained for Ni-NTA
purified p180 we used the ECL™ Advance Western Blotting Detection System (GE
Healthcare Life Sciences) (Figure 3.4.4, ECL Advance panel). Potentially of
significance, the p180 signal observed in lanes 3 and 5 displayed an increased high
molecular weight smear and this was independent of MDM2transfection, which
might be indicative of multiple-mono- or poly-ubiquitylation of p180. However,
bands corresponding to the main (presumably mono- or unmodified) p180 were also
presentin other lanes of the Ni-NTA section (Figure 3.4.4, lanes 3-7) whenever p180
was transfected which underminesany such conclusion (Figures 3.4.3-4).
Since the previous experiments were significantly compromised by the
binding of p180 to Ni-NTA beads another approach was tested. To examine whether
p180 was ubiquitylated in the cells and whether MDM2wasinvolvedin that process,
cells were transfected with HA-tagged ubiquitin, MDM2 and p180 in different
combinations (Figure 3.4.5 lanes 1-5) and an antibody that recognizes the HA tag
was used to immunoprecipitate protein complexes from cell lysates.
Immunoprecipitation was carried out as described in Materials and methods(section
2.10), and samples were then separated by SDS-PAGEand analysed by western
blotting. No bands corresponding to p180 could be detected in the IP panel, which
suggests that p180 was not conjugated to ubiquitin in vivo (Figure 3.4.5, p180 IP
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panel). As expected MDM2 wasdetected in lanes 3 and 4 which is indicative of
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Figure 3.4.5 Co-immunoprecipitation experiment with HA-tagged ubiquitin,
p180 and MDM2. H1299cells were transfected with HA-tagged ubiquitin (30 pg),
pl80 (30 pg) and MDM2 (30 ug) using GeneJuice™ reagent in several
combinations, as indicated. Immunoprecipitation was performed on 3.5mgoftotal
protein with anti-HA (16B12) antibody (IP panel) and anti-CD20 (Leul6) as an
antibody control (AC panel). For western blot analysis anti-p180 (N-19) and anti-
MDM2 (Abl, clone IF2) antibodies were used; Ponceau-S staining served as a
loading control.
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In the light of presented results (Figure 3.4.3-5), there is no clear evidence for
p180 ubiquitylation in the cells studied. Since in immunoprecipitation experiments
MDM2 was shown to form a complex with DNA polymerase « in cells, there is a
possibility that apart from interacting with catalytic subunit of DNA polymerase a
(p180) MDM2 might interact with other subunits of this heterotetrameric enzyme
complex. This notion seems to be further supported by immunoprecipitation data
with MDM2 mutants either consisting of the amino-terminal 166 amino acids or
lacking this region. Whilst MDM2 was shownto interact directly with p180, where
the amino-terminal 166 amino acids of MDM2 appeared to be required for that
interaction in vitro, on the contrary for complex formation in cells this region was
dispensable. Hence, it appeared that the first 166 amino acids of MDM2interact
directly with p180, whereas the remaining region could be involved in interaction
with other subunits of DNA polymerase q in cells explaining complex formation
between DNA polymerase & and MDM2 mutants lacking the amino-terminal 166
amino acids. The possibility of this potential MDM2interaction with other subunits
of DNA polymerase encouraged us to perform anotherin vivo ubiquitylation assay
in order to examine modification of both primase subunits of DNA polymerase a.
H1299 cells were transfected with combinations of p180, MDM2and6xHis-
tagged ubiquitin as described in Figure 3.4.6. Transfected cells were processed as
described in Materials and methods (section 2.14), and harvested after 48 hours,
howeveron this occasion either 101M ofMG132 (in DMSO) was addedto cells four
hours before harvest in order to block proteasome dependent degradation and thus
increase the amount of ubiquitylated proteins in the cells, or DMSOtotest the effect
of the drug vehicle on cells. During harvest cells were divided into twoaliquots: one,
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aliquot consisting of 10% of harvested cells was used for western blot analysis, a
second aliquot consisting of 90% of the sample was processed for the in vivo
ubiquitylation assay. In order to purify proteins conjugated to 6xHis-tagged
ubiquitin, lysates from 90% aliquots were incubated with Ni-NTA beads for 4 hours,
washedand eluted with sample buffer supplemented with 200mM imidazole. Eluted
samples along with cells lysates were subjected to SDS-PAGEfollowed by western
blot analysis with antibodies against 48kDa primase subunit (PRIM1), 58kDa second
primase subunit (PRIM2), p180 (N-19) and MDM2(Ab1, clone IF2) (Figure 3.4.6).
We failed to address the main question, whether primase subunits were
ubiquitylated, since we were unable to detect both subunits either in the lysates nor
Ni-NTApurified probably due to problems with antibodies (Figure 3.4.6). However,
we observed that in the cells treated with MG132, p180 appeared to be affinity
purified with ubiquitin (lane 7), while the amount ofp180 purified with 6xHis-tagged
ubiquitin seems to be diminished upon co-transfection with MDM2 (lane 8).
Contrary to results presented in previous experiments (see Figure 3.4.3-5) we can
observe that p180 might be indeed subject to ubiquitylation in cells, whilst MDM2
appears to have an inhibitory effect on mediating that p180 modification. However,
these findings need to be further tested since the results presented here are an
example of a single experiment performed at the end of the time available for this
project.
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Figure 3.4.6 In vivo ubiquitylation assay with 6xHis-tagged ubiquitin, p180 and
MDM? with addition of MG132. Cells were transfected with 6xHis-tagged
ubiquitin (15 pg), p180 (30 pg) and MDM2 (30 pg) using PEI (polyethylenimine)
reagent at a 1:1 w:v ratio to DNA,in several combinations as indicated. Ni-NTA
purified section (upper panels as indicated) presents data for proteins purified with
6xHis-tagged ubiquitin on Ni-NTA agarose beads; Lysates section (lower panels as
indicated) illustrate the steady-state levels of the indicated proteins with or without
transfection. Note that all transfected samples included a plasmid that expresses B-
galactosidase (6g) to enable comparison of transfection efficiency and also actin
provides loading information. Western blots were performed with anti -p180 (N-19),
-MDM2(Abl, clone IF2), -p48 (PRIM1), -p58 (PRIM2) antibodies. Cells were
treated either with DMSO or MG1324 hourspriorto harvesting as indicated.
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3.5 In vivo NEDDylation assay to examine MDM2 involvement in mediating
p180 modification
MDM2has been shown to mediate ubiquitylation ofitself and of manyofits
interacting proteins (64,151). Recently, several reports have linked MDM2 with
NEDDpylation, a process during which NEDD8protein (a ubiquitin-like protein) is
covalently linked to its substrates. Apart from promoting auto-NEDDylation, MDM2
has been reported to promote NEDDylation of p53 and of full-length (TA) p73,
resulting in abrogation of their transcriptional activities (135, 136).
Evidence presented in this thesis suggests that MDM2 canbind to p180 and
forms in vivo complexes with p180, therefore one possible consequence ofthis might
be MDM2 mediated NEDDylation of p180. In order to test this hypothesis, we
utilized a 6xHis-tagged NEDD8construct (kindly provided by Dr. D. Xirodimas) for
in vivo NEDDylation assays performedessentially as previously described for in vivo
ubiquitylation assays in section 2.14.
H1299 cells were transfected with combinations of 6xHis-tagged NEDD8,
MDM2and p180 expression vectors. We wanted to examine whether p180 would be
affinity purified with 6xHis-tagged NEDD8 by Ni-NTA,in either the presence or
absence oftransiently transfected MDM2 (Figure 3.5.1 lanes 3 and 4 respectively).
By using an MDM2RINGfinger mutant we were anticipating overcoming potential
endogenouseffect of wild type MDM2 on promoting p180 NEDDylation following
the same argument weused previously for in vivo ubiquitylation (Figure 3.5.1, lane
5). Lanes 1, 2, 6 and 7 presented in Figure 3.5.1 serve as controls for the assay, since
6xHis-tagged NEDD8 was not transfected and thus only proteins that bind non-
specifically to Ni-NTA agarose should be detected here. Finally, lane 4 serves as a
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positive control (Figure 3.5.1) since, MDM2 wastransfected along with 6xHis-
tagged NEDD8&(and p180) and was expected to be present as a substrate for NEDD8
in lane 4 of Ni-NTA purified panel (Figure 3.4.3). This would confirm assay
specificity, since MDM2 was previously shown to mediate its own NEDDylation
(135).
Transfected cells were processed as described in Materials and methods
(section 2.14), and harvested after 48 hours and then divided into twoaliquots: one,
aliquot consisting of 10% of harvested cells was used for western blot analysis, a
second aliquot consisting of 90% of the sample was processed for the in vivo
NEDDylation assay. In order to purify proteins conjugated to 6xHis-tagged NEDD8,
lysates from 90% aliquots were incubated with Ni-NTA beads for 4 hours, washed
and eluted with sample buffer supplemented with 200mM imidazole. Eluted samples
along with cells lysates were subjected to SDS-PAGE followed by western blot
analysis with antibodies against p180 (N-19) and MDM2(Ab1, clone IF2) (Figure
3.3.1):
In Figure 3.5.1, MDM2 auto-NEDDylation is clearly detectable (see lane 4,
Ni-NTApurified panel) as is the inhibitory effect of expression of an MDM2 RING
finger mutant upon MDM2 auto-NEDDylation. The weaker signal in lane 5 likely
derives from continued NEDDylation of the mutant by endogenous wild type MDM2
protein (Ni-NTA purified panel). As previously presented for the in vivo
ubiquitylation assay (see Figure 3.4.4), we used ECL™ Advance Western Blotting
Detection System (GE Healthcare Life Sciences) to increase the sensitivity of
detection of p180 which can then be detectedin all lanes. Comparing lanes 2 and 3
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suggests that p180 maybe a substrate for NEDDylation by an endogenous enzyme.
Comparing lanes 3 and 4 suggests that this enzyme is not MDM2.
In summary, results obtained for both in vivo ubiquitylation and
NEDDylation assays do not provide clear evidence for these modifications of p180.
Although a number of MDM2interacting proteins are subjected to ubiquitylation
and/or NEDDylation due to MDM2activity, we cannot find clear evidence that this
occurs for p180. Nevertheless, data shownin Figure 3.4.6 do suggest that some p180
may be ubiquitylated albeit that MDM2 seems to play no positive role in this
process. Onepotential explanation for our somehow equivocalresults in cells may be
that DNA polymerase @ exists in more than one form. Two differentially
phosphorylated forms have been described and it is possible that MDM2interacts
preferentially with one of these. The studies that follow represent our investigation of
this question.
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Figure 3.5.1 In vivo NEDDylation assay with 6xHis-tagged NEDD8, p180 and
MDM2. H1299 were tranfected with 6xHis-tagged NEDD8(5 pg), p180 (10 pg) and
MDM2(10 pg) using GeneJuice™ reagent in several combinations,as indicated. Ni-
NTApurified section presents proteins purified with 6xHis-tagged NEDD8 on Ni-
NTA agarose beads; Lysates section show effect of cell’s transfection, with B-
galactosidase (2ug) as a transfection efficiency control and actin as an loading
control. Western blot was performed with anti -p180 (N-19), -MDM2 (AbI1, clone
IF2), -actin (C-2) and -B-galactosidase (Abl, clone 200-193) antibodies. ECL
Advance Western Blotting Detection System was used to provide greater sensitivity
(GE Healthcare) as indicated.
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3.6 MDM2interacts preferentially with hypophsophorylated DNA polymerase
a
Among manyreports published on DNA polymerase q, in particular one by
Dehde S. et al. (116) has drawn our attention. This report described studies
performed by the group of Professor Irene Dornreiter, which revealed that DNA
polymerase exists in two subpopulations defined by its phosporylation status.
Furthermore, these two subpopulations of DNA polymerase a display different
functions during replication, as proposed by Prof. Dornreiter’s group, the non- or
hypophosphorylated form synthesizes the primer for leading strand, whereas the
phosphorylated form is involved in lagging strand primer synthesis. It is noteworthy
that both subpopulations of DNA polymerase & may be distinguished using different
antibodies, as reported by DehdeS.ef al. (116) - HP180-12 antibody recognizes non-
or hypophosphorylated form, while phosphorylated form could be detected with
SJK132-20 antibody.
Both antibodies were generously provided to us by Prof. Dornreiter and we
have used them in immunoprecipitation experiments to determine whetherthere are
any differences in interaction between MDM2 and differentially phosphorylated
forms of DNA polymerase .
Weinitially performed immunoprecipitation on untransfected Clone cells,
which are derived from H1299 cells but express high levels of MDM2(cells were
stably transfected with pCMVNeoBamMdm2) and do not express p53. The
immunoprecipitation procedure was carried out as described in Materials and
methods (section 2.10) with HP180-12 (recognizes hypophosphorylated DNA
polymerase ) and SJK132-20 (recognizes phosphorylated DNA polymerase «)
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antibodies used along with isotype control (CD20). Samples were subjected to SDS-
PAGEanalysis followed by western blot with appropriate antibodies as presented in
Figure 3.6.1.
IP:DNA pol a
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Figure 3.6.1 MDM2interacts preferentially with hypophosphorylated DNA
polymerase & in Clone 9 cells. Western blot of immunoprecipitation experiment
performed on 2.5 mgoftotal protein from untransfected Clone 9 (H1299)cells with
HP180-12 antibody and SJK132-20 recognizing non/hypophosphorylated or
phosphorylated DNA polymerase a, respectively. Western blot performed on
samples from lysates (L), isotype control (IC) - CD20 (Leu-16), HP180-12 (HP) and
SJK132-20 (SJK) with anti-p180 (N-19) and anti-MDM2 (AbI1, clone IF2) antibodies
(A - short exposure; B - long exposure); M — indicates protein molecular weight
marker.
In Figure 3.6.1 we can see that the main MDM2 band(c.90kDa)is clearly
present in the sample immunoprecipitated with HP180-12 (Figure 3.6.1), whilst there
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is little of this form of MDM2present in the sample immunoprecipitated with
SJK132-20. It is noteworthy that more p180 is precipitated with the phospho-specific
antibody than with the hypophosphorylated specific antibody and this makes the
already apparent differences between MDM2precipitations even morestriking. In
addition, the band pattern for MDM2protein precipitated with SJK132-20 antibody
as presented in the Figure 3.6.1 appeared to be unusual. In summary, it appears likely
that MDM2preferentially binds to the non- or hypophosphorylated form of DNA
polymerase o in Clone9 cells in culture.
To investigate this possibility further, we added two additional cell lines to
this analysis. Human embryonic kidney cells 293 (HEK293)cells express high levels
of MDM2 which makesthe detection of co-precipitating proteins easier and we also
added H1299 cells which express relatively low levels of MDM2 (especially in
comparison to Clone 9 cells). The immunoprecipitation experiment was performed
on these three cell lines (H1299, Clone 9 and HEK293) as described in Materials and
methods (section 2.10) with HP180-12 and SJK132-20 antibodies used along with
isotype control (CD20). Samples were subjected to SDS-PAGEanalysis followed by
western blot with appropriate antibodies as presented in Figure 3.6.2.
Results presented in Figure 3.6.2 confirmed the previously made observation
that MDM2 interacts preferentially with non- or hypophosphorylated DNA
polymerase «, since onthe presented blots, there was abundant MDM2protein band
in the lane corresponding to samples immunoprecipitated with HP180-12 antibody,
for each cell line tested (Figure 3.6.2 A,B,D). Again, an unusual MDM2bandpattern
was displayed in lanes corresponding to SJK132-20 samples, and use of a second
anti-MDM2antibody (Ab6) for western blot analysis (Figure 3.6.2D) confirmed the
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identity of these as unusual MDM2bands(Figure 3.6.2A,B). We also observed as we
had previously that the SJK132-20 (phosphorylation specific) antibody precipitated
more p180 than the HP180-12 antibody thus the observed bias towards MDM2-
hypophosphorylated p180 is likely to be greater thanit at first appears.
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Figure 3.6.2 MDM2 interacts preferentially with hypophosphorylated DNA
polymerase a in Clone 9, H1299 and HEK293 cells. Western blot of
immunoprecipitation experiment performed on 2.5 mg of total protein from
untransfected Clone 9, H1299 and 293 cells with HP180-12 antibody and SJK132-20
recognizing non/hypophosphorylated or phosphorylated DNA polymerase 4,
respectively. Western blot performed on samples from lysates (L), isotype control
(IC) — CD20 (Leu-16), HP180-12 (HP) and SJK132-20 (SJK) with anti-p180 (N-19)
and anti-MDM2(AbI1, clone IF2) antibodies (A - short exposure; B - long exposure);
C - anti-p180 (N-19) — very long exposure; D - anti-p180 (N-19) and anti-MDM2
(Ab6, clone 5B10C)antibodies.
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In summary, we conclude that formation of a complex between MDM2 and
non- or hypophosphorylated subpopulation of DNA polymerase « in the cells in
culture seems to occur independently of p53, the expression level of MDM2andis
notlimited to cells of one type oforigin.
DNA polymerase a has previously been shownto interact with SV40 T large
antigen (45, 47, 48) we wondered therefore whether the presence of T antigen may
affect the interaction between MDM2 and DNA polymerase a HEK293T cells
stably express SV40 large T antigen and were used for an immunoprecipitation
experiment along with HEK293 cells. The immunoprecipitation experiment was
performed on untransfected HEK293 and HEK293Tcells as described in Materials
and methods (section 2.10) with HP180-12 and SJK132-20 antibodies used along
with isotype control (CD20). Samples were subjected to SDS-PAGEanalysis
followed by western blot with appropriate antibodies as presented in Figure 3.6.3.
As Figure 3.6.3 shows, abundant MDM2protein band can be detected in both
cell lines following immunoprecipitation with HP180-12 antibody. Thus it appears
that MDM2interacts preferentially with non/hypophosphorylated subpopulation of
DNA polymerase & in both cell lines. In addition, it seems that the presence of T
antigen, does not affect formation of a complex between MDM2andthe non- or
hypophosphorylated form ofDNA polymerase & (Figure 3.6.3A).
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Figure 3.6.3 MDM2 interacts preferentially with hypophosphorylated DNA
polymerase a in HEK293 and MHEK293T cells. Western blot of
immunoprecipitation experiment performed on 2.5 mg of total protein from
untransfected 293 and 293T cells with HP180-12 antibody and SJK132-20
recognizing non/hypophosphorylated or phosphorylated DNA polymerase a,
respectively. Western blot performed on samples from lysates (L), isotype control
(IC) — CD20 (Leu-16), HP180-12 (HP) and SJK132-20 (SJK) with anti-p180 (N-19)
and anti-MDM2 (Ab1, clone IF2) antibodies (A - short exposure); B with anti-p180
(N-19) - long exposure.
Our observations that MDM2 interacts preferentially with one of DNA
polymerase & subpopulations may have implications for processes regulated by DNA
polymerase phosphorylation i.e. initiation of DNA replication. As stated
previously, the hypophosphorylated form of DNA polymerase © is linked with
synthesizing the primer for the leading strand duringinitiation of replication (116).
The fact that non-/hypophosphorylated subpopulation of DNA polymerase © is
involved in forming a complex with MDM2in the cell may suggest a role of MDM2
in the replication initiation process via interaction with that DNA polymerase ©
subpopulation. Clearly, further research needs to be done in order to shed light on
this subject.
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3.7 Cell cycle profile analysis on cells expressing different amounts of MDM2
Research performed on transgenic mice has provided information that
overexpression of MDM2 maytrigger several rounds of replication without cell
division, leading to polyploidy (97). These findings indicate an involvement of
MDM2in the processes of DNA synthesis and/or cell division, which is independent
of p53 and E2F1 (97, 139). The new observations presented in this thesis, regarding
MDM2 forming a complex with hypophosphorylated DNA polymerase a, may
provide a part of the mechanism forthis effect ofMDM2.
In the first instance, to investigate whether MDM2 alters DNA
synthesis/initiation of DNA synthesis we analysed the cell cycle profile of cells
expressing differing levels of MDM2. Whilst this cannot determine the rate or
initiation rate of DNA synthesis, it might provide evidence that MDM2 has an
impact on the cell cycle (clearly this need to be done in p53 null cells to exclude the
well known effects of p53 on the cell cycle). We were interested in elucidating
whether different levels of MDM2 expressed in the sametype of cells may influence
their cell cycle profiles. In order to address this question flow cytometry analysis was
performed on H1299 and Clone 9 (H1299) cells expressing different amounts of
MDM2.Cells were harvested by trypsinization at 30 — 40 and 70 — 80% confluency
and processed as described in Materials and methods (section 2.15), followed by
samples’ analysis in a Beckman Coulter Epics XL flow cytometer using FL2
(propidium iodide) channel.
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Figure 3.7.1 Flow cytometric analysis of H1299 and Clone 9 cells. Cells were
harvested at 30-40 and 70-80% confluency, stained with propidium iodide. Twenty
thousand events were collected per condition. Data were analyzed using A) WIN
MDIsoftware and B) Cylchred software.
Figure 3.7.1 presents results from flow cytometric analysis performed on
untreated/untransfected H1299 and Clone 9 (H1299) cells. Based on the chart and
values showninthe table there do not appear to be major differencesin the cell cycle
profiles of these cells.
In the next step we wanted to examine whether cell cycle profiles could be
affected by reducing endogenous levels of MDM2. Hence, MDM2 small interfering
RNA (siRNA) #1 was delivered to H1299 and Clone 9 (H1299) cells, while
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scrambled siRNA (base composition matched to MDM2 siRNA #1) served as a
negative control for MDM2 knockdown. The siRNAtransfection was performed as
described in Materials and methods(section 2.5), then cells were subjected to SDS-
PAGE followed by western blot analysis, in order to verify effectiveness of the
procedure. As shown in Figure 3.7.2 reducing the endogenous MDM2expression
level with MDM2 siRNA #1 was successful, both in H1299 and Clone 9 (H1299)
 
cells.
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Figure 3.7.2 MDM2 knock-down with siRNA in H1299 and Clone 9 cells.
Western blot analysis of siRNA transfected H1299 and H1299-Clone 9 cells
performed with anti-MDM2 (Ab1, clone IF2) and anti-actin (C-2) antibodies; lane
marked with U represents untransfected cells; S — cells transfected with scrambled
siRNA and M cells transfected with MDM2 #1 siRNA,actin served as a loading
control.
Having tested the efficacy of siRNA knock-down of MDM2 in H1299 and
Clone 9 (H1299) (Figure 3.7.2), remaining cells from the same transfection were
analysed in a Beckman Coulter Epics XL flow cytometer using FL2 (propidium
iodide) channel.
A considerable difference in cell cycle profiles was observed both for H1299
and Clone 9 (H1299) cells with reduced endogenous levels of MDM2(transfected
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with MDM2 siRNA #1). It seemed that numberofcells in S phase was reduced by
approximately 10% when compared to either untransfected cells or to cells
transfected with scrambled siRNA (Figure 3.7.3).
The results shown in Figure 3.7.3 appear to indicate a role for MDM2 in
regulating the cell cycle. Given the function of DNA polymerase © in initiation of
DNAsynthesis, we proposed to examine the incorporation of BrdU as a means of
measuring the rate of DNA synthesis, however since time was running outforthis
project and this technique wasnot already established in our laboratory, we thought
it might be worthwhile to measure the total DNA synthesis in a population ofcells
using a simpler assay. We therefore measured (°H]-thymidine incorporation, an assay
usually used to measure cell proliferation rate based on incorporation of CH]-
thymidine into nucleic acid.
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Results
Figure 3.7.3 Flow cytometric analysis of H1299 and Clone 9 cells with knocked-
down MDM2.A,B) Flow cytometric analysis of H1299; C, D) Clone 9 (H1299)
cells transfected with scrambled and MDM2 #1 siRNA, stained with propidium
iodide. Twenty thousand events were collected per condition. Data were analyzed
using A, C) WIN MDIsoftware and B,D) Cylchred software.
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H1299 cells were transfected with either MDM2 siRNA #1 or scrambled
siRNA (matched to MDM2 siRNA #1). In addition, cells were treated with siRNA
transfecting agent - Lipofectaminein order to detect any effect of this reagent on cell
proliferation. The siRNA transfection was performed as described in Materials and
methods (section 2.5), then cells were subjected to SDS-PAGEfollowed by western
blot analysis, in order to verify effectiveness of performed procedure. As shown in
Figure 3.7.4 MDM2 siRNA #1 successfully reduced the level of MDM2protein in
H1299 cells.
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Figure 3.7.4 MDM2 knock-down with siRNA in H1299. Western blot analysis of
siRNA transfected H1299 cells performed with anti-MDM2 (Abl1, clone IF2) and
anti-actin (C-2) antibodies; lane marked with U represents untransfected cells; L —
Lipofectamine treated cells; S — cells transfected with scrambled siRNA and M -
cells transfected with MDM2#1 siRNA,actin served as a loading control.
Cells from the same transfection were also processed for [3H]-thymidine
incorporation as described in Materials and methods (section 2.15), followed by
analysis in a Beckman Coulter Epics XL flow cytometer using FL2 (propidium
iodide) channel.
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Results presented in Figure 3.7.5 do not fully support previously made
observations (Figure 3.7.3). As previously there is a lower percentage of S and a high
percentage of G2 cells in the population treated with MDM2 siRNA#1, but on this
occasion the effect is reduced andit is not possible to determine the significance of
this effect.
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Figure 3.7.5 Flow cytometric analysis of H1299 cells with knocked-down
MDM2.Flow cytometric analysis of H1299 cells transfected with scrambled and
MDM2#1 siRNA, stained with propidium iodide. Twenty thousand events were
collected per condition. Data were analyzed using: A) WIN MDIsoftware and B)
Cylchred software.
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The [3H]-thymidine incorporation assay was performed alongside with flow
cytometry analysis by incubating H1299 cells with [3H]-thymidine for 2 hours,
followed byscintillation counting in order to measure [3H]-thymidine incorporation
into nucleic acid. As shown in Figure 3.7.6, although the mean signal for MDM2
siRNA #1 treated cells is lower, this is not significant, which is in agreement with
the flow cytometry results presented in Figure 3.7.5.
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Figure 3.7.6 [3H] thymidine incorporation assay performed on H1299 cells.
Coloured boxes indicate [3H] thymidine incorporation in H1299 cells: untransfected,
treated with Lipofectamine, transfected with scrambled and MDM2 #1 siRNA (CPM
— counts per minute). Data are shown as mean + standard error of the mean.
In summary, the rather preliminary results presented in this section of the
thesis do not succeed in addressing the question, whether knockdown ofMDM2 may
alter the cell cycle profiles as a consequence ofaltering DNA synthesis/initiation of
DNAsynthesis. However, in the light of our observations that MDM2selectively
forms a complex in a cell with the hypophosphorylated form of DNA polymerase ©,
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which is engaged in synthesizing first primer on the leading strand during DNA
replication, and previous findings indicating a role for MDM2in the regulation of
DNAsynthesis independent of p53 and E2F1 (97, 139), further research definitely
needs to be donein order to elucidate the possible role ofMDM2 — DNApolymerase
© interaction in cells.
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CHAPTER IV
DISCUSSION
The aim of work presented in this thesis was to investigate interaction
between MDM2 and DNApolymerase a. These studies were prompted following the
discovery that MDM2 co-purifies with DNA polymerase a made during course of
studies in our research group on the interaction between MDM2 and DNA
polymerase € (58,59) (these two protein complexes co-purify in partially overlapping
fractions from mammalian cells). Preliminary data that contributed to the planning of
the work contained in this thesis project, consisted of experiments performed by
former members of our research group — Dr. Maria Maguire and Dr. Paul Nield.
They showed that DNA polymerase a, based on detection of its catalytic subunit
(p180), co-purifies with 6xHis-tagged MDM2 from a nickel charged column by
affinity chromatography (Figure 3.1.1). In addition Dr. Maguire showed that MDM2
could be detected in a complex with DNA polymerase a as demonstrated by the co-
immunoprecipitation of these endogenous proteins from HEK293 cells (Figure
3.2.1). However, since these experiments do not provide information about direct
interaction between MDM2and DNApolymerase @, we wanted,in the first instance,
to addressthis issue.
In order to examine the direct interaction between MDM2 and DNA
polymerase a and to define protein regions involved in protein binding, we have
utilized an in vitro binding assay, which has been used previously in our laboratory
(56,58). In this assay, one partnerprotein is radiolabeled, which allowsvisualization
of the signal, while the other one is 6xHis-tagged which aids purification. To
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successfully purify 6xHis-tagged MDM2 and MDM2 mutants, it was necessary to
first determine optimal conditions for expression and purification of these proteins.
Based on results shown in Figures 3.1.2-5, we decided that the optimal induction
time with IPTG for expression of 6xHis-tagged MDM2 was4 hours, which conferred
high protein expression levels, and in addition may result in less toxicity and protein
degradation than might arise at later time points. For the purification of MDM2
proteins adjustments were made to the wash buffers such that the pH wasraised for
MDM2fragments since they appeared to display reduced affinity for Ni-NTA beads
(Figure 3.1.3). This approach works because by increasing the pH of the buffers we
reduced protonation of histidine residues in the 6xHis tag and thus this retains the
electrostatic attraction betweenhistidine and nickelions.
Once proteins were successfully purified (Figures 3.1.4) in vitro binding
assays were performed with protein partners as presented in Table 3.1.1. Since the
amounts of purified 6xHis-tagged MDM2proteins were variable (Figure 3.1.4), in
particular carboxy-terminal half of MDM72being present on the Ni-NTA beadsat
higher levels than the other proteins, we attempted to normalize these amounts as
presented in Figure 3.1.9. Nevertheless for the assay we decided to use both — greater
amount of carboxy-terminal MDM2 (Figure 3.1.4) and normalized amount of
carboxy-terminal MDM2 (Figure 3.1.9) along with other 6xHis-tagged proteins.
Results presented in Figure 3.1.10 suggest that full length p180, as well as amino-
and carboxy-terminal halves of p180 preferentially bind to amino-terminal half of
MDM2,consisting of the first 246 amino acids, as well as to full length MDM2.
These results may not be surprising, since the amino-terminal region of MDM2is
known to be involved in MDM2 binding to a numberofproteins, including DNA
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polymerase € (58), p53 and E2F1 (151). In addition, despite the fact that we have
also used an excess of the carboxy-terminal half of MDM2 compared to full length
or amino-terminal half of MDM2(Figure 3.1.4), and yet did not observe interaction
between p180 and the carboxy-terminal half of MDM2,strengthens the evidence for
preferential p180 binding to the amino-terminus ofMDM2.
To further analyse the role of the MDM2 amino-terminusin binding to p180,
an MDM2 mutant lacking the amino-terminal 166 amino acids (A166 MDM2) of
MDM2 was examined in the in vitro binding assay (Figure 3.1.11). Similarly, to
what we have observed previously with carboxy-terminal half of MDM2 (Figure
3.1.4), A166 MDM2protein was present on the beads at a much higherlevel than the
other 6xHis-tagged proteins examined for comparison (Figure 3.1.11A). Hence, we
normalized the amountofproteins as presented in Figure 3.1.11B, but as before we
have used both the high level and a reduced normalized amount of Al66 MDM2
protein, along with other 6xHis-tagged proteins for the assay (3.1.11). Results
presented in Figure 3.1.12 show that there is no detectable interaction between A166
MDM2and p180. Theseresults suggest that the amino terminal 166 aa of MDM2are
necessary for binding to the catalytic subunit of DNA polymerase o (p180). This
notion is further supported by the fact that A166 MDM2protein wasalso presentat
higher levels than the other 6xHis-tagged protein in the assay, and yet interactions
between A166 MDM2and p180 werestill not observed.
Based on the same approach, we attempted to determine the region of p180
that is necessary for interaction with MDM2. However, it seems that both amino- and
carboxy-terminal halves of p180 bind equally well to the amino terminal region of
MDM2(Figures 3.1.10, 3.1.12), suggesting that multiple regions of p180 might be
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involved in MDM2 binding. Multiple binding sites between MDM2 and an
interacting protein are not unusual. For example, both ARF and p53 proteins display
more than onesite of interaction with MDM2(200, 201).
After performing a set of in vitro studies, based on which we concludedthat
pl80 subunit binds preferentially to amino-terminal part of MDM2 and that the
amino-terminal 166 amino acids of MDM2 seems to be indispensable for this
interaction, we wanted to further analyse this interaction in cells in culture by
immunoprecipitation (IP). The IP method is based on antibody binding to a specific
target protein whichis precipitated using beads (in this instance agarose) coupled to
an antibody capturing protein, in this case Protein G. Interacting proteins are then
captured together with the primary protein and the complexes can then be
interrogated by a number of means, the simplest being with a second antibodyto the
suspected binding partner. This methodis relatively simple and can besensitive, but
it cannot be used to discriminate between direct and indirect protein interaction. We
were not concerned with this issue in the present set of experiments since we had
already determined the region/s of MDM2 and DNA polymerase @ required for
direct interaction through our in vitro studies (Figure 3.1.10, 3.1.12). It is also
noteworthy, that formation of the complex between endogenous MDM2 and DNA
polymerase a in the cells in culture has been already demonstrated by the
immunoprecipitation experiment performed by Dr. Maria Maguire (Figure 3.2.1).
To further examine MDM2and p180 interaction, particularly to determine the
region of MDM2necessary for this interaction in vivo, a series of HA-tagged MDM2
carboxy-terminal deletion mutants (generated by Dr. Tim Devling) were used. These
mutants contain amino-terminal 335, 280, 230, and 166 amino acids of MDM2
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protein. Of particular interest was the MDM2 mutantcontaining onlythefirst 166 aa,
since this region was required for binding to pl80 in vitro. Prior to the
immunoprecipitation assay, p180 and MDM2 carboxy-terminal deletion mutants
were transfected into H1299 cells, which were chosen because they are easily
transfectable and also do not express p53. Since p53 was shownto interact with p180
(13,14) as well as MDM2(5), we wanted to exclude any potential involvement of
p53 in p180-MDM2interaction. Immunoprecipitation was performed with an anti-
p180 antibody and co-immunoprecipitated complexes analysed by western blotting.
Results of these experiments (Figure 3.2.10A) show that pl80  co-
immunoprecipitates with all of the MDM2 carboxy-terminal deletion mutants
described, supporting conclusions from in vitro studies suggesting that amino-
terminal 166 amino acids fragment of MDM2is required for binding to p180. These
studies also demonstrated that p180 and carboxy-terminal MDM2 mutants form a
complex in cells in p53-independent manner, as expected from the in vitro binding
experiments.
In order to refine the MDM2region involved in interaction with p180, an
MDM2 mutantlacking amino-terminal 49 amino acids (A49MDM2) was usedin an
immunoprecipitation experiment. This IP experiment demonstrated that p180 was
co-immunoprecipitated with A49MDM2 from H1299 cells, suggesting that the
region of MDM2between aa 50 and 166 seemsto be sufficient for binding to p180
(Figure 3.2.10A). Finally, we created and tested an MDM2 mutant lacking the
amino-terminal 166 amino acids (A166MDM2)for immunoprecipitation experiments
with p1l80. Surprisingly and contrary to our expectations, pl80 was co-
immunoprecipitated with Al166MDM2as shownin Figure 3.1.10B.It is difficult to
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interpret this result, however, it is possible that another protein (or proteins) mediate
MDM2-p180 interaction or that MDM2 may notonly interact with p180 but also
with other subunits of DNA polymerase «. We wanted to further analyse the latter
possibility. As we had demonstrated MDM2 appears to interact directly with the
catalytic p180 subunit of DNA polymerase & in vitro, and additionally, we could also
detect a complex containing the p180 subunit in cells. However, since the MDM2
mutant lacking the first 166 amino acids was also shown to form a complex with
p180, but does not interact directly with this subunit in vitro, we concludedthat this
latter complex probably interacts with other proteins and the most likely candidates
for this would be other subunits of DNA polymerase a. Unfortunately, our attempts
to test antibodies for the other subunits of DNA polymerase a, only succeeded in
demonstrating that some of those tested detected multiple bands on a western blot
and moreover many ofthese were not of the expected molecular weight (data not
shown) and some did not detect any protein (Figure 3.4.6).
Since we hadestablished that MDM2interacts with the catalytic subunit p180
which harbours the DNA polymerase activity, we wanted to investigate whether
MDM2 had any affect on the enzymatic activity of p180 by utilizing a DNA
polymerase assay. The assay enables us to measure enzyme activity based on
incorporation of [3H]dTTPs.In earlier studies it had been demonstrated that MDM2
can stimulate the enzymatic activity of the DNA polymerase o-related DNA
polymerase € (59) by 20-40-fold and therefore it was not unreasonable to suspectthat
MDM2mightstimulate DNA polymerase © as well.
DNApolymeraseactivity assay was performed with catalytic subunit of DNA
polymerase & (p180) and MDM2protein which were expressed in insect cells using
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a baculovirus system with the proteins subsequently purified by virtue of their 6xHis
tags using Ni-NTA beads.Initial experiments suggested that the DNA polymerase
activity of the p180 subunit was stimulated upon addition of MDM2enrichedprotein
fractions as shown in Figure 3.3.4. However, unlike previous studies with DNA
polymerase €, these latter studies were based for purely practical reasons on less
highly purified MDM2andalso the stimulatory effect was only moderate, being at
best a few-fold. The possibility exists, that during MDM2purification process other
contaminant proteins were eluted together with MDM2. Therefore, the stimulatory
effect observed in Figure 3.3.4 might be an effect of protein or proteins other than
MDM2, which could either possess intrinsic polymerase activity or mediate the
stimulatory effect by acting upon p180. Since our main concern here wasthe purity
of MDM2usedfor the assay (Figure 3.3.7), we decided to include specificity protein
controls consisting of proteins purified from uninfected insect cells under exactly the
same conditions as MDM2 used for the assay (Figures 3.3.5, 3.3.7). We also
examined whether proteins from uninfected insect cells or of MDM2 fractions
possess intrinsic polymerase activity, but we have not detected any evidence of such
activity, except of course in fractions from insect cells expressing p180 fraction
(Figure 3.3.8). When p180 activity was assayed with proteins purified from the
uninfected insect fraction, adjusted to have comparable amounts of background
protein as MDM2fraction, we observed that the catalytic activity of p180 was
stimulated to the same extent as with MDM2 (Figure 3.3.10). Based onthese results,
it was not clear whether MDM2is responsible for the stimulatory effect on p180
activity or whetherit is mediated by other protein/proteins. To try to examinethis
question further we tested antibodies against MDM2that could potentially prevent
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MDM2 from stimulating p180. We envisaged that this might work either through
competitive inhibition of MDM2-p180 interaction or by havingstructural effects on
MDM2that might for example prevent potential allosteric changes in MDM2 that
could be required for the stimulatory effect. Antibodies were added to purified
MDM2 and p180 in a DNA polymerase assay. Results of these experiments show
that stimulatory effect on p180 enzymatic activity was not diminished upon addition
of MDM2antibodies. Unfortunately this result is ambiguous suggesting that either
the antibodies used had no effect on MDM2stimulation or that stimulation is
mediated by other proteins purified from the insect cells rather than MDM2.It is
worth noting that in Figure 3.3.17 this approach,that is, use of an antibody to inhibit
the polymerase activity of p180 was used successfully. Finally, we decided to test
whether MDM2purified from bacterial cells could alter the activity of p180. The
rationale for this approach was as follows: we have recently performed experiments
using GST-MDM2and these demonstrated (as others have described) that MDM2
can retain its E3 ligase activity for approximately 24h, as verified by in vitro
ubiquitylation assays (134). Thus we could test whether an active and an inactive
form (stored at -80°C) of bacterially expressed GST-MDM2 would have any impact
on p180activity. In addition to this, purification of MDM2 from a different system
based upon an organism other than the insect cell system would provide not only
purer MDM2butalso a protein preparation with a different set of contaminants.
Moreover, the stimulatory effect of bacterially purified MDM2 wasalso observed
previously on DNA polymerase € (59). In the assay p180 was mixed either with
enzymatically inactive or active preparations of MDM2. The results demonstrated no
effect on the activity of p180 with either form of MDM2(Figures 3.3.13, 3.3.16). In
182
 
Discussion
contrary to previous findings on the effect of MDM2 on DNA polymerase € (59) we
failed to obtain clear evidence for any effect of MDM2 on DNA polymerase
activity. A major problem we experienced was that the purity of MDM2 obtained
from the insect cells fraction was demonstrably lower than that used previously in
studies of DNA polymerase € (59). Therefore, we collaborated with Prof. Stuart Linn
again at U.C. Berkeley to examinethe effect of this more highly purified MDM2 on
DNA polymerase «. Based on the experiment performed by Prof. Linn it can be
observed that the activity of DNA polymerase & was impressively stimulated upon
addition of baculovirus expressed purified MDM2aspresented in Figure 3.3.17.
These results suggest that MDM2 mayindeed have stimulatory effect on DNA
polymerase © activity. This experiment, which clearly requires further examination
was based upon purified DNA polymerase & holoenzyme obtained from large scale
biochemical purification of DNA polymerase from HeLa cells (5 columnsandc. 40
liters of cells). The magnitude of this stimulation may therefore derive from the more
highly purified MDM2 used, or from the use of the holoenzyme, or both. Future
studies will be aimed at further examiningthis.
After having tested the effect of MDM2 on DNA polymerase @ activity, we wanted
to determine whether MDM2 mayaffect the enzyme in other ways. As described in
the Introduction chapter of this thesis, MDM2possesses E3 ubiquitin ligase activity
and mediates ubiquitylation and thus promotes proteasome-mediated degradation of
several of its interacting partners. Therefore, we wanted to investigate whether
MDM2can mediate ubiquitylation of p180. Initially, it was important to determine
whether p180 is subject to degradation via ubiquitin/proteasome-dependent pathway
at all. Based on our findings with MCF-7, Clone 9 and H1299 cells treated with
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MG132,an inhibitor of 26S proteasomes, it is possible that p180 mightbe stabilized
in MCF-7 and Clone 9 cells, however not in H1299 (Figure 3.4.1-2). This may
suggest a role for MDM2in that process, since H1299 cells express relatively low
levels of MDM2especially comparing to Clone 9 cells. Overall though, the data do
not provide clear evidence for degradation of p180 via the ubiquitin/proteasome-
dependent pathway,particularly in the light of results from others which showed no
evidence for p180 intracellular degradation (109). However, since MDM2 wasalso
shown to promote mono-ubiquitylation of some of its interacting proteins (151),
which does notresult in proteasomal degradation, we wanted to examinethe role of
MDM2in mediating that modification of p180. Noteworthy is the fact that mono-
ubiquitylation mediated by MDM2 was shownto alter the enzymatic activity of
DHFR(134), which suggests that similar effects might be detectable for p180 if it
were to be modified by MDM2. To examine the question of whether p180 is
ubiquitylated by MDM2 weperformed a series of in vivo ubiquitylation assays.
Based onresults presented in Figures 3.4.3 and 3.4.4 there wasa hint that p180 might
be ubiquitylated either in presence or absence of MDM2. Howeverthese assays were
significantly compromised by the non-specific binding of p180 to Ni-NTA beads and
therefore we decided to use another approachto addressthis issue.
Wealso performed immunoprecipitation experiments to examine whether
pl80 was i) ubiquitylated and ii) whether this was MDM2 dependent. These
experiments utilised HA-tagged ubiquitin, which was transfected along with p180
and MDM2expressing constructs in various combinations. The results (Figure 3.4.5)
did not detect any evidence that p180 is ubiquitylated. We therefore attempted to
examine whether other subunits of DNA polymerase & complex might be subjected
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to ubiquitylation.
Weperformed an in vivo ubiquitylation assay as we had previously, however
on this occasion MG132 wasalso addedto cells prior harvesting, in order to prevent
protein degradation and hence increase the amount of ubiquitylated proteins in
present in the cells. As shown in Figure 3.4.6 we failed to detect primase subunits of
DNApolymerase ©, probably due to the unsatisfactory quality of antibodies used for
detection. However, more importantly we observed for the first time that p180 seems
to be ubiquitylated in the absence of MDM2,whilst addition of MDM2 appears to
inhibit p180 ubiquitylation (Figure 3.4.6). In addition, p180 non-specific binding to
Ni-NTA beads was relatively lower than previously observed, probably due to
improved signal to noise following from the use of MG132. MDM2waspreviously
shownto inhibit ubiqutylation of E2F1 and the mechanism ofthis appears to be that
MDM?binds to E2F1 and displaces SCF*“”’, resulting in stabilization of E2F1 (155).
Thus our results with DNA polymerase «© and MDM2in Figure 3.4.6 may represent
a similar situation, but clearly further experiments will be required to investigatethis.
Ubiquitylation is not the only modification mediated by MDM2duetoits
E3 ligase activity. MDM2 is also capable of mediating NEDDylation, which is a
process analogous to ubiquitylation, where a ubiquitin-like protein - NEDD8 is
conjugated to its substrate. Thus far, apart from mediating its own NEDDylation,
MDM2has been observed to NEDDylate p53 and full-length (TA) p73, which
resulted in inhibition of transcriptional activity of both targeted proteins (135,136).
We wanted to examine whether MDM2 might mediate NEDDylation of p180 by
performing in vivo NEDDylation assays with 6xHis-tagged NEDD8(kindly provided
by Dr. D. Xirodimas). As presented in Figure 3.5.1 the assay findings confirmed
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auto-NEDDylation of MDM2, howeverit was impossible to determine whether p180
was NEDDylated as well, since the p180 background due to non-specific binding to
Ni-NTAagain compromisedthe assay with respect to p180.
Experiments performed to examine an effect of MDM2 on mediating p180
modifications provided us with ambiguous results. The p180 was observed to be
ubiquitylated in cells, and rather than promoting this it appears as though MDM2
was engaged in inhibition of this process. One potential explanation for our
seemingly equivocal results in cells may be that DNA polymerase & exists in more
than one form. Therefore we focused our attention on findings regarding DNA
polymerase & phosphorylation status and how this impacts uponits activity in DNA
replication, as reported by Professor Irene Dornreiter’s research group (116). It is
noteworthy that DNA polymerase a is subject to modification by phosphorylation on
its two biggest subunits — p180 and the B subunit (109). Professor Dornreiter’s
research group reported that DNA polymerase o forms two sub-populationsin cells
distinguishable by their phosphorylation status with the non- or hypo-
phosphorylated form being the more active enzyme and present mostly at the G1/S
boundary. In addition it was shownthat the differentially phosphorylated forms of
DNApolymerase a, associated with different cyclin/CDK complexes such that the
non- or hypo- phosphorylated form of DNA polymerase a forms a complex with
cyclin E-Cdk2 (and PP2A phosphatase), while the phosphorylated form
preferentially forms a complex with cyclin A-Cdk2 (116). In addition, these authors
showedthat the phosphorylated form of DNA polymerase & was unableto bind to T
antigen protein, a well-documented DNA polymerase o binding protein (45), and
this inhibition could be reversed upon dephosphorylation with PP2A. The role of
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each of the phosphorylation-defined sub-populations of DNA polymerase @ was also
examined by confocal microscopy, wherein co-localization of the phosphorylated
polymerase form with active replication sites visualized by BrdU (nucleotide analog)
staining was observed. Conversely, there was a lack of co-localization of the non-
/hypophosphorylated form with active DNA synthesis sites. Since the non-
/hypophosphorylated form appeared in the nucleoplasm but was not concentrated in
regions of active DNA synthesis, it was suggested that the non-/hypophosphorylated
form of DNA polymerase a might be engaged in initiation of DNAreplication on the
leading strand by synthesizing the first primer, while phosphorylated enzyme could
be involved in primer synthesis on the lagging strand. Further investigation of this
hypothesis was carried out based on co-localization and immunoprecipitation
experiments with MCM2, a protein engaged in forming ofpre-replication complex
and then excluded from the replication fork. The different function of each DNA
polymerase a, was confirmed by findings that only the non-/hypophosphorylated
form appeared to co-localize and immunoprecipitate with MCM2specifically during
G1/S phasetransition.
These findings regarding activity and the existence of two forms of DNA
polymerase © are in accord with earlier observations of murine DNA polymerase o
in which the presence of two subpopulations was also reported with regard to
polyomavirus virus T antigen affinity and again distinguished the ability of these
formsto initiate polyomavirus origin-dependent DNA synthesis (194).
To determine whether MDM2 mightbind preferentially to one of these
DNApolymerase subpopulations, we obtained the phosphorylation status specific
antibodies from Professor Dornreiter. Initial immunoprecipitation experiments were
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carried out in a p53-null background on untransfected Clone 9 cells (H1299-
derivative) which stably express high levels of MDM2. The results indicate that
MDM2 preferentially co-immunoprecipitates with the non-/hypophosphorylated
form of DNA polymerase & and this was morestriking when taken together with the
fact that considerably more of the phosphorylated form was immunoprecipitated
(regardless of whether this was due to greater abundance or more efficient
immunoprecipitation) (Figure 3.6.1). Experiments show that the non-
/hypophosphorylated form is present in cells at lower levels than the phosphorylated
form, andthis is not surprising since it is required for initiation of replication, and
after that is rapidly phosphorylated, presumably as an additional regulatory event to
prevent re-replication (116). Further experiments to examine this association of
MDM2with the non-/hypophosphorylated form were performed in untransfected
H1299 cells, and HEK293 cells (immortalised non-cancer derived cells that express
wild-type p53) in order to test whether co-immunoprecipitation between MDM2 and
non-/hypophosphorylated DNA polymerase a occurs in heterologous cells and
whether MDM2levels impact upon this. We also examined whether the presence of
T antigen influenced complex formation between MDM2 and the non-
/hypophosphorylated DNA polymerase in HEK293T cells. Results from these
experiments indicate that the interaction between MDM2 and the non-
/hypophosphorylated form of DNA polymerase o take place regardless of MDM2
expression levels, p53 status, the cells origin or the presence of T antigen.
These findings may provide a newinsight regarding a role for MDM2 in
eventsrelating to initiation of DNAreplication via preferential binding to a complex
containing the non-/hypophosphorylated subpopulation of DNA polymerase a, since
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this latter has a clear role in this process. MDM2has beenlinked previously with
promoting S-phase entry via interactions with the retinoblastoma protein (Rb) by
inhibiting Rb function as a tumour suppressor, as well as via interactions with the
E2F1 transcription factor (51,52,98,99,195). It is potentially noteworthy that E2F1 is
a transcription factor that can promote expression of DNA polymerase a, hence it
may be that MDM2hasan influence on DNA polymerase « activity through both
indirect regulation of its expression via interaction with E2F1 and through postulated
direct effects that we are only beginning to reveal in the studies presented herein.
Studies performed on transgenic animal models wherein cells over-expressed
MDM2,revealed that these cells went through multiple rounds ofreplication, either
prior to cytokinesis or because they failed to undergo cytokinesis, leading to
polyploidy in a p53-null background (97), and (which is more important in the
present context) also in an E2F1-null background (139). These results suggest a role
for MDM2in promoting S-phase independently of p53 and E2F1. In light of these
observations, we consider that our observations regarding the preferential interaction
of MDM2 with the non-/hypophosphorylated form of DNA polymerase @ may
ultimately provide a basis for an additional mechanism by which MDM2can impact
upon S-phase promotion.
Data presented in this thesis, provide supporting evidence for an
involvement of the MDM2protein in initiation of the DNA replication process
through interaction with a key S-phase initiator — non-/hypophosporylated DNA
polymerase o&. We therefore wanted to investigate whether we could detect any
impact of MDM2 uponthis process. Given limitations of time and resource, we
initially examined whether the cell cycle profile would be altered upon reducing
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MDM2levels. We performed siRNA transfections targeting MDM2 in H1299 and
Clone 9 (H1299) cells followed by flow cytometry analysis. The results obtained
indicated that knockdown of MDM2leads to approximately a 10% reduction in the
numberof cells in S phase comparedto cells with unchanged MDM2levels (Figure
3.7.3). In other studies the MDM2 knockdown in H1299 cells was observed to lead
to 66% decrease in proliferation comparing to parental cells (155), supporting the
idea of a role for MDM2in p53-independent promotion ofcell cycle progression and
cells proliferation, which may contribute to p53-independent oncogenic potential of
MDM2. However, when we examinedthe effect of MDM2 knock-down with siRNA
and measured thymidine incorporation as an indicator of DNA synthesis we observed
a smaller reduction in S-phase (c.4%) and perhaps not surprisingly in this one-off
experiment, we did not detect a significant reduction in thymidine incorporation,
although there was a trend towards a reduction which clearly requires further
investigation (Figure 3.7.5-6).
In conclusion, since MDM2 binds preferentially to the non- /hypo-
phosphorylated population of DNA polymerase a and may even have an effect on S-
phase more studies are clearly warranted to shed more light on involvement of
MDM2proteinin initiation of DNA replication. Such studies may subsequently lead
to a better understanding of the mechanisms through which MDM2contributes to
oncogenesis. In particular, future studies need to take into account the potential
involvement of other subunits of DNA polymerase @ in complex formation with
MDM2in cells, as we have argued from our immunoprecipitation studies with
MDM2 deletion mutants (Figure 3.2.10). It will be important to examine the
potential of MDM2 to modulate the activity of the primase subunits of DNA
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polymerase a given their responsibility for synthesizing RNA primers both on
leading and lagging strand during DNAreplication. Such an involvement of MDM2
protein in altering the primase activity of DNA polymerase a could add support to
the notion of DNAreplication promotion by MDM2,followed by potential increase
in cells proliferation which may well contribute to MDM2 oncogenic functions.
Since DNA polymerase «, in addition to its well-documented role in the
initiation of DNA replication, seems to be also engaged in cell cycle regulation
(66,67), telomere maintenance (68) and epigenetic control (156,160) as described in
the Introduction section ofthe thesis, it would also be interesting to establish whether
MDM2mayinfluence any of these processes via interaction with DNA polymerase
a. Thusthis thesis begs more questions than it has answered, but hopefully has shed
sufficient light on new avenuesfor investigation.
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